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 With the advent of antiretroviral drug therapy in the late 1980s, human 
immunodeficiency virus (HIV) is no longer a death sentence, but remains to be a chronic 
disease. Of concern, however, an estimated 2.1 million individuals were newly infected 
with HIV globally as of 2015. Further, HIV remains to be a pandemic that requires 
attention from scientific researchers to push forward the development of novel drug 
therapies that mitigate viral resistance and improve overall safety profiles. Rilpivirine 
(RPV) a second generation non-nucleoside reverse transcriptase inhibitor (NNRTI) was 
FDA approved in 2011 for administration to treatment-naïve HIV-infected individuals. 
Prior to this work, the hepatic metabolism of RPV was unknown. By in vitro assay, we 
observed that cytochrome P450s CYP3A4 and CYP3A5 primarily contributed to the 
oxidative metabolism of RPV and that uridine diphosphate glucuronosyl transferases 
UGT1A1 and UGT1A4 could contribute to the conjugative metabolism of RPV and its 
metabolites. In these studies, it was observed RPV could modulate CYP3A4 mRNA 
expression through activation of the nuclear receptor and xenobiotic sensor pregnane X 
receptor (PXR). In line with this, efavirenz (EFV) a first generation NNRTI and the most-
widely prescribed antiretroviral despite exhibiting a poor safety profile, has been 
previously observed to activate PXR. Using an array of structural analogs of EFV, we 
explored the structure-activity relationship of EFV-mediated activation of PXR. In doing 
so, we identified a lower size limit ranging of > 223 Da to < 289 Da for ligand-dependent 
activation of PXR. In addition, we observed that the addition of a hydroxyl group to the 
Cl-phenyl ring of EFV did not impede ligand binding but attenuated PXR activation 
potentially through destabilizing a key hydrophobic area within the ligand-binding 
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pocket. Building upon this work, we investigated other hepatic pathways that may be 
stimulated by EFV and/or impacted by PXR activation. To this end, we observed EFV, 
but not RPV, could disrupt hepatic cholesterol homeostasis by stimulating lipid droplet 
formation as evidenced in primary mouse hepatocytes. EFV was also observed to 
increase the expression of the nuclear receptor small heterodimer partner (SHP), which 
has been implicated in facilitating the developments of dyslipidemia. However, further 
studies need to be performed in order to determine whether an EFV-mediated increase of 
SHP has a causal role in lipid droplet formation. In addition to studying antiretrovirals 
within the context of chronic HIV maintenance therapy, we also investigated RPV and 
the nucleoside reverse transcriptase inhibitor tenofovir (TFV) as pharmacological agents 
for HIV pre-exposure prophylaxis (PrEP). Moreover, in retrospective analyses, we 
identified genetic variants in the genes encoding enzymes responsible for RPV and TFV 
metabolism and activation, respectively. These findings lay the groundwork for future 
pharmacogenetic studies investigating inter-individual variability and toxicity associated 
with HIV PrEP.  
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Chapter 1: Introduction 
HIV Maintenance Therapy and Pre-Exposure Prophylaxis 
With the advent of antiretroviral drug therapy in the late 1980s, human 
immunodeficiency virus (HIV)  is no longer a death sentence, but a chronic disease that 
can be alleviated pharmacologically (1). That being said, as of 2015, the Joint United 
Nations Programme on HIV/AIDS estimated 2.1 million individuals were newly infected 
with HIV globally, with the greatest prevalence of infections occurring in eastern and 
south Africa (2). Further, within the scope of the United States, over 1.2 million 
Americans are reported to be HIV infected, with approximately 50,000 new infections 
occurring annually (3). These alarming statistics demonstrate HIV remains to be a global 
pandemic that requires attention from scientific researchers to push forward the 
development of novel drug therapies that mitigate viral resistance and improve overall 
safety profiles. 
Several druggable targets of the HIV replication cycle have been elucidated to 
date, however, the most pharmacologically exploited steps of the HIV lifecycle are viral 
entry, reverse transcription of viral RNA, integration of viral DNA into the host cell 
genome, transcription of proviral DNA, viral assembly as well as proteolytic processing 
(4).  Zidovudine, a thymidine analog that competitively inhibits the HIV reverse 
transcriptase enzyme, was the first FDA-approved drug for the treatment of HIV 
infection as a monotherapy in 1987 (1, 5). Nearly a decade later, a clinical trial 
demonstrated that zidovudine dosed in combination with lamivudine, a cytidine analog 
that also targets the HIV reverse transcriptase enzyme, improved drug efficacy in terms 
of viral suppression and resistance in addition to immunologic response compared to 
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when either agent was administered independently to HIV-infected patients (6). Since 
these initial findings, current clinical guidelines by the World Health Organization 
(WHO) have evolved to recommend a triple drug combination as first-line antiretroviral 
therapy consisting of two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) 
plus a non-nucleoside reverse transcriptase inhibitor (NNRTI) (7).  
Unlike NRTIs, NNRTIs non-competitively inhibit HIV reverse transcriptase by 
binding allosterically to a hydrophobic binding pocket causing a conformational change 
and rendering the enzyme inactive. Efavirenz (EFV; Figure 1) is a first-generation 
NNRTI FDA-approved in 1998 and remains to be the most prescribed antiretroviral 
worldwide. This is primarily impart to WHO guidelines that recommend EFV be dosed 
as a third agent to treatment-naïve HIV-infected adults in combination with two NRTIs 
tenofovir disoproxil fumarate and emtricitabine (7). Further, this coformulated tablet, 
marketed as AtriplaTM, was the first triple drug combination approved by the FDA for 
treating HIV infection (8). Yet, despite being the most widely prescribed antiretroviral, 
EFV is associated with several serious adverse events, the most notably being psychiatric 
and nervous system symptoms, rash, hepatotoxicity and dyslipidemia (9). A dose 
reduction study comparing 400 mg EFV to the standard of care 600 mg EFV-containing 
once-daily drug regimen demonstrated an improved toxicity profile and fewer treatment 
discontinuations without compromising viral suppression, however, the relatively high 
risk for the emergence of treatment-resistance mutations has continued to drive the 
development of new antiretroviral therapies (10). 
Rilpivirine (RPV; Figure 1) is a second-generation NNRTI that was one of a 
family of diarylpyrimidine (DAPY) small molecules designed using a novel 
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multidisciplinary approach by Janssen Pharmaceuticals (11). This drug class has an 
inherent degree of flexibility and rotational freedom that enable the DAPY molecules to 
bind in multiple modalities to the NNRTI binding pocket of the HIV reverse transcriptase 
enzyme thereby allowing for adaptation to potential resistance mutations (11). By in vitro 
assay, RPV was observed to be 10 to 20 times more potent than EFV towards the 
inhibition of wild-type HIV reverse transcriptase and, more compelling, phase II clinical 
trials of once-daily dosing of RPV at 25, 75 and 150 mg all demonstrated a more 
favorable safety profile relative to 600 mg EFV once-daily dosing with decreased 
frequency of psychiatric and neurological adverse events as well as rash and lipid 
abnormalities (11, 12). RPV was eventually FDA-approved in 2011 for administration to 
treatment-naïve HIV infected adults. Further, because RPV was found to be highly 
efficacious and well tolerated with chronic oral administration, it was concurrently 
developed into a long-acting injectable formulation (RPV-LA) (13). One can envision 
that less frequent dosing of an antiretroviral due to an extended drug half-life may 
improve compliance as this is a primary contributor to the development of resistance. In 
addition to use for HIV maintenance therapy, RPV-LA is presently under investigation 
for use in pre-exposure prophylaxis (PrEP). 
PrEP is a preventative drug strategy for uninfected adults at risk of acquiring HIV 
by either sexual or blood-born transmission. As of 2015, WHO guidelines recommend 
PrEP should be offered to populations with an HIV infection rate of 3 in 100 people per 
year, which includes but is not limited to serodiscordant couples, men who have sex with 
men, transgender women and people who inject drugs (14). The notion of dosing a 
healthy individual long-term with an antiretroviral first became most plausible with the 
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2001 approval of the NRTI tenofovir (TFV; Figure 1). TFV is a nucleoside 
monophosphate analog administered as the prodrug TFV disoproxil fumarate (TDF) due 
to poor oral bioavailability and is generally well-tolerated with the exclusion of rare 
incidences of renal toxicity as well as decreased bone density with chronic administration  
(15-17). To counter these potential risks associated with long-term exposure to TFV, a 
key benefit of this NRTI is the extensive intracellular half-life of its active metabolite, 
TFV-diphosphate, ranging from 60 to > 175 h, which may contribute to improved 
efficacy and allow for flexibility in dosing frequency (18).  
Moreover, as TFV was proven to be an effective agent for use in treating HIV 
infection, it became a clear candidate for further exploration in PrEP under varying 
formulations and in differing target populations. For example, the CAPRISA 004 trial 
provided the first evidence that a 1% TFV microbicide gel applied vaginally before and 
after sex could reduce the risk of infection by 39%, 54% when corrected for adherence, in 
HIV-uninfected women (19). TFV, however, is only approved for oral administration as 
the prodrug TDF and is commonly coformulated with the nucleoside analog emtricitabine 
(FTC) as a backbone for NNRTIs, such as EFV and RPV, for HIV maintenance therapy. 
To that end, the Preexposure Prophylaxis Initiative (iPrEx) trial was the first study to 
report efficacy for oral dosing of TDF-FTC in seronegative men and transgender women, 
observing a 44% risk reduction in HIV transmission, an overall 92% reduction when 
adjusting for detectable levels of TFV in blood (20). Taking this work a step further in 
serodiscordant couples, our laboratory contributed to the Partners PrEP study showing 
once-daily TDF alone or TDF-FTC decreased the rate of HIV infection by 67% and 75%, 
respectively, with a greater than 85% relative risk reduction in participants who had 
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detectable TFV concentrations in blood regardless of the formulation (21). Furthermore, 
the data acquired from pivotal clinical trials, such as iPrEx and Partners PrEP, clearly 
demonstrated that the coformulation of TDF-FTC is effective at reducing the risk of HIV 
infection through sexual transmission giving way to Truvada as the first, and currently 
the only, approved drug for HIV PrEP in 2012 (22). As has been aforementioned, TFV as 
well as other classes of antiretrovirals remain to be under intensive investigation for 
indication in HIV PrEP with > 40 open label, demonstration and implementation projects 
reported to be planned or underway across Africa, Europe, Latin America and the United 
States as of June 2016 (23). 
 
Figure 1. Structural comparison of NNRTIs efavirenz and rilpivirine and the NRTI 
tenofovir. EFV is a first-generation NNRTI and is the most widely-prescribed 
antiretroviral to date. RPV is a second-generation NNRTI that has an increased genetic 
barrier to resistance relative to EFV as well as an improved safety profile. Both EFV and 
RPV are coformulated with the prodrug of TFV known as TFV disoproxil fumarate and 
emtricitabine (not shown) marketed as AtriplaTM and CompleraTM, respectively, for 
administration to treatment-naïve HIV-infected adults. In addition, the coformulation of 
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TFV disoproxil fumarate and emtricitabine alone, also known as Truvada, is the only 
FDA-approved drug strategy for HIV pre-exposure prophylaxis. 
Pharmacokinetics and Small Molecule Drug Metabolism  
The most common routes for drug administration are (1) enteral by oral ingestion, 
in which the drug passes through the gastrointestinal tract prior to reaching systemic 
circulation, (2) parenteral injection, in which the drug rapidly reaches systemic 
circulation and (3) topical application, in which drug exposure is localized and may or 
may not reach systemic circulation. Regardless of the route of administration, each drug 
will have its own unique pharmacokinetic parameters for absorption, distribution, 
metabolism and elimination (Figure 2). Although there are limitations, oral dosing in 
general is considered the safest, most convenient and most economical route of 
administration for medications. All currently approved anti-HIV drugs for both 
maintenance therapy and PrEP are small molecules (< 900 Da) dosed orally; therefore, 
the pharmacokinetic properties most relevant to oral tablets will be described herein. 
Absorption is the movement of drug from the site of administration into the 
bloodstream. Following ingestion of a drug, there are several mechanisms by which a 
small molecule can traverse cell membranes for absorption into the gastrointestinal tract, 
those being passive or facilitated diffusion as well as active transport. Orally dosed drugs 
tend to be highly lipophilic and, therefore, will passively diffuse across lipid bilayers 
driven by the concentration gradient. The rate at which this occurs is primarily regulated 
by the surface area at the site of absorption. The intestinal mucosa, for example, has a 
large surface area thereby facilitating rapid absorption. The overall absorption of a drug 
determines its bioavailability, which is the extent to which a drug can access its site of 
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action when administered orally. Drugs that are readily absorbed by the stomach and the 
intestinal wall will be transported through the portal vein into the liver. Drug 
metabolizing enzymes highly expressed in the liver can then biotransform the parent drug 
into an inactive metabolite ultimately decreasing the amount of active drug that reaches 
systemic circulation to take pharmacological effect. This phenomenon is commonly 
referred to as “first-pass metabolism” and can have a significant impact on drug 
bioavailability. Following absorption into the bloodstream, a drug can distribute from the 
systemic circulation and permeate into extra- and/or intra-cellular spaces. A compound 
will distribute to highly perfused organs, such as the heart, liver, kidney and brain, more 
quickly after absorption has occurred compared to less perfused tissues, such as muscle 
and fat. The rate of blood flow to these organs and tissues will further impact the extent 
of distribution that takes place. In addition, the concentration of “free” drug actually 
distributed to the periphery and ultimately the site of action is directly dependent upon 
the degree of plasma protein binding.  
As previously mentioned, drugs absorbed by the stomach or intestinal wall will be 
subjected to first-pass metabolism. This is a process in which a lipophilic molecule is 
biotransformed into a more polar species in order to facilitate excretion. Moreover, a 
polar compound will have physiochemical properties less favorable for reabsorption by 
the kidneys to reenter the bloodstream. This is presumably an evolved defense 
mechanism of the body’s in order to prevent the recirculation of potentially toxic foreign 
substances. That being said, although drug metabolites usually do not exert a biological 
effect, drug metabolizing enzymes do have the propensity to catalyze the formation of 
unstable and/or toxic metabolites. A well-studied example of this phenomenon is the 
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reactive metabolite N-acetyl-p-benzoquinoneimine formed from the cytochrome P450-
dependent metabolism of acetaminophen (25). The biotransformation of xenobiotics 
primarily occurs in the hepatocytes of the liver and to a lesser extent in the intestinal 
epithelium due to the high concentration of drug metabolizing enzymes in these organs. 
Further, the biotransformation of drugs can be categorized into two types of mechanisms, 
phase I and phase II reactions, which do not imply order but the type of modifications 
that can occur to a substrate (Figure 3). Phase I drug metabolizing enzymes catalyze 
“functionalizing” reactions in which a functional group, such as –OH, –NH2 and –SH, is 
introduced to or unmasked on a substrate, whereas phase II drug metabolizing enzymes 
are generally transferases and conjugate an endogenous, polar cofactor onto a substrate 
(26). As previously alluded to, phase I and phase II metabolism can occur either 
sequentially or concurrently, conceivably yielding several metabolites for each parent 
drug. With respect to anti-HIV drugs, our laboratory alone has demonstrated the 
NNRTIs, EFV, RPV, etravirine and dapivirine, as well as the HIV entry inhibitor 
maraviroc undergo extensive phase I and phase II metabolism (27-31).  
The cytochromes P450 are heme-containing monooxygenases that insert an 
oxygen onto a substrate and are responsible for 75% of phase I metabolism, with more 
marginal contribution by alcohol dehydrogenases, esterases, aldehyde dehydrogenases, 
epoxide hydrolases, NADPH:quinone oxidoreductases and dihydropyrimidine 
dehydrogenases  (32). Uridine diphosphate glucuronosyltransferases contribute to 
approximately 30% of phase II reactions through the conjugation of glucuronic acid onto 
its substrate, producing a glucuronide. Sulfotransferases are then responsible for an 
estimated 25% of phase II reactions followed by glutathione S-transferases, N-acetyl 
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transferases, catechol O-methyl transferases and thiopurine methyl transferases (32, 33). 
Several of these drug metabolizing enzymes are highly polymorphic thereby modifying 
the biotransformation of a drug. The presence of such genetic variants can lead to 
heterogeneity in the way in which an individual may respond to a medication in terms of 
efficacy and/or toxicity. 
Following absorption, distribution and metabolism, an ingested drug is eventually 
excreted from the body either unchanged or as a more polar metabolite. The process of 
elimination can occur through several biological fluids, mainly urine, bile or feces. In 
addition, depending on the physiochemical properties of parent drug and/or metabolites, 
elimination can also occur through excretory gland secretion, such as sweat, saliva, tears 
as well as breast milk. Renal excretion, however, is considered to be the primary route by 





Figure 2. Pharmacokinetic parameters of a drug. Schematic demonstrating the 
interrelationship of absorption, distribution, metabolism and elimination of a drug. These 
four pharmacokinetic properties are unique to each drug and the extent and rate at which 
these processes occur will be dependent on the route of administration. (Schematic 




Figure 3. Phase I and phase II biotransformation. Drug metabolizing enzymes can be 
classified into catalyzing two types of mechanisms, phase I and phase II reactions. Phase 
I enzymes either introduce or unmask a polar functional group onto their substrates, 
whereas phase II enzymes conjugate an endogenous cofactor onto their substrates. Both 
mechanisms yield a metabolite with increased polarity relative to the parent drug in order 
to facilitate excretion from the body. 
The Cytochromes P450 
A “microsomal carbon monoxide-binding pigment” was first observed in rat 
subcellular liver fractions in the late 1950s (34). Shortly thereafter, in 1962, this heme-
containing pigment was further characterized and designated as “cytochrome P450” 
(P450) due to the characteristic red tint of the microsomes enriched with this protein and 
the distinct absorption of light at 450nm in the presence of carbon monoxide (35). In 
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rapid succession, the first reports describing P450 function were published demonstrating 
monooxygenation of both endogenous and exogenous substrates, such as the steroid 
hormone 17-hydroxyprogesterone and the analgesic acetanilide, respectively (36, 37). 
P450s, now preferably termed “heme-thiolate proteins” as will be later discussed, are an 
established superfamily of enzymes, with over 18,000 protein-coding genes identified in 
nature thus far (38, 39). Due to the extensive diversity of P450s, each isozyme of the 
superfamily is identified using a specific gene nomenclature. A P450 is named starting 
with the gene symbol “CYP” for cytochrome P450, followed by an Arabic number 
designating the P450 family, then a letter indicating the subfamily, and lastly an Arabic 
number specific to the individual gene, for example, CYP3A4 (38). P450s within a given 
family share > 40% amino acid sequence identity and > 55% amino acid sequence 
identity for subfamilies (38). The human genome itself comprises of 18 P450 families 
and 44 subfamilies, encoding a total of 57 putatively functional genes (39). 
 Mammalian P450s are localized in subcellular compartments, primarily in the 
endoplasmic reticulum and to a lesser extent the inner mitochondrial membrane (39, 40). 
Moreover, P450s are highly concentrated in hepatocytes, the parenchymal cell of the 
liver, with certain isozymes also expressed in a range of extrahepatic tissues, such as the 
intestines, kidneys, testes and uterus to name a few (41). Microsomal P450s are anchored 
to the ER membrane by their N-terminus exposing the remainder of the polypeptide to 
the cytosol, whereas mitochondrial P450s are synthesized in the cytoplasm as soluble 
precursors, imported into the mitochondria, proteolytically processed and then 
incorporated into the inner membrane (42, 43). Interestingly, conversely to higher order 
eukaryotic P450s that are restricted to a subcellular membrane, prokaryotic P450s are 
13 
 
soluble enzymes that lack an N-terminal membrane anchor. Moreover, the relative ease in 
the expression and purification of bacterial P450s allowed for the swift progression of 
structural studies with first high-resolution P450 crystal structure solved in 1987 of 
P450cam isolated from Pseudomonas putida (44). 
Although differing in terms of cellular localization and solubility, P450s across all 
eukaryotic and prokaryotic organisms exhibit a similar tertiary structure arranged in a 
series of helices and folds, with the most conserved helices denoted as A through L (45). 
Helices I and L contact the active site heme, and helices B, F and I can form electrostatic 
interactions with the substrate, thereby influencing catalytic selectivity as demonstrated 
through extensive site-directed mutagenesis experiments (45). At the level of the primary 
structure, the most conserved amino acid residue across P450s is a cysteine residue that 
acts as a thiolate ligand to the heme iron, hence the preferred terminology of “heme-
thiolate protein” as previously mentioned (45). A somewhat less conserved amino acid is 
a threonine residue, which can donate a proton during substrate oxidation in the P450 
catalytic cycle (45).  
P450s primarily catalyze mixed-function oxidation reactions, in which an oxygen 
is inserted onto their substrate using molecular oxygen and NADPH as an electron source 
(45). The major events of the P450 catalytic cycle can be grossly simplified into a series 
of nine steps (45) (Figure 4). The cycle begins by the binding of substrate in proximity to 
the active site heme iron poised for catalysis in the ferric state (Fe+3) (45). An electron is 
then transferred to the ferric iron from NADPH via a neighboring accessory protein 
NADPH-P450 reductase, yielding reduced ferrous (Fe+2) iron and forming an unstable 
intermediate with molecular oxygen (45). A second electron is then transferred to the 
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Fe+2-O2 complex by either NADPH-reductase or an alternative redox partner cytochrome 
b5, followed by the addition of a proton from surrounding water or a nearby threonine 
residue, cleavage of the O-O bond and formation of one water molecule (45). The 
resulting P450-compound intermediate undergoes a series of rearrangements, yielding 
oxidation of the substrate and release of a hydroxylated product (45). It is important to 
note, that the P450 catalytic cycle can become “uncoupled” once molecular oxygen is 
bound to the ferrous iron, producing superoxide as well as hydrogen peroxide byproducts, 
and the extent to which this uncoupling occurs impacts the rate of catalytic efficiency and 
substrate turnover (46). That being said, the most common oxidation reactions that result 
from the P450 catalytic cycle are carbon hydroxylation, heteroatom (N, S, P or I) 
oxygenation, heteroatom release or dealkylation following hydroxylation of an adjacent 
carbon atom and epoxidation (45). 
 Although P450s generally exhibit similar tertiary structure, they do differ 
substantially in terms of active site size even within the same species. For example, the 
active sites of human P450s 2E1 and 3A4 range from 190 Å3 to 1385 Å3 in volume, 
respectively (47, 48). In addition to size, P450 active sites can also vary drastically in 
three-dimensional shape as well, with the human P450 2C8 observed to have an L-shaped 
cavity compared to P450 3A4 which exhibits a more open cavity (40). Taken together, 
both the size and shape of the hydrophobic P450 active site are key determinants for 
substrate specificity. While human P450s tend to exhibit substrate overlap, families 1 
through 4 are commonly considered to primarily contribute to xenobiotic metabolism, 
whereas the remaining P450 families are responsible for the metabolism of endogenous 
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compounds such as sterols, fatty acids, eicosanoids and vitamins in addition to several 
orphan P450s with unknown biological function (40).  
Reiterating the former discussion of first-pass drug metabolism, human P450s 
contribute to roughly 75% of phase I biotransfromation (32). There are a total of 16 
P450s expressed at the protein level in the human liver and these isozymes are ranked 
here in order of relative hepatic content from lowest to highest concentration: CYP2C18, 
-2J2, -3A43, -1A1, -3A7, -2C19, -4F2, -2D6, -2B6, -3A5, -2C8, -2A6, -1A2, -2C9, -2E1 
and -3A4 (49-51). Drawing from the literature, the major hepatic isozymes that 
participate in the metabolism of drugs either under development or currently on the 
market are the P450s 3A4 (27%), 2D6 (13%), 2C9 (10%), 2C19 (9%) and 1A2 (9%), 
with more minor contribution from the P450s 3A5 (6%), 1A1 and 2C8 (5%), 2B6 (4%), 
2E1 (3%) and 2A6 (2%) (52). From these data, one can see that the CYP3A subfamily 
account for the largest fraction of P450-mediated drug metabolism which allows for an 
increased frequency of potential drug-drug interactions. Of additional concern, the highly 
polymorphic P450s 2D6 and 2C19 combined account for almost the second largest 
fraction of P450-metabolited drug metabolism, allowing for greater heterogeneity or 
inter-individual variability in the response to a medication. 
The common occurrence of polymorphisms in drug metabolizing enzymes, 
particularly in P450s, gave rise to the practice of “pharmacogenetics,” in which the 
existence of a genetic variant for a drug metabolizing enzyme is translated into a 
predicted outcome or drug response (53). Variants in the genes encoding these enzymes 
can result in amino acid mutations that cause high, low or no activity towards a substrate 
due to decreased expression or loss-of-function of the enzyme at the protein level 
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allowing for a profound effect on toxicity and efficacy of a drug. In the past, clinically 
relevant polymorphisms in enzymes responsible for drug metabolism and disposition 
were initially identified by phenotypic observation in a study population administered 
drug (32).  Presently, functionally important polymorphisms are typically elucidated pre-
clinically using basic molecular pharmacology techniques. For example, individual 
cDNA-expressed hepatic P450s, mainly for CYP1A2, -2B6, -2C8, -2C9, -2C19, -2D6, -
3A4 and -3A5, are commonly employed to determine their relative contribution to a 
drug’s oxidative metabolism. If a polymorphic P450 is found to metabolize an 
investigational new drug, then this work can be taken a step further into a more complex 
system using genotyped human liver microsomes, allowing for a better representation of 
the global impact of the polymorphism on hepatic metabolism and for potential 
extrapolation to an in vivo outcome. An excellent proof of concept of this method for 
identifying clinically relevant polymorphisms was recently demonstrated by our 
laboratory in which we found that the HIV entry inhibitor maraviroc was primarily 
metabolized by the polymorphic P450 3A5 by in vitro assay (28). We then translated this 
work in vivo and observed the presence of a CYP3A5 loss of function allele significantly 
increased maraviroc plasma concentrations and decreased clearance (54). Moving 
forward, although the regulation of P450 expression and activity is multifactorial, there is 
a clear utility for understanding genotype-phenotype correlations in order to better predict 




Figure 4. The cytochrome P450 catalytic cycle. Schematic demonstrating the nine 
primary events of the P450 catalytic cycle. The substrate (RH) binds in proximity to the 
ferric heme causing a conformational change and inducing an electron transfer from 
NADPH-P450 reductase. Molecular oxygen binds to the now ferrous heme, which then 
undergoes a second electron transfer from either NADPH- P450 reductase or cytochrome 
b5. This is followed by rapid protonation, release of water and formation of a P450-
compound intermediate. Following a series of rearrangements, this intermediate yields 
oxidation of the substrate and is ultimately released as a hydroxylated product. 
(Schematic adapted from F. Peter Guengerich, Common and Uncommon Cytochrome 





Uridine Diphosphate Glucuronosyltransferases 
In contrast to the extensive studies published characterizing the cytochromes 
P450, uridine diphosphate glucuronosyltransferases (UGTs) have been historically less 
well investigated. Glucuronidation, however, is indeed a major detoxification pathway 
that has evolved to conjugate endogenous molecules, most notably bilirubin, and a wide-
array of pharmacological agents, such as morphine and acetaminophen (55, 56). Similarly 
to P450s, however, UGTs are a superfamily of enzymes expressed in all kingdoms of life 
and as such require the utilization of a gene nomenclature for the identification of 
individual isozymes. A UGT is named starting with the gene symbol “UGT” for uridine 
diphosphate glucuronosyltransferase, followed by an Arabic number designating the 
UGT family, then a letter indicating the subfamily, and lastly an Arabic number specific 
to the individual gene, for example, UGT1A1 (57). UGTs within a given family share > 
45% amino acid sequence identity and > 60% amino acid sequence identity for 
subfamilies (57). The human genome itself comprises of four UGT families, UGT1, -2, -
3 and -8, encoding a total of 22 putatively functional genes (58, 59). 
 Mammalian UGTs are almost exclusively localized to the endoplasmic reticulum 
(ER) and, in parallel to P450s as well as other drug metabolizing enzymes, are highly 
expressed in hepatocytes (60). Although glucuronidation primarily occurs in the liver in 
addition to the intestines, UGTs are also expressed in a variety of extrahepatic tissues, 
such as the brain, kidneys, prostate and uterus (61, 62). In the initial studies of this 
superfamily, two opposing hypotheses were formed regarding the topology of UGTs. The 
first hypothesis proposed the enzyme is buried in the ER membrane and transport of the 
substrate across the membrane is required in order to reach the catalytic site, contrary to 
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the alternate hypothesis which proposed the enzyme is extensively membrane bound, 
however, the catalytic site is freely exposed to the cytosol for substrate binding (63-65). 
Subsequent studies observed UGT activity was proportional to substrate lipophilicity, 
suggesting the presence of a membrane barrier preventing access of hydrophilic 
substrates to the enzyme’s active site (66). The implementation of cDNA cloning in 
addition to the use of hydropathy analyses put forth the current topological model that the 
enzyme is indeed located within the ER membrane (63). It is now well-accepted that 
UGTs are synthesized as precursors containing an N-terminal signal peptide, thereby 
mediating integration of the polypeptide into the ER membrane (67). The signal peptide 
is then cleaved, yielding a 505 residue transmembrane protein, with approximately 95% 
of the polypeptide chain retained in the lumen of the ER and a 20 residue C-terminal 
cytoplasmic tail (68, 69). Interestingly, across all UGTs there is a highly conserved 44 
residue long region in the C-terminus and the cytoplasmic portion of this signature 
sequence is the proposed binding site for the nucleotide moiety of uridine diphosphate 
glucuronic acid (UDPGA) (57, 70). Unfortunately, obtaining further structural detail of 
UGTs has remained a challenge due to the protein’s extensive membrane binding.  
The general mechanism catalyzed by UGTs can be reduced to a second order 
nucleophilic substitution reaction, in which a substrate or aglycone attacks UDPGA at the 
electrophilic C1 position of the sugar yielding a glucuronide conjugate and a uridine 
diphosphate byproduct (Figure 5) (71). The UDPGA cofactor is synthesized exclusively 
in the cytosol from UDP-glucose mediated by UDP-glucose-6-dehydrogenase (60).  In 
addition, recent studies have demonstrated UGTs have the ability to conjugate other 
endogenous uridine-based sugars to their substrates, such as glucose and xylose (71). 
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Several substrate nucleophiles can serve as an acceptor functional group for glucuronic 
acid primarily aliphatic alcohols, phenols, carboxylic acids, aromatic or aliphatic amines, 
and thiols (71).  
As previously discussed, there is substantial experimental evidence demonstrating 
the UGT active site is located within the lumen of the ER, however, data is severely 
lacking in regards as to how charged and bulky species, mainly UDPGA and the resulting 
glucuronide conjugate, move into and out of the luminal compartment, respectively. Over 
decades of work, studies using membrane vesicles have demonstrated and confirmed that 
active transport of UDPGA is certainly required to cross the microsomal membrane, yet 
the discrete membrane protein(s) responsible for its translocation remains ambiguous (72-
75). UGT itself has been hypothesized to facilitate the efflux of glucuronide conjugates 
from the luminal space into the cytosol, however, there is no experimental evidence 
supporting this theory. One publication thus far has reported that glucuronides 
synthesized in the lumen of the ER can leave via an “antiport” driven by the concurrent 
uptake of UDPGA into the compartment though supporting evidence demonstrating the 
existence of such a protein carrier has not been published (76). In addition to these 
hypotheses, it is also highly probably that a glucuronide can bypass active transport and 
instead undergo vesicular trafficking from the lumen of the ER to the plasma membrane 
following a path similar to secreted proteins (63). 
Of the four human UGT families, UGT1 and UGT2 members are expressed in the 
liver with the exception of UGT1A5, -1A7, -1A8, -1A10 and -2A1. Moreover, the most 
abundantly expressed hepatic isozyme is UGT2B4 (44.5% of total UGT hepatic content) 
followed by UGT2B15 (12.8%), -2B10 (10.6%), -2B7 (6.9%), -1A1 (6.7%), -1A9 
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(6.1%), -1A4 (4.9%), -1A6 (4.5%), -2B17 (1.5%) and -1A3 (1.3%) (71). As previously 
mentioned UGTs catalyze the glucuronidation of both endogenous and xenobiotic 
substrates and correspondingly to P450s tend to exhibit substrate overlap. For example, 
within the liver and intestines, UGT1A subfamily members actively conjugate bilirubin, 
steroid hormones and bile acids, with the exclusion of UGT1A5, -1A6 and -1A7 which 
have no known function (63). Further, UGT2B subfamily members also share activity 
towards steroid hormones and bile acids in addition to acidic steroids with no known 
endogenous substrate for UGT2B4 (63). With respect to drug metabolism, however, the 
most clinically relevant isozymes are UGT1A1, -1A3, -1A4, -1A6, -1A9 and -2B7, 
contributing to approximately 30% of phase II drug-conjugating reactions (32, 33, 71). 
Similarly to P450s, several of the UGT isozymes are highly polymorphic and as such 
have been correlated to the establishment of a disease state and/or interindividual 
variability for a drug response.  
To date, genetic variants demonstrated to have a functional impact have been 
detected within the promoter and coding regions of UGT1A1, -1A3, -1A4, -1A6, -1A7, -
1A8, -1A9, -1A10, -2B7 and -2B17 (71). Of these isoforms, polymorphisms within the 
gene encoding UGT1A1 have been the most well-studied as the clinical manifestation of 
hyperbilirubinaemia is a direct result of reduced UGT1A1 protein expression and activity 
(77, 78). Bilirubin, a byproduct of red blood cell lysis, is toxic and lack of excretion in 
the bile as a glucuronide conjugate can result in kernicterus, a type of neurotoxicity due 
to high levels of circulating bilirubin, and even death if left untreated (79). Further, 
UGT1A1 loss-of-function polymorphisms also have a causal role in the toxicity 
associated with administration of the chemotherapeutic agent irinotecan, due to 
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compromised clearance of the reactive metabolite SN-38 (80). As previously discussed 
within the context of P450s, functionally important polymorphisms for UGTs can also be 
elucidated pre-clinically. Individual cDNA-expressed hepatic and intestinal UGTs, 
mainly for UGT1A1, -1A3, -1A4, -1A6, -1A7, -1A8, -1A9, -1A10, -2B4, -2B7, -2B15 
and -2B17 are routinely employed to determine their relative contribution to the 
glucuronidation of a drug. If a polymorphic UGT is found to conjugate an investigational 
new drug, then this work can be taken a step further into a more complex system using 
genotyped human liver microsomes, allowing for a better representation of the global 
impact of the polymorphism on hepatic metabolism and for potential extrapolation to an 
in vivo outcome. 
 
Figure 5. Mechanism of glucuronidation. Schematic demonstrating the conjugation of 
an aglycone (H-X-R) with uridine diphosphate (UDP) glucuronic acid. UDP-
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glucuronosyltransferases covalently link an endogenous cofactor, glucuronic acid, to an 
acceptor functional group on a substrate through nucleophilic substitution, yielding a 
glucuronide conjugate and uridine diphosphate. (Schematic adapted from A. Rowland et 
al., The UDP-glucuronosyltransferases (71).) 
Transcriptional Regulation of Drug Metabolizing Enzymes by the Pregnane X 
Receptor 
 The notion of a “general adaption syndrome” was put forth in the Journal of 
Pharmaceutical Sciences in 1971 describing a phenomenon in which the body has a 
physiologic response to a foreign stimulus initiating rapid induction of drug metabolizing 
enzymes to “destroy the aggressor” and accelerate its excretion (81). This “catatoxic 
effect” was believed to be distinct from classic hormonal action, yet correlated with 
increased levels of circulating glucocorticoids (81). Concurrent studies observed a similar 
effect in vitro demonstrating the induction of P450 and UGT activity through the 
treatment of isolated rat hepatocytes with the glucocorticoid dexamethasone and the anti-
glucocorticoid pregnenolone 16α-carbonitrile (PCN), thereby suggesting activation of a 
cellular mechanism independent of the glucocorticoid receptor (82-85). Not until 1998 
was the novel nuclear receptor, pregnane X receptor (PXR; NR1I2), first identified as the 
signaling pathway primarily responsible for the transcriptional modulation of these drug 
metabolizing enzymes (86).  
 PXR is part of an extensive superfamily of transcription factors that contribute to 
the regulation of cellular growth, development and homeostasis through either gene 
activation or repression. There are 48 nuclear receptors (NRs) expressed in humans, 
categorized into six subfamilies and further divided into 28 groups based on phylogeny 
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and sequence homology (87, 88). In a manner similar to the nomenclatures used for 
identifying P450s and UGTs, a receptor is named starting with the gene symbol “NR,” 
followed by an Arabic number designating the subfamily, then a letter indicating the 
group, and lastly an Arabic number specific to the individual gene, such as the NR 
subfamily 1 group I member 2, or NR1I2, as an alternative name for PXR (89). NRs in 
general exhibit a modular structure organized into five to six domains, designated as A 
through F moving from N- to C-terminus, respectively (87). Of these domains, the most 
conserved regions are C, the DNA-binding domain (DBD) containing two zinc fingers, 
and E, the ligand-binding domain (LBD) which serves as the docking site for a ligand, 
and the coordinated actions of these domains culminate into the modulation of target 
gene expression (87).  
 PXR was first cloned from mouse liver, as a 431 residue long isoform PXR.1 and 
a 390 residue splice variant PXR.2, with both isoforms exhibiting high sequence 
homology with the human vitamin D receptor of 64% and 29% within the DBD and 
LBD, respectively (86). By northern blot analyses, murine PXR (mPXR) mRNA 
transcripts were highly abundant in the liver and intestines and to a lesser extent the 
stomach and kidneys, exhibiting an expression pattern similar to drug metabolizing 
enzymes (86). In addition, using a yeast-two hybrid system in which the LBD of mPXR 
was fused with the DBD of the yeast transcription factor GAL4, both isoforms were 
activated to varying degrees by dexamethasome and PCN, the same synthetic steroids 
previously reported to induce P450 and UGT activity in rodent hepatocytes (86). Taking 
this work a step further, pregnenolone was identified as a potent ligand of mPXR 
suggesting a pregnane was the likely natural ligand of the NR hence its namesake (86). 
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 In rapid succession, two subsequent reports were published characterizing a 434 
residue long human ortholog denoted simply as human PXR (hPXR) and formerly as the 
“steroid and xenobiotic receptor,” respectively, with mRNA expression detected in the 
liver, intestines and colon (86, 90, 91). Interestingly, sequence alignments demonstrated 
hPXR exhibits 95% identity to the mPXR DBD, yet 73% identity to the mPXR LBD, 
suggesting an evolutionary divergence potentially pressured by exposure to toxins in the 
diets of rodents relative to primates (91). Adding to this observation, PCN was observed 
to have a low to modest activation of hPXR in contrast to the potent activation of mPXR, 
while rifampicin, an antibiotic used to treat tuberculosis, was an effective activator of 
hPXR but not mPXR (90, 91). The successive cloning of additional orthologs from rat 
and rabbit further demonstrated PXR is pharmacologically distinct due to sequence 
divergence in the LBD (92).  
 In the initial reports investigating PXR, it was observed that the NR requires 
heterodimerization with 9-cis retinoic acid receptor (RXR, NR2B1) in order to bind to 
response elements within the proximal and distal promoter regions of target genes, the 
most prototypic being CYP3A, to facilitate transcription (86, 90, 91). Its overall 
mechanism of action, however, was largely unknown until relatively recently and was 
primarily informed by preceding studies pertaining to the fellow NR1I group member 
constitutive androstane receptor (CAR; NR1I3), which has a less prominent role in the 
regulation of drug metabolism. Experimental evidence using a murine model has 
demonstrated that under basal conditions PXR is sequestered in the cytosol by the 
chaperones cytoplasmic CAR retention protein and heat shock protein 90 (Figure 6) (93, 
94). Upon ligand binding, PXR dissociates from the chaperone protein complex and 
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translocates to the nucleus where it can then heterodimerize with RXR and bind to 
response elements in the promoter regions of target genes to facilitate transcription (95). 
PXR/RXR binding sites of a direct repeat (DR-3) and/or an everted repeat (ER-6) motif 
have been characterized in proximal promoter regions of CYP3A genes across species 
(96). In addition, to these proximal promoter binding sites, a distal xenobiotic response 
element consisting of DR-3 and ER-6 motifs has been extensively studied in the human 
CYP3A4 gene (97). Although this is not an exhaustive list, PXR/RXR binding sites have 
also been detected in the promoter regions of other P450 subfamilies and drug 
metabolizing enzymes such as CYP1A, CYP2A, CYP2B, CYP2C,  CYP4F12, the 
carboxyesterases CES1 and CES2, UGT1A1, UGT1A3, UGT1A6,  as well as the drug 
transporter multidrug resistance gene MDR1 (98-103). 
 DNA binding, however, is spurred by ligand-dependent activation and to that end 
PXR requires broad ligand specificity in order to function as a “xenobiotic sensor.” The 
first crystal structure of the hPXR-LBD were solved in 2001, which identified a unique 
13 residue flexible loop (residues 309 to 321) flanking the ligand-binding cavity (Figure 
7) (104). In addition, the ligand-binding pocket itself was estimated to have a volume of 
1150 Å3 and relatively hydrophobic in nature (104). Of the 28 residues that line the 
ligand-binding pocket, there are six polar amino acids that commonly form electrostatic 
interactions with ligands, Met243, Ser247, Gln285, Trp299, His407 and Phe420, with the 
large macrolide rifampicin (823 Da) making additional contacts to Ser208 and Arg410 
(95). Interestingly, a single residue Leu308 adjacent to the flexible loop has been 
observed to confer hPXR ligand specificity through mutagenesis studies (105). Although 
extensive structural studies have been performed, experimental evidence is lacking as to 
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whether electrostatic interactions alone within the binding pocket are sufficient to 
stabilize an active conformation of the LBD. Steroid receptor coactivator 1 (SRC-1) is a 
coregulator that enhances NR-mediated transcription by acting as a weak histone 
acetyltransferase and facilitating the recruitment of basal machinery, such a CREB-
binding protein and p300 (106, 107). SRC-1 contains three LXXLL motifs that can bind 
to the surface of PXR adjacent to a highly mobile AF-2 helix forming a stabilizing 
“charge clamp” (108). Previous work has demonstrated that the concurrent binding of a 
prototypic hPXR agonist SR12813 and a 25-mer SRC-1 peptide to the LBD exerted an 
additive effect on receptor stabilization as observed using circular dichroism thermal 
denaturation studies (108). However, despite mounting structural studies, predicting 
ligand regulation of PXR remains to be a confounding problem for drug discovery and 
development. Extensive structure-activity studies of novel PXR activators are required in 
order to identify key pharmacophores that may inform the design of pharmacological 




Figure 6. Ligand-dependent activation of the pregnane X receptor. PXR is 
sequestered in the cytosol by cytoplasmic CAR retention protein (CCRP) and heat shock 
protein 90 (HSP90). Upon ligand binding, PXR dissociates and translocates to the 
nucleus where it can then heterodimerize with RXR and bind to xenobiotic response 
elements (XREM) in the promoter regions of target genes to facilitate transcription. 





Figure 7. Crystal structure of human pregnane X receptor ligand-binding domain. 
Three-dimensional structure of the apo form of hPXR-LBD (PDB ID 1ILG). A flexible 
loop (dark blue, residues Glu309 to Glu321) is well-conserved across species and allows 
for expansion of the hydrophobic pocket to accommodate a variety of ligands. The polar 
residues, Met243, Ser247, Gln285, Trp299, His407, Phe420, Ser208 and Arg410 (shown 
in light blue), line the ligand-binding cavity and commonly form stabilizing electrostatic 
interactions with ligands. A single residue Leu308 (shown in purple) adjacent to the 
flexible loop has been observed to confer hPXR ligand specificity. Crystal structure was 
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Chapter 2: Human Biotransformation of the Non-nucleoside Reverse Transcriptase 
Inhibitor Rilpivirine and a Cross Species Metabolism Comparison 
Abstract 
Rilpivirine is a non-nucleoside reverse transcriptase inhibitor used to treat HIV-1. 
In the present study, the pathways responsible for the biotransformation of rilpivirine 
were defined. Using human liver microsomes, the formation of two mono- and two di-
oxygenated metabolites were detected via ultra high-performance liquid chromatography-
tandem mass spectrometry (UHPLC-MS/MS). Mass spectral analysis of the products 
suggested that these metabolites resulted from oxygenation of the 2,6-dimethylphenyl 
ring and methyl groups of rilpivirine. Chemical inhibition studies and cDNA-expressed 
cytochromes P450 (CYP) assays indicated that oxygenations were catalyzed primarily by 
CYP3A4 and CYP3A5. Glucuronide conjugates of rilpivirine and a 
monomethylhydroxylated metabolite of rilpivirine were also detected and were found to 
be formed by UDP-glucuronosyltransferases (UGTs), UGT1A4 and UGT1A1, 
respectively. All metabolites that were identified in vitro were detectable in vivo. Further, 
targeted UHPLC-MS/MS-based in vivo metabolomics screening revealed that rilpivirine 
treatment versus efavirenz treatment may result in differential levels of endogenous 
metabolites, including tyrosine, homocysteine and adenosine. Rilpivirine 
biotransformation was also assessed across species using liver microsomes isolated from 
a range of mammals, and the metabolite profile identified using human liver microsomes 
was largely conserved for both oxidative and glucuronide metabolite formation. These 
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studies provide novel insight into the metabolism of rilpivirine and the potential 
differential effects of rilpivirine- and efavirenz-containing antiretroviral regimens  
on the endogenous metabolome. 
Introduction 
Rilpivirine (RPV; EdurantTM), 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-
dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile, is a more recently developed 
non-nucleoside reverse transcriptase inhibitor that has been FDA approved for oral 
administration in combination therapy for the treatment of drug-naïve individuals 
infected with the human immunodeficiency virus (HIV)-1 (1). RPV is a cyanovinyl 
diarylpyrimidine and as such has inherent molecular flexibility, allowing for multiple 
modes of allosteric binding within the hydrophobic binding pocket of the HIV reverse 
transcriptase; therefore, RPV has a higher genetic barrier to resistance than the initially 
developed non-nucleoside reverse transcriptase inhibitors, efavirenz and nevirapine (2, 
3). In addition, because of its antiviral efficacy, RPV is being developed as an injectable, 
long-acting formulation for potential use in HIV pre-exposure prophylaxis (4, 5). ECHO 
and THRIVE clinical trials, comparing RPV-tenofovir-emtricitabine (CompleraTM) 
treatment to that of efavirenz-tenofovir-emtricitabine (AtriplaTM), demonstrated that the 
RPV co-formulation has more potent antiviral activity and fewer adverse side effects 
relative to a daily antiretroviral efavirenz-based regimen. In these studies, the most noted 
adverse events associated with the efavirenz-containing regimen were psychiatric 
symptoms and rash; however, the molecular mechanism(s) that underlie the differences in 
the safety profiles of RPV-containing versus efavirenz-containing regimens are unknown 
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(6, 7). While we recently demonstrated that the primary metabolite of efavirenz, 8-
hydroxyefavirenz, may play a causal role in efavirenz-mediated toxicities, including 
hepatic and neuronal toxicity, this type of analysis is not yet possible for RPV as the  
metabolites of this drug have yet to be defined (8, 9).  
The cytochromes P450 (CYP) superfamily of heme-containing monooxygenases 
play a major role in the metabolism of a variety of clinically relevant drugs including 
many antiretrovirals. The package inserts for EdurantTM and CompleraTM state that RPV 
is primarily metabolized in the liver by CYP3A4 (10, 11); however, primary data 
detailing the identities of the RPV metabolites and the relative contributions of individual 
CYP isozymes to the formation of these metabolites have yet to be reported. In addition, 
a potential role for conjugative metabolism of RPV by phase II drug metabolizing 
enzymes including UDP-glucuronosyltransferases (UGTs) has yet to be demonstrated. 
Since RPV is taken in combination with other therapeutic agents, defining the routes of 
RPV metabolism should help to facilitate a more robust and reliable prediction of 
potential drug-drug interactions involving RPV. Further, elucidation of the pathways of 
RPV metabolism may lend mechanistic insight to the understanding of potential inter-
individual differences in RPV exposure and clearance.  
The objectives of this study were to: 1) comprehensively characterize the 
biotransformation of RPV in vitro through the utilization of human liver microsomes, 
cDNA-expressed CYP and UGT isozymes as well as primary human hepatocytes 
analyzed by ultra high-performance liquid chromatography-tandem mass spectrometry 
(UHPLC-MS/MS); 2) gain an understanding of the profiles of endogenous small 
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molecules that regulate key cellular processes in individuals receiving CompleraTM versus 
AtriplaTM in order to spur the elucidation of molecular mechanism(s) that may underlie 
the observed differences in the safety profiles of RPV and efavirenz clinically. 
Collectively, these data lend novel insight into the routes of RPV metabolism which we 
anticipate will help to facilitate the prediction of drug-drug interactions involving RPV. 
Further, these studies provide a foundation for a mechanistic understanding of the 
pathways that modulate RPV exposure in vivo.   
Materials and Methods 
Materials 
Rilpivirine (RPV) was obtained through the National Institutes of Health AIDS 
Research and Reference Reagent Program (Germantown, MD). Dimethyl sulfoxide 
(DMSO) was used as the vehicle for all reagents and purchased from Mediatech Inc. 
(Manassas, VA). (+)-N-3-benzylnirvanol, furafylline, ketoconazole, sulfaphenazole and 
quinidine were purchased from Sigma-Aldrich, Co. (St. Louis, MO), and 2-phenyl-2-(1-
piperidinyl)propane (PPP) from Santa Cruz Biotechnology Inc. (Santa Cruz, CA).  
RPV metabolism by liver microsomes, cDNA-expressed CYPs and cDNA-expressed 
UGTs 
RPV (20 µM) was incubated with the following liver microsomes (Xenotech 
LLC., Lenexa, KS) at a concentration of 2 mg/ml: human (mixed sex, pool of 50), beagle 
dog (male, pool of 8), Golden Syrian (GS) hamster (male, pool of 100), Hartley Albino 
(HA) guinea pig (male, pool of 50), Sinclair minipig (male, pool of 3), cynomolgus 
(CYN) monkey (male, pool of 10), rhesus monkey (male, pool of 6), BALB/c mouse 
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(male, pool of 800), CD1 mouse (male, pool of 1000), New Zealand (NZ) rabbit (male, 
pool of 8) and Sprague Dawley (SD) rat (male, pool of 433). For CYP and UGT 
individual contribution experiments, 20 µM RPV was incubated with the following 
cDNA-expressed enzymes (SupersomesTM, BD Biosciences): CYP1A2, -2B6, -2C8, -
2C9, -2C19, -2D6, -3A4, -3A5 and UGT1A1, -1A3, -1A4, -1A6, -1A7, -1A8, -1A9, -
1A10, -2B4, -2B7, -2B15 and -2B17 at concentrations of 10 pmol/ml and 0.2 mg/ml, 
respectively.  
Liver microsomes (2 mg/ml) were pre-incubated with RPV at 37°C for 5 min in 
100 mM potassium phosphate buffer pH 7.4 prior to the addition of an NADPH-
regenerating system (BD Biosciences). RPV incubations with human liver microsomes 
and different species liver microsomes proceeded at 37°C for a total of 30 min. 
Formation of glucuronidated metabolites in the liver microsome preparations required the 
simultaneous addition of NADPH and a UGT reaction mix (BD Biosciences), containing 
25 mM uridine 5’-diphosphoglucuronic acid (UDPGA) and alamethicin, and reactions 
proceeded at 37°C for 60 min.   
cDNA-expressed CYPs (10 pmol/ml) were pre-incubated with RPV at 37°C for 5 
min in 100 mM potassium phosphate buffer pH 7.4 prior to the addition of an NADPH-
regenerating system from which the reaction proceeded at 37°C for a total of 30 min. 
cDNA-expressed UGT assays, however, required a modified reaction preparation. RPV 
was pre-incubated for 30 min at 37°C in 100 mM potassium phosphate buffer pH 7.4 
with 10 pmol/ml CYP3A4 and an NADPH-regenerating system in order to allow for 
hydroxylated metabolite formation, to which the UDPGA and alamethicin-containing 
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reaction mix was added. Glucuronide metabolite formation was then initiated by the 
addition of 0.2 mg/ml of each individual UGT isozyme and reactions proceeded at 37°C 
for an additional 60 min.  
Chemical inhibition of CYPs was performed by pre-incubating 2 mg/ml human 
liver microsomes for 5 min in a reaction mixture containing a NADPH-regenerating 
system, 100 mM potassium phosphate buffer pH 7.4 and the following concentrations of 
inhibitor or vehicle: 20 µM furafylline (CYP1A2 inhibitor), 30 µM PPP (CYP2B6 
inhibitor), 20 µM sulfaphenazole (CYP2C9 inhibitor), 10 µM (+)-N-3-benzylnirvanol 
(CYP2C19 inhibitor), 1 µM quinidine (CYP2D6 inhibitor), 1 µM ketoconazole (CYP3A4 
and -3A5 inhibitor) and 0.2% DMSO. These final concentrations of reagents were based 
on previously reported studies (12-14). Following the 5 min pre-incubation at 37°C, RPV 
was added to each inhibitor or DMSO control treatment, and the reactions were allowed 
to proceed at 37°C for a total of 30 min. 
The resulting 100 µl reaction volumes from the previously described metabolism 
assays were quenched with 100 µl of acetonitrile at the indicated times and incubated on 
ice for 10 min prior to centrifuging at 10,000 × g for 10 min at 4°C. Following 
centrifugation, supernatants of these assays were dried under vacuum before 
reconstituting in 100 µl of methanol, from which 1 µl was injected for UHPLC-MS/MS 
analysis. 
UHPLC-MS/MS analysis of RPV oxygenated and glucuronide metabolites 
A UHPLC-MS/MS method was developed and optimized for the detection of 
RPV metabolites using a Dionex UltiMate 3000 UHPLC system (Thermo Scientific, 
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Pittsburgh, PA) coupled to a Thermo Scientific TSQ Vantage Triple Stage Quadrupole 
mass spectrometer. Samples were resolved using a Polaris C18-A column (5 µm, 100 × 
2.0 mm; Agilent Technologies, Santa Clara, CA) at a flow rate of 0.4 ml/min. A multi-
step gradient was implemented using mobile phases A (water, 0.1% formic acid) and B 
(acetonitrile, 0.1% formic acid): 10% B for 0.0 to 1.0 min, increased from 10% B to 55 
B% over 1.0 to 8.0 min, held at 100% B from 8.0 to 8.3 min and then decreased to 10% B 
for 8.3 to 10 min for column re-equilibration. The electrospray ionization interface was 
set to positive ion mode and the following instrument parameters were used: ion transfer 
capillary temperature, 300°C; spray voltage, 5500 V; sheath and auxillary nitrogen gas 
pressures, 60 and 15, respectively; collision energy, 30 V for RPV and oxygenated 
metabolites and 60 V for glucuronidated metabolites. Metabolite identification was 
initially performed in product ion (MS/MS) mode, and selected reaction monitoring 
(SRM) mode was used for the detection of the relative abundance levels of metabolites. 
Metabolites were identified as those ions with a signal-to-noise ratio of five or greater 
that exhibited NADPH- and/or UDPGA-dependence. The following transitions in SRM 
mode were monitored (parent mass, Q1→product ion, Q3): 367→195 m/z (RPV), 
383→222 m/z (monohydroxylated RPV; M1 and M2), 399→183 m/z (dihydroxylated 
RPV; M3), 399→196 m/z (dihydroxylated RPV; M4), 543→367 m/z (RPV glucuronide 
conjugate; M5), 559→383 m/z (monohydroxylated RPV glucuronide conjugate; M6) and 
575→399 m/z (dihydroxylated RPV glucuronide conjugate; M7). The approximate 
retention times for metabolites M1 through M7 were 5.51, 5.66, 5.78, 5.88, 5.74, 5.90, 
and 5.32 min, respectively, and 6.48 min for RPV. 
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RPV treatment of primary human hepatocytes 
Six- and twelve-well plates of primary human hepatocytes with matrigel overlay 
were purchased from Xenotech, LLC. that had been isolated from three individual donors 
(Lots 1155, 1157 and 1158). Ages in years and sex of donors were as follows: 43 female, 
59 female and 36 male. Cell viabilities were reported to be 74.7%, 77.9% and 74.9%, 
respectively. Hepatocytes were incubated overnight in Williams’ Medium E (Invitrogen, 
Carlsbad, CA) supplemented with 10% fetal bovine serum, 1% penicillin-streptomycin 
and 1% L-glutamine at 37°C in a 5% CO2 humidified environment. Prior to treatment, 
hepatocytes were placed into fresh medium to which either 0.1% DMSO vehicle or 10 
µM RPV were added for 6, 12 and 24 h incubations. Medium from each DMSO and RPV 
time point was collected, dried under vacuum and reconstituted in 100 µl of methanol of 
which 1 µl was injected onto the UHPLC-MS/MS system for analysis.  
Human plasma and urine sample preparation for UHPLC-MS/MS analysis  
De-identified plasma and urine samples were obtained from participants (a total 
of six) already on an antiretroviral drug regimen and had been recruited by the Drug 
Development Unit of the Johns Hopkins University School of Medicine Division of 
Clinical Pharmacology after providing written informed consent for participation in a 
protocol approved by the institutional review board of the Johns Hopkins Medical 
Institutions. Blood and urine samples were obtained from three HIV-1 infected 
individuals receiving CompleraTM, a co-formulation of RPV-tenofovir-emtricitabine, and 
from three HIV-1 infected individuals receiving AtriplaTM, a co-formulation of efavirenz-
tenofovir-emtricitabine. Ages in years and sex of participants being treated with 
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CompleraTM were as follows: 29 male, 45 female and 42 male. Ages in years and sex of 
participants being treated with AtriplaTM were as follows: 50 male, 58 female and 40 
male. Whole blood was centrifuged for 10 min at 1,100 × g in EDTA-coated tubes, from 
which the resulting supernatant was collected as plasma and live virus was heat 
inactivated for 10 min at 60°C. Urine was centrifuged for 10 min at 12,000 × g and the 
resulting supernatant was collected. For UHPLC-MS/MS analysis, 100 µl of plasma or 
urine was extracted with 500 µl of acetonitrile, incubated on ice for 10 min, followed by 
centrifugation at 10,000 × g for 10 min. For RPV metabolite detection, CompleraTM 
clinical samples were dried under vacuum and then six individual extracts of either 
plasma or urine were pooled and reconstituted in a total of 100 µl of methanol, of which 
5 µl was injected on the UHPLC-MS/MS system for analysis. 
UHPLC-MS/MS-based targeted screen of plasma and urine endogenous 
metabolomic profiles 
Plasma and urine from the previously described CompleraTM clinical samples 
were utilized in a targeted screen of endogenous small molecule metabolites. The 
metabolic profiles of these samples were further analyzed in comparison to plasma and 
urine of HIV-infected individuals receiving therapeutic treatment with AtriplaTM. Non-
infected, antiretroviral untreated human plasma was prepared by the manufacturer using 
an EDTA anticoagulant (Lots BRH642964, BRH642965, BRH642967) as the 
experimental samples were and urine (Lots BRH720679, BRH720681, BRH720682) that 
was purchased from Bioreclamation, LLC (Westbury, NY) was processed in the same 
manner as the experimental samples. Separate positive ion and negative ion mode 
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UHPLC-MS/MS methods were developed and optimized for the detection of a range of 
metabolites using a Dionex UltiMate 3000 UHPLC system coupled to a Thermo 
Scientific TSQ Vantage Triple Stage Quadrupole mass spectrometer using the same 
instrument parameters as defined above. Samples were resolved using a Polaris C18-A 
column (5 µm, 100 × 2.0 mm; Agilent Technologies). The positive ion mode method 
used a multi-step gradient of mobile phases A (water, 0.5% acetic acid) and B (methanol, 
0.5% acetic acid): 5% B for 0.0 to 1.1 min at 0.3 ml/min, increased from 5 to 95% B for 
1.1 to 4.5 min at 0.3 ml/min, held at 95% B for 4.5 to 5.0 min at 0.4 ml/min, then 95% B 
for 5.0 to 5.1 min at 0.3 ml/min and the column was re-equilibrated with 5% B from 5.1 
to 6 min at 0.3 ml/min. The negative ion mode method used a flow gradient at 0.35 
ml/min of mobile phases A (water, 0.1% formic acid) and B (acetonitrile, 0.1% formic 
acid): 10% B for 0.0 to 0.9 min, increased from 10 to 90% B for 0.9 to 4.0 min and the 
column was re-equilibrated with 10% B for 4.0 to 5 min.  Extracted plasma and urine 
samples as previously described were reconstituted in either 50 µl of mobile phase A 
(water, 0.1% formic acid) for analysis by positive ion mode or 50 µl of a 1:1 solution of 
mobile phase A to methanol for negative ion mode analysis, of which 5 µl was injected 
for both UHPLC-MS/MS analyses. SRM mode transitions were developed for the 
detection and determination of relative abundance levels of each endogenous metabolite 
via infusion of synthetic standards for each molecule. The optimized parent mass to 
product ion transitions and collision energies used for each metabolite in this targeted 
screen, as well as their approximate retention times, are listed in supplementary Tables 1 




Table 1. Endogenous metabolites detected by positive ionization. SRM transitions 
were developed for the detection of small molecules present in the plasma and urine of 
individuals receiving either CompleraTM or AtriplaTM antiretroviral therapy and for those 
present in the biological samples of non-infected, antiretroviral untreated individuals. The 
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above metabolites were detected by a positive ion mode UHPLC-MS/MS screen using 
the stated parent mass, [M+H]+, to product ion transitions at the specified collision 
energies (CE) and resulted in the approximate retention times (RT). 
 
Table 2. Endogenous metabolites detected by negative ionization. SRM transitions 
were developed for the detection of small molecules present in the plasma and urine of 
individuals receiving either CompleraTM or AtriplaTM antiretroviral therapy and for those 
present in the biological samples of non-infected, antiretroviral untreated individuals. The 
above metabolites were detected by a negative ion mode UHPLC-MS/MS screen using 
the stated parent mass, [M-H]-, to product ion transitions at the specified collision 






Data analysis was performed using GraphPad Prism (version 6; GraphPad 
Software Inc., San Diego, CA). Statistical significance was determined by Student’s t 
test: *, p < 0.05; **, p < 0.01; and ***, p < 0.001. 
Results 
In vitro detection of RPV oxygenated and glucuronide metabolites 
RPV metabolites were initially characterized using a human liver microsome 
assay and analyzed by UHPLC-MS/MS. Tandem mass spectrometry was used for 
metabolite detection and provided structural information of metabolites based on the 
resulting fragment ions; however, SRM mode allowed for greater sensitivity in detecting 
metabolites and was, therefore, utilized in determining the relative abundance for all 
metabolites. Since the metabolites of RPV were previously unreported, synthetic 
standards of these compounds could not be obtained. Thus, the assays that were 
developed here for the purpose of metabolite identification are solely qualitative. A total 
of seven RPV metabolites were detected using the human liver microsome in vitro assay 
and have been denoted as metabolite 1 (M1) through metabolite 7 (M7). Two 
monohydroxylated metabolites, M1 and M2, (383 m/z) and two dihydroxylated 
metabolites, M3 and M4, (399 m/z) resulted from oxygen insertion into RPV (Figure 1). 
Three glucuronides resulted from direct glucuronidation of RPV (543 m/z) and 
glucuronidation of mono- and di-oxygenated RPV metabolites (559 m/z and 575 m/z, 
respectively) (Figure 2). Hydroxylated metabolites were monitored via SRM mode using 
the following transitions (parent mass, Q1→product ion, Q3): 383→222 m/z (M1 and 
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M2), 399→183 m/z (M3), 399→196 m/z (M4). From a 30 min human liver microsomal 
metabolism assay, M2 was observed to be more abundant than M1 by an approximate 
13.0-fold, and M4 was more abundant than M3 by an approximate 2.3-fold. The 
following transitions were used for monitoring glucuronidated metabolites, 543→367 m/z 
(M5), 559→383 m/z (M6) and 575→399 m/z (M7). From a 60 min human liver 
microsomal metabolism assay in the presence of UDPGA, glucuronide M6 was observed 
to be approximately 1500.0-fold and 163.3-fold greater than the relative abundance of 
M5 and M7 glucuronides, respectively. Other phase II metabolites, such as sulfated 
metabolites, were not detected under these experimental conditions.  
 Chemical structures of these metabolites were proposed through use of individual 
fragmentation spectra observed in MS/MS mode. For monohydroxylated metabolite M1, 
it is proposed that fragment ions 179.42, 195.15, 206.37 and 221.82 m/z correspond to the 
loss of C9H14N4, C9H14N4O, C10H14N4O and C11H16N4O, respectively. The observed 
fragment ions 192.48, 221.63 and 247.59 m/z for the more abundant monohydroxylated 
metabolite M2 are proposed to correspond to the loss of C9H12N4O, C11H16N4O, and 
C13H20N4O, respectively (Figure 3). For dihydroxylated metabolite M3, the fragment ions 
182.82, 209.23, 284.25 and 336.62 m/z are proposed to be consistent with the loss of 
C8H14N4O, C10H16N4O, C16H20N4O and C19H21N5O, respectively (Figure 3). 
Dihydroxylated metabolite M4 fragment ions, 170.24, 194.60 and 234.79 m/z were 
predicted to result from the loss of C7H14N4O, C9H14N4O and C12H18N4O, respectively 
(Figure 3). The structures of glucuronidated metabolites were elucidated in a similar 
fashion and the resulting fragmentation spectra were compared to those observed for 
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RPV or for the predicted corresponding oxidative metabolite. Glucuronide M5 is 
proposed to result from direct N-linked glucuronidation of RPV on the pyrimidine ring as 
evidenced by the fact that human liver microsomes could form this metabolite in the 
absence of an NADPH-regenerating system (required for cytochrome P450-dependent 
activity). In addition, the mass-to-charge ratio of this metabolite as well as the 
fragmentation pattern was consistent with direct conjugation of glucuronic acid to RPV 
itself (Figure 4). The most abundant 167.81 m/z fragment ion of M5 was commensurate 
with the loss of C8H16N4 and was also observed to be a predominant fragment ion for 
RPV (Figure 4). Comparison of the M6 fragmentation spectrum to that of the 
monohydroxymethyl metabolite M2 suggested O-linked glucuronidation occurring after 
initial oxidative metabolism with the fragment ion 382.62 m/z corresponding to loss of 
M2 itself, C22H18N6O, and the fragment ion 220.06 m/z corresponding to the loss of 
C11H16N4O as was similarly observed for the fragmentation of M2 (Figure 4). 
Furthermore, comparison of the fragment ions of M7 to those of the dihydroxymethyl 
metabolite M4 also indicated O-linked glucuronidation after initial oxidative metabolism 
with the fragment ions 170.43, 195.36 and 235.10 m/z proposed to correlate to the loss of 
C7H14N4O, C9H14N4O and C12H18N4O, respectively, as was similarly observed for the 
fragmentation of M4 (Figure 4). From the predicted modes of fragmentation for these 
metabolites, we propose that M1 results from oxygen insertion on the 2,6-dimethylphenyl 
ring, M2 results from oxygen insertion on either methyl group, M3 results from oxygen 
insertion on a methyl group as well as the dimethylphenyl ring and M4 results from 




Figure 1. Extracted ion chromatograms for RPV monohydroxylated metabolites, 
M1 and M2, and dihydroxylated metabolites, M3 and M4. Human liver microsomes 
(2 mg/ml) were incubated with 20 µM RPV for 30 min at 37°C in the presence of an 
NADPH-regenerating system. RPV metabolites were detected by UHPLC-MS/MS in 
SRM mode using the following transitions: 383→222 m/z (M1 and M2), 399→183 m/z 
(M3) and 399→196 m/z (M4). Chromatograms are representative of three individual 
experiments. It should be noted that the y-axes differ for each metabolite due to the 




Figure 2. Extracted ion chromatograms for RPV glucuronidated metabolites, M5, 
M6 and M7. Peaks not indicated as metabolites in these chromatograms were also 
present in the minus-NADPH and UDPGA controls and resulted in intensities below a 
signal-to-noise ratio of five. Human liver microsomes (2 mg/ml) were incubated with 20 
µM RPV for 60 min at 37°C in the presence of an NADPH-regenerating system and 
UDPGA. Metabolites were detected by UHPLC-MS/MS in SRM mode using the 
following transitions: 543→367 m/z (M5), 559→383 m/z (M6) and 575→399 m/z (M7). 
Chromatograms are representative of three individual experiments. It should be noted that 




Figure 3. Fragmentation spectra of monohydryoxylated metabolites M1 and M2 
(top) and dihydroxylated metabolites M3 and M4 (bottom). Proposed modes of 
fragmentation are indicated by the fragment ion corresponding to the appropriate mass-
to-charge ratio. Human liver microsomes (2 mg/ml) were incubated with 20 µM RPV for 
30 min at 37°C in the presence of an NADPH-regenerating system. Metabolites were 
detected in MS/MS mode using parent masses of 383 m/z for M1 and M2 and 399 m/z for 




Figure 4. Fragmentation spectra of RPV (top) and glucuronidated metabolites M5 
(top), M6 and M7 (bottom). Proposed modes of fragmentation are indicated by the 
fragment ion corresponding to the appropriate mass-to-charge ratio. Human liver 
microsomes (2 mg/ml) were incubated with 20 µM RPV for 60 min at 37°C in the 
presence of an NADPH-regenerating system and UDPGA. Metabolites were detected in 
MS/MS mode using parent masses of 367, 543, 559 ad 575 m/z for RPV, M5, M6 and 
M7, respectively. Spectra are representative of three individual experiments. 
CYP3A4 and CYP3A5 are primarily responsible for the oxidative metabolism of 
RPV 
Following identification of RPV metabolites, cDNA-expressed CYPs were 
employed in order to determine which CYP isozymes had the ability to catalyze the 
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formation of RPV metabolites. The cDNA-expressed CYPs used in these experiments 
were CYP1A2, -2B6, -2C8, -2C9, -2C19, -2D6, -3A4 and -3A5 and are representative of 
the principle drug metabolizing CYPs expressed in human liver (15). CYP3A5 was found 
to metabolize RPV to M1, M2, M3 and M4 metabolites at the greatest abundance, 
followed by CYP1A2 and CYP3A4 (Figure 5). CYP2C19 also displayed the ability to 
catalyze the formation of metabolite M3, while relatively minor formation of M3 by 
CYP2C9 was also observed. 
 Chemical inhibition experiments were performed in an effort to probe the role of 
each CYP in the biotransformation of RPV in a system in which all of the 
abovementioned isozymes were present. Human liver microsomes were pre-incubated for 
5 min with DMSO vehicle or CYP inhibitor prior to the addition of RPV. Treatment of 
microsomes with 1 µM ketoconazole, which is an inhibitor of both CYP3A4 and 
CYP3A5 due to their high amino acid sequence similarities, resulted in the most 
significantly decreased formation of M1, M2, M3 and M4 metabolites relative to the 
DMSO control, with approximate decreases of 33.3 ± 6.3%, 30.5 ± 11.1%, 4.6 ± 2.3% 
and 8.1 ± 2.8%, respectively (n=3 ± SD). In addition, M1 formation was inhibited by 30 
µM PPP (CYP2B6 inhibitor), 20 µM sulfaphenazole (CYP2C9 inhibitor) and 10 µM (+)-
N-3-benzylnirvanol (CYP2C19 inhibitor) with decreases of 58.1 ± 17.2%, 64.8 ± 16.7% 
and 49.1 ± 17.4%, respectively, relative to DMSO control. (+)-N-3-benzylnirvanol 
additionally inhibited M2 formation with a decrease of 51.8 ± 17.2% as compared to 
control incubations. PPP and (+)-N-3-benzylnirvanol inhibited M3 formation as well with 
decreases of 59.5 ± 14.2% and 53.4 ± 14.3%, respectively, relative to the control 
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samples. Pre-treatment with furafylline (20 µM; CYP1A2 inhibitor) and 1 µM quinidine 
(CYP2D6 inhibitor) did not result in abrogation of oxidative metabolite formation.  
Since RPV and the structurally similar antiretroviral drug etravirine were 
previously demonstrated to increase CYP3A4 mRNA expression (16-18), we tested 
whether RPV had the ability to autoinduce its own metabolism using primary human 
hepatocytes. Hepatocytes isolated from three donors were treated with either DMSO 
vehicle or 10 µM RPV for 6, 12 or 24 h. Hepatocyte medium was collected after each 
time point for UHPLC-MS/MS analysis (Figure 6). Hydroxylated metabolites, M1, M2, 
and M4 were detectable at all time points with the exclusion of M3, which was only 
observed at 6 h and 24 h. Glucuronides M5 and M6 were present at each time point 
examined following RPV treatment, however, glucuronide M7 was not detected in the 
medium of any of the three hepatocyte preparations. While metabolites M1 and M2 
exhibited a trend towards an increase in abundance over 24 h of RPV treatment, these 
levels did not reach statistical significance; interestingly, an increase in the mRNA 
expression of CYP3A4 over time was indeed observed with fold changes of 7.4-fold 
(range, 2.3- to 17.4-fold), 8.8-fold (range, 3.05- to 13.6-fold) and 19.5-fold (range, 3.02- 




Figure 5. Relative contribution of individual drug metabolizing CYPs (left panel) 
and UGTs (right panel) to RPV metabolite formation. cDNA-expressed CYPs (10 
pmol/ml) were incubated with 20 µM RPV for 30 min at 37°C in the presence of an 
NADPH-regenerating system. For UGT assays, cDNA-expressed CYP3A4 (10 pmol/ml) 
was pre-incubated with 20 µM RPV, an NADPH-regenerating system and UDPGA from 
30 min at 37°C to which 0.2 mg/ml cDNA-expressed UGTs were added for an additional 
60 min incubation. Metabolite formation was detected by UHPLC-MS/MS in SRM mode 
using the following transitions: 383→222 m/z (M1 and M2), 399→183 m/z (M3), 
399→196 m/z (M4), 543→367 m/z (M5) and 559→383 m/z (M6). Glucuronide M7 was 
not detected under the UGT assay conditions. Data are representative of the mean relative 




Figure 6. Metabolites detected in medium collected from RPV-treated primary 
human hepatocytes. Hepatocytes from three donors were treated with either DMSO or 
10 μM RPV for 6, 12 and 24 h prior to medium collection for UHPLC-MS/MS analysis 
in SRM mode using the following transitions: 383→222 m/z (M1 and M2), 399→183 m/z 
(M3), 399→196 m/z (M4), 543→367 m/z (M5) and 559→383 m/z (M6). Glucuronide M7 
formation was not detectable for any of the hepatocyte treatments. Data are representative 
of the mean relative intensities for three separate hepatocyte preparations n=3 ± 28 SD. 
UGT1A1 and UGT1A4 contribute to glucuronidation of RPV and monooxygenated 
metabolite M2  
In order to determine which individual UGT isozymes contribute to the formation 
of glucuronidated metabolites of RPV, denoted here as M5, M6 and M7, assays were 
performed using cDNA-expressed UGTs. Metabolite M5 was formed by direct N-linked 
glucuronidation of RPV on the pyrimidine ring in a non-NADPH-dependent manner as 
determined by incubation with human liver microsomes. The formation of glucuronides 
M6 and M7 were observed to be NADPH-dependent, suggesting initial oxygenation of 
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RPV prior to UGT-mediated conjugation with glucuronic acid. As such, CYP3A4 was 
used for co-incubations with individual cDNA-expressed UGT isozymes in the presence 
of RPV, a NADPH-regenerating system and UDPGA in order to ensure that the 
oxygenated metabolites were formed at levels that would allow for the facile detection of 
the subsequent glucuronide conjugated metabolites M6 and M7. The cDNA-expressed 
UGT isozymes used for these assays were UGT1A1, -1A3, -1A4, -1A6, -1A7, -1A8, -
1A9, -1A10, -2B4, -2B7, -2B15 and -2B17, all of which are expressed in human liver 
(19). UGT1A4 was found to be primarily responsible for the formation of M5, and 
UGT1A1 was found to be primarily responsible for the formation of M6 (Figure 5). 
Glucuronide M7 was not formed under these experimental conditions using any of the 
UGTs tested. 
In vivo detection of RPV metabolites in the plasma and urine of individuals 
receiving CompleraTM  
In an effort to determine whether the metabolites that were identified through our 
in vitro studies were also formed in vivo, RPV metabolites were measured in plasma and 
urine collected from individuals receiving the RPV-containing drug CompleraTM, a co-
formulation of RPV-tenofovir-emtricitabine The UHPLC-MS/MS SRM transitions 
developed for the analysis of in vitro metabolite formation by human liver microsomes 
and cDNA-expressed CYP and UGT isozymes were employed in detecting oxygenated 
and glucuronidated RPV metabolites in these clinical samples. While all of the 
metabolites that were identified in vitro were indeed detectable in vivo, variation in the 
abundance of metabolites was observed across the three subjects (Figure 7). Further, 
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although M7 was detectable in all of the urine samples that were analyzed, this 
metabolite was present in the plasma of only one subject. Monohydroxylated metabolites, 
M1 and M2, were more abundant in plasma than dihydroxylated metabolites, M3 and 
M4, while M4 was the most abundant oxygenated metabolite detected in urine. M5 was 
the most abundant glucuronide in plasma while M5 and M6 were observed to be similarly 
more abundant than glucuronide M7 in urine. Relative RPV plasma levels were 
determined to be approximately 70% of the combined non-metabolized drug and 
metabolite plasma levels in these subjects. Glucuronide M5 accounted for 24-34% of this 
total, followed by glucuronide M6 with 5-10% and monooxygenated M2 with 1-2%. M1, 
M3 and M4 metabolites accounted for <1% of the total. In contrast, RPV was found to be 
a relatively minor component of the urine collected as it only accounted for 
approximately <1% of the collective non-metabolized drug and metabolite levels in urine. 
The glucuronide urine levels for M5 and M6 were approximately 50% of total detectable 




Figure 7. In vivo detection of RPV metabolites, M1 through M4 (top) and M5 
through M7 (bottom) in human plasma and urine. Samples were collected from 
clinical subjects on a RPV-based antiretroviral regimen. Plasma and urine were extracted 
with acetonitrile in preparation for UHPLC-MS/MS analysis. Metabolites were detected 
in SRM mode using the following transitions: 383→222 m/z (M1 and M2), 399→183 m/z 
(M3), 399→196 m/z (M4), 543→367 m/z (M5), 559→383 m/z (M6) and 575→399 m/z 





Comparison of CompleraTM and AtriplaTM endogenous metabolomic profiles using 
a UHPLC-MS/MS targeted screen 
A novel UHPLC-MS/MS-based metabolomics screen was developed in an effort 
to characterize differences in the endogenous metabolomes of HIV-infected individuals 
receiving CompleraTM (RPV-tenofovir-emtricitabine) or AtriplaTM (efavirenz-tenofovir-
emtricitabine). While the purpose of the analysis was to probe for variation in the levels 
of endogenous small molecules that participate in critical cellular processes in subjects 
being treated with each of these drugs, plasma and urine samples from HIV negative 
individuals that had not received CompleraTM or AtriplaTM were also measured. The latter 
samples were used to provide a context for understanding levels of these molecules in 
human subjects that have not previously been treated with either drug. In this screen, 
nineteen total metabolites, including essential and non-essential amino acids, nucleotides 
and key intermediates of the citric acid cycle, methionine-homocysteine cycle and urea 
cycle were targeted for detection by UHPLC-MS/MS (Tables 1 and 2) in the plasma and 
urine collected from both drug-treated groups as well as the non-infected, antiretroviral 
untreated group. Of the detectable endogenous metabolites, ten exhibited significant 
differences in relative abundance levels in the comparison of plasma and urine samples 
from the two treatment groups (Figure 8). Specifically, aspartate, glutamic acid, histidine, 
uridine, lysine and arginine were observed at lower levels in the plasma of those subjects 
treated with AtriplaTM. In contrast, levels of adenosine, homocysteine and tyrosine in 
plasma were higher in these subjects as compared to subjects receiving CompleraTM. 
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Finally, significantly lower levels of aspartate and succinic acid were also observed in the 





Figure 8. Metabolic profiles of plasma and urine collected from HIV-infected 
individuals receiving either CompleraTM (RPV-tenofovir-emtricitabine) or 
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AtriplaTM (efavirenz-tenofovir-emtricitabine). The observed relative abundances of 
each analyte are shown alongside those in plasma and urine collected from non-infected, 
antiretroviral untreated individuals. The data for the ten endogenous metabolites, of the 
nineteen monitored, that were determined to be significantly different in either the 
plasma, urine or both between the drug-treated groups are shown. Plasma and urine was 
extracted with acetonitrile in preparation for UHPLC-MS/MS analysis. The relative 
abundance of each metabolite was detected in SRM mode using either positive or 
negative ionization. The transitions that were used for each analyte are listed in Tables S1 
and S2. Data are representative of the mean relative intensities for three subjects per 
treatment, n=3 ± SD. Statistical significance of AtriplaTM treatment from CompleraTM are 
indicated as: *, p < 0.05; **, p < 0.01; and ***, p < 0.001. 
RPV oxidative and glucuronide metabolite formation across species 
The metabolism of RPV by a range of species used in preclinical drug 
development was investigated in order to determine whether biotransformation of RPV 
by any of these animals paralleled what we observed in humans. Using liver microsomes, 
monohydroxylated metabolites, M1 and M2, as well as dihydroxylated metabolites, M3 
and M4, were found to be formed at varying abundance by each species of the ten 
mammals that were investigated in these studies (Figure 9). Interestingly, the formation 
of M1, M2 and M3 by Golden Syrian hamster liver microsomes were an approximate 
11.0-fold, 4.6-fold and 4.3-fold, respectively, greater than production by human liver 
microsomes. However, all of these species formed metabolite M4 at lower levels than 
was observed using human liver microsomes. RPV glucuronide formation was observed 
 75 
 
to also be rather conserved across species (Figure 10). The abundance of glucuronide, 
M5, which we have previously identified in human plasma to be the predominant in vivo 
glucuronidated metabolite, was greatest in the beagle, Sinclair minipig, rhesus monkey 
and New Zealand rabbit liver microsomal incubations. The lowest levels of M5 
production was observed when Golden Syrian hamster, BALB/c mouse and CD1 mouse 
liver microsomes were employed. In addition, the formation of the glucuronidated 






Figure 9. Comparison of RPV oxidative metabolism across species. Liver microsomes 
(2 mg/ml) from the following species: human, beagle, Golden Syrian (GS) hamster, 
Hartley Albino (HA) guinea pig, Sinclair minipig, cynomolgus (CYN) monkey, rhesus 
monkey, BALB/c mouse, CD1 mouse, New Zealand (NZ) rabbit and Sprague Dawley 
(SD) rat were incubated with 20 µM RPV for 30 min at 37°C in the presence of an 
NADPH-regenerating system. RPV metabolites were detected by UHPLC-MS/MS in 
SRM mode using the following transitions: 383→222 m/z (M1 and M2), 399→183 m/z 
(M3), 399→196 m/z (M4). Data are representative of the mean relative intensities for n=3 
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± SD. Statistical significances from human liver microsome metabolite formation are 




Figure 10. Comparison of RPV phase II metabolism across species. Liver 
microsomes (2 mg/ml) from the following species: human, beagle, Golden Syrian (GS) 
hamster, Hartley Albino (HA) guinea pig, Sinclair minipig, cynomolgus (CYN) monkey, 
rhesus monkey, BALB/c mouse, CD1 mouse, New Zealand (NZ) rabbit and Sprague 
Dawley (SD) rat were incubated with 20 µM RPV for 60 min at 37°C in the presence of 
an NADPH-regenerating system and UDPGA. Metabolites were detected by UHPLC-
MS/MS in SRM mode using the following transitions: 543→367 m/z (M5), 559→383 
m/z (M6) and 575→399 m/z (M7). Data are representative of the mean relative intensities 
for n=3 ± SD. Statistical significances from human liver microsome glucuronide 




 In this study, the routes of RPV metabolism were systematically investigated in 
order to identify the metabolites of RPV as well as the enzymes that contribute to the 
formation of these products (Figure 11). In total, seven RPV metabolites were 
characterized. Tandem mass spectral analysis revealed that the oxidative metabolites, 
denoted as M1 through M4, resulted from mono- or di-oxygenation of the 2,6-
dimethylphenyl ring itself or either of the two methyl groups located on this phenyl ring. 
Even though we did indeed observe distinct fragments for M1 and M2, there were a 
number of similarities in the fragmentation spectra of these metabolites that made it 
difficult to definitively assign oxygen insertion onto the methyl group or the 2,6-
dimethylphenyl ring for either of these metabolites; however, due to the fact that the 
methyl group of the 2,6-dimethylphenyl ring may be more readily accessible for 
oxygenation as compared to direct oxygen insertion on one of the carbon atoms within 
the phenyl ring, we propose that it is reasonable for M2 to result from 
methylhydroxylation of RPV since it was observed at an apparent greater abundance than 
M1. Glucuronide M5 resulted from direct N-linked glucuronidation of RPV, and 
glucuronides M6 and M7 were proposed to be produced via O-linked glucuronidation of 
mono- and di- hydroxymethyl metabolites M2 and M4, respectively. Fecal excretion has 
been previously demonstrated to be the primary route of RPV clearance (20). Although 
we did not analyze fecal samples in the present study, using plasma and urine from 
individuals receiving a RPV-containing regimen we were able to demonstrate that all of 
the metabolites that were identified here in vitro were indeed formed in vivo. 
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Complementary liver microsomal metabolism studies were performed in order to 
examine the conservation of RPV biotransformation across species. While the assay 
developed here to monitor metabolite formation were not quantitative, it facilitated the 
identification of RPV metabolites and perhaps lays the foundation for the development of 
a quantitative assay for the measurement of RPV metabolites. Synthetic standards are 
required in order to definitively determine the levels of these molecules since differences 
in ionization could contribute to the observed variability in relative abundances. As such, 
the results presented here can be used to guide the synthesis of RPV metabolite standards 
for this purpose. Interestingly, each of the species investigated in these studies were able 
to form all of the metabolites of RPV that were observed in humans, with Golden Syrian 
hamster liver microsomes being the only to produce several metabolites of RPV to 
greater abundance than human liver microsomes. Further, no additional metabolites 
beyond those that were identified through the human liver microsomal metabolism assays 
were produced in the incubations performed using liver microsomes isolated from the 
non-human animals. These data suggest that several of these animals may have utility as 
preclinical species for use in studies to gain an increased understanding of RPV exposure 
in vivo. 
The present study is the first to report primary data detailing the routes of RPV 
metabolism. As demonstrated through the use of cDNA-expressed CYP isozymes, 
CYP1A2, -3A4 and -3A5 were able to catalyze the oxygenation of RPV to products M1 
through M4. Subsequent chemical inhibition experiments revealed that CYP3A4 and 
CYP3A5 were predominantly responsible for mono- and di-oxygenation of RPV, as the 
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most significant reduction in metabolite formation was observed with the dual CYP3A4/5 
inhibitor ketoconazole. Treatments with furafylline, a mechanism-based inactivator of 
CYP1A2 (21), did not block metabolite formation. This could be the result of 
compensation of the loss of CYP1A2 activity by another CYP isozyme, for instance 
CYP3A4 and/or CYP3A5, resulting in a lack of a significant decrease in RPV 
metabolism following chemical inhibition of CYP1A2. We observed statistically 
significant inhibition of M1 formation following incubation of liver microsomes with 
chemical inhibitors of CYP2B6 (PPP), CYP2C9 (sulfaphenazole) and CYP2C19 ((+)-N-
3-benzylnirvanol); however, RPV was not metabolized to M1 by cDNA-expressed 
CYP2B6, CYP2C9 or CYP2C19. This variability in the catalytic activities of cDNA-
expressed isozymes as compared to human liver microsomes could be the result of 
differences in the protein concentrations of each CYP in these two systems in addition to 
the fact that in human liver microsomes RPV was being concurrently metabolized to all 
of the oxygenated products. As such, the overall kinetics of formation differ in these two 
assays. Still, the studies using both cDNA-expressed isozymes and human liver 
microsomes were congruent and demonstrated a primary role for CYP3A4 and CYP3A5 
in RPV oxidative metabolism.  
A recent report demonstrated that RPV, similar to the non-nucleoside reverse 
transcriptase inhibitors etravirine and efavirenz, was able to activate the pregnane X 
receptor in primary human hepatocytes (17). The pregnane X receptor is a key regulator 
of drug metabolizing enzymes including CYP3A and UGT1A isozymes (22-24). In our 
study, although we were able to recapitulate the increase in CYP3A4 mRNA expression 
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following incubation of primary human hepatocytes with RPV, we did not observe an 
increase in the abundance of RPV metabolites via UHPLC-MS/MS analysis of the 
hepatocyte medium. Oxidative metabolism did not appear to be shunted to glucuronic 
acid conjugation as the glucuronides that were detectable in the hepatocyte medium, 
namely metabolites M5 and M6, also did not exhibit an increase in abundance over the 24 
h incubation time. Although we have previously reported that autoinduction of etravirine 
metabolism is readily detectable following 24 h of incubation with primary human 
hepatocytes (17), longer treatment times may be required to observe this effect using 
RPV. For instance, CYP3A4 protein may not have yet been elevated over the time points 
that we measured. Further, the metabolites may not be stable in culture medium, thereby 
resulting in our inability to detect increases in metabolite levels over time. This would 
need to be tested using synthetic standards for each of these molecules.  
Assays performed using cDNA-expressed UGT isozymes demonstrated that 
UGT1A1 and UGT1A4 were able to catalyze the conjugation of glucuronic acid to 
moonoxygenated metabolite M2 and RPV, respectively. These results correlated well 
with our proposed glucuronide metabolite structures as UGT1A1 is known to facilitate 
alkyl- and aryl-O-glucuronidation while UGT1A4 has been demonstrated to participate in 
the N-glucuronidation of tertiary amines (25). UGT1A1 and UGT1A4 are members of the 
UGT1A gene superfamily and are most abundantly expressed in the human liver. Of note, 
glucuronide M7 was not formed by any of the cDNA-expressed UGT isozymes tested 
under our experimental conditions, nor was this product detectable in hepatocyte medium 
following up to 24 h of incubation with RPV; however, metabolite M7 was detectable in 
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the urine of all three subjects receiving CompleraTM that were analyzed in this study in 
addition to being present in the plasma of one of the subjects. As such, this metabolite 
that was initially identified through the use of human liver microsomes appears to indeed 
be formed in vivo. M7 may be produced by a UGT isozyme beyond those tested and the 
lack of formation in the primary human hepatocytes may be due to inter-individual 
variability (the human liver microsomes are isolated from a pool of 50 donors) and/or 
lower levels of drug metabolizing enzyme expression as a result of the isolation or 
culturing of the hepatocytes. Since this metabolite was observed to be the more minor of 
the glucuronides detected in vivo, its formation may be more sensitive to the 
aforementioned variables. 
We sought to probe for potential differential physiological effects of a RPV-
containing therapy versus an efavirenz-containing therapy through analysis of the plasma 
and urine endogenous metabolomes. Since analysis at the level of the metabolome can 
generate large volumes of data, we opted to prioritize the pathways that we investigated. 
To this end, we developed a targeted UHPLC-MS/MS-based method to detect thirty-two 
intracellular metabolites that have been demonstrated to play a role in maintaining 
cellular homeostasis. Further, while global metabolomics provides relative quantitation of 
intracellular small molecules, a targeted approach allows for markedly improved 
detection of less abundant chemical species. Tyrosine plasma levels were observed to be 
higher in AtriplaTM subjects. In a reaction that predominantly occurs in the liver, the 
essential amino acid phenylalanine is converted to tyrosine via phenylalanine 
hydroxylase (26). Phenylalanine plasma levels, however, were comparable between 
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subject groups, suggesting a potential increase in phenylalanine hydroxylase activity with 
an efavirenz-containing treatment as compared to a RPV-based regimen, thus resulting in 
the increased synthesis of tyrosine byproduct. Homocysteine and adenosine plasma levels 
were also greater with AtriplaTM drug therapy. The S-adenosylmethionine-dependent 
transmethylation pathway, which is extensively active in the liver, is responsible for the 
synthesis of homocysteine and adenosine through the hydrolysis of S-
adenosylhomocysteine via S-adenosylhomocysteine hydrolase (27). Interestingly, 
methionine plasma levels were comparable between treatments. As part of the 
transmethylation cycle, the conversion of homocysteine to methionine is regulated by 
methionine synthase (34); therefore, we would anticipate observing greater methionine 
levels in the plasma AtriplaTM samples. This, however, was not observed suggesting 
possible impairment of methionine synthase activity with AtriplaTM treatment. Moreover, 
it is also plausible that methionine plasma levels remain unchanged as a result of 
immediate conversion to S-adenosylmethionine. The small molecules, S-
adenosylhomocysteine and S-adenosylmethionine, were initially included in this 
metabolomics screen, yet neither was consistently detectable in these biological samples. 
Aspartate and arginine are two examples of metabolites that were both observed 
to be in lower abundance in the plasma collected from the AtriplaTM drug treatment group 
relative to those receiving CompleraTM. Interestingly, lower arginine plasma levels have 
been observed to parallel decreasing HIV RNA levels with an established antiretroviral 
drug regimen (28). Moreover, arginine and aspartate are key components of the urea 
cycle where argininosuccinate synthase catalyzes the conversion of aspartate to 
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argininosuccinate that is further hydrolyzed into arginine and fumarate via 
argininosuccinate lyase, ultimately producing urea (29). Lower arginine and aspartate 
levels would suggest an increase in the activity of both argininosuccinate synthase and 
argininosuccinate lyase enzymes. Separate from its role in the urea cycle, lower aspartate 
plasma levels can result from increased aspartate aminotransferase activity, which 
catalyzes the conversion of the amino acid and α-ketoglutarate to oxaloacetate and 
glutamate, and has served as a biomarker for diagnosing fibrosis and cirrhosis of the liver 
in individuals co-infected with HIV and the hepatitis C virus (30). This proposed 
mechanism is challenging to fully assess since α-ketoglutarate and oxaloacetate were not 
detectable in these samples by UHPLC-MS/MS analysis and glutamic acid plasma levels 
were also observed to be lower in those receiving AtriplaTM. Potential confounding 
factors for our analyses include the fact that the subjects involved in this study could have 
co-morbidities or be concomitantly taking medications that might also have an impact on 
their plasma and urine metabolomes. In addition, due to the small sample size we cannot 
rule out potential effects of the mean age difference between the subjects receiving 
AtriplaTM  or CompleraTM. However, the levels of the endogenous small molecules that 
we measured were consistent amongst individuals within each of the drug treatment 
groups so much so that the standard deviations were less than 5% indicating that there 
may indeed be distinct endogenous small molecule signatures that can be attributed to 
RPV- and efavirenz-containing regimens. Further, these data demonstrate for the first 
time that endogenous metabolites can be readily detected in plasma and urine of 
individuals receiving these drugs and we provide an assay that can be applied broadly in 
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measuring these molecules in biological matrices. Overall, these endogenous 
metabolomic studies need to be further extended to a larger population of individuals for 
both CompleraTM and AtriplaTM subject groups; however, the present findings suggest 
possible biochemical pathways that can be tested for modulation by CompleraTM and 
AtriplaTM. 
 In summary, this study has defined the in vitro routes of phase I (primarily 
CYP3A4/5) and phase II (glucuronic acid conjugation) RPV metabolism. Additionally, 
RPV metabolism was observed to be conserved across a range of mammals and these 
data should inform the selection of preclinical animal models for subsequent 
investigation of RPV pharmacology and/or toxicology in vivo. Taken together, these data 




Figure 11. Schematic summarizing the phase I and phase II metabolism of RPV. 
Monohydroxylated metabolites, M1 and M2, and dihydroxylated metabolites, M3 and 
M4, result from oxygenation of RPV by CYP3A4 and CYP3A5. M5 results from direct 
glucuronic acid conjugation to RPV by UGT1A4. M6 results from glucuronidation of 
monooxygenated metabolite M1 by UGT1A1, and M7 results from glucuronidation of 
dioxygenated metabolite M4, however, the UGT responsible for this conjugation was 
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Chapter 3: Identification of Cytochrome P450 and Uridine Diphosphate 
Glucuronosyltransferase Genetic Variants in Participants of the HIV Prevention 
Trial Network Study HPTN 076 
Abstract  
Rilpivirine (RPV) is a second-generation non-nucleoside reverse transcriptase 
inhibitor FDA-approved in 2011 for administration to treatment-naïve HIV infected 
adults and is under current investigation as long-acting injectable formulation (RPV-LA) 
for use in HIV maintenance therapy as well as in pre-exposure prophylaxis (PrEP). The 
phase II clinical trial HPTN 076 investigated the safety and acceptability of a RPV-LA 
injectable for use in PrEP. We isolated genomic DNA from HIV-uninfected female 
participants (n=136) of the HPTN 076 study for next-generation sequence of the coding 
regions for CYP3A4, CYP3A5, UGT1A1 and UGT1A4 in order to investigate the presence 
of genetic polymorphisms that may impact RPV metabolism. A total of 12 previously 
reported CYP3A4 genetic variants were detected in 56 (41%) participants, 20 previously 
reported CYP3A5 genetic variants were detected in 129 (95%) participants, 8 previously 
reported UGT1A1 genetic variants were detected in 134 (99%) participants, and 20 
previously reported UGT1A4 genetic variants were detected in 135 (100%) participants. 
In addition, RPV and its primary oxidative metabolite 2-hydroxymethyl RPV (M2) were 
quantitated in the plasma of HPTN 076 participants (n=83) taking 25 mg RPV once-daily 
for four weeks. Mean parent and M2 levels were determined to be 77.77 ng/mL ± 57.93 
ng/mL and 3.04 ng/mL ± 1.60 ng/mL, respectively. Further, loss of function CYP3A5 
alleles detected in these HPTN 076 participants demonstrated a trend of decreased 
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metabolite M2 formation. In summary, genetic variants have been identified in the genes 
encoding the enzymes that contribute to RPV metabolism, which could compromise drug 
biotransformation adding to interindividual variability and potentially impact the 
occurrence of drug-associated toxicities. 
Introduction 
Rilpivirine (RPV) is a second-generation non-nucleoside reverse transcriptase 
inhibitor (NNRTI) that was one of a series of diarylpyrimidine (DAPY) small molecules 
designed using a novel multidisciplinary approach by Janssen Pharmaceuticals (1). This 
drug class has an inherent degree of flexibility and rotational freedom that enable DAPY 
molecules to bind in multiple modalities to the NNRTI binding pocket of the HIV reverse 
transcriptase enzyme thereby allowing for adaptation to potential resistance mutations 
(1). RPV was FDA-approved in 2011 for administration to treatment-naïve HIV infected 
adults and because it was found to be highly efficacious and well tolerated with chronic 
oral administration, it was concurrently developed into a long-acting injectable 
formulation (RPV-LA) (2). One can envision that less frequent dosing of an antiretroviral 
due to an extended drug half-life may improve compliance as this is a primary contributor 
to the development of viral resistance. In addition to use for HIV maintenance therapy, 
RPV-LA is presently under investigation for use in pre-exposure prophylaxis (PrEP). 
PrEP is a preventative drug strategy for uninfected adults at risk of acquiring HIV 
by either sexual or blood-born transmission. As of 2015, WHO guidelines recommend 
PrEP should be offered to populations with an HIV infection rate of 3 in 100 people per 
year, which includes but is not limited to serodiscordant couples, men who have sex with 
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men, transgender women and people who inject drugs (3). The notion of dosing a healthy 
individual long-term with an antiretroviral first became most plausible with the 2001 
approval of the nucleoside reverse transcriptase inhibitor tenofovir (TFV).  
As TFV was proven to be an effective agent for use in treating HIV infection, it 
became a clear candidate for further exploration in PrEP under varying formulations and 
in differing target populations. For example, the CAPRISA 004 trial provided the first 
evidence that a 1% TFV microbicide gel applied vaginally before and after sex could 
reduce the risk of infection by 39%, 54% when corrected for adherence, in HIV-
uninfected women (4). TFV, however, is only approved for oral administration as the 
prodrug TDF and is commonly coformulated with the nucleoside analog emtricitabine 
(FTC) as a backbone for NNRTIs, such as efavirenz and RPV, for HIV maintenance 
therapy. To that end, the Preexposure Prophylaxis Initiative (iPrEx) trial was the first 
study to report efficacy for oral dosing of TDF-FTC in seronegative men and transgender 
women, observing a 44% risk reduction in HIV transmission, an overall 92% reduction 
when adjusting for detectable levels of TFV in blood (5). Taking this work a step further 
in serodiscordant couples, our laboratory contributed to the Partners PrEP study showing 
once-daily TDF alone or TDF-FTC decreased the rate of HIV infection by 67% and 75%, 
respectively, with a greater than 85% relative risk reduction in participants who had 
detectable TFV concentrations in blood regardless of the formulation (6). Furthermore, 
the data acquired from pivotal clinical trials, such as iPrEx and Partners PrEP, clearly 
demonstrated that the coformulation of TDF-FTC is effective at reducing the risk of HIV 
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infection through sexual transmission giving way to Truvada as the first, and currently 
the only, approved drug for HIV PrEP in 2012 (7).  
The HPTN 076 study was a phase II clinical trial conducted by the HIV 
Prevention Trials Network to investigate the safety and acceptability of a RPV-LA 
injectable (1200 mg dosed in eight week intervals) for use in PrEP as a potential 
alternative to Truvada (8). HIV-uninfected women (n=136) were recruited across four 
cities for this study: (1) Bronx, New York, (2) Newark, New Jersey, (3) Cape Town, 
South Africa and (4) Harare Zimbabwe. We obtained whole blood from each participant 
for genomic DNA isolation to investigate the presence of genetic polymorphisms in drug 
metabolism enzymes that may impact RPV biotransformation. We have previously 
published that RPV is extensively oxidatively metabolized by the cytochromes P450, 
mainly CYP3A4 and CYP3A5, and RPV as well as its metabolites are primarily 
conjugated by the uridine diphosphate glucuronosyltransferases UGT1A1 and UGT1A4 
(9). Taking this work a step further, we sequenced the coding regions of CYP3A4, 
CYP3A5, UGT1A1 and UGT1A4 in HPTN 076 participants using next-generation 
sequencing. Deleterious and potentially damaging variants were identified in the exonic 
regions of all four genes, however, CYP3A5 genetic variants exhibited the greatest 
frequency (93%) overall. Moreover, loss of function CYP3A5 alleles demonstrated a 
distinct decrease in the formation of RPV’s primarily oxidative metabolite 2-
hydroxymethyl RPV (M2). Further, genetic variants have been identified that could 




Materials and Methods 
Reagents 
 RPV was provided through the National Institutes of Health AIDS Reagents 
Program. Metabolite M2 (2-hydroxymethyl RPV) and rilpivirine-d6 (RPV-d6) were 
synthesized and purchased from Toronto Research Chemicals (Toronto, ON). 
Clinical samples 
Whole blood and plasma was obtained from HIV-uninfected females (n=136) 
enrolled in the HIV Prevention Trials Network Study HPTN 076 across four study sites: 
Bronx Prevention Center CRS, Bronx, NY, USA (n=19); New Jersey Medical School 
Clinical Research Center CRS, Newark, NJ, USA (n=17); Emavundleni CRS, Cape 
Town, South Africa (n=48); Spilhaus Clinical Research Site, Harare, Zimbabwe (n=52) 
(8). The current analysis was approved by the Johns Hopkins Medicine IRB. 
Genomic DNA isolation  
Genomic DNA was isolated from 200 µL of whole blood using the QIAamp 96 
DNA Blood Kit (Qiagen, Valencia, CA). Purified DNA was eluted using 200 µL of 
elution buffer. 
Sample preparation for Next-generation sequencing  
Samples were prepared following the TSCA library preparation guide using 250 
ng of template DNA per reaction. Agencourt AMPure XP beads (Beckman Coulter, Inc., 
Brea, CA) were used for PCR clean-up and library normalization was performed 
according to the TSCA protocol. The final pooled DNA library (6 μL) was diluted in 594 
μL HT1 buffer and spiked with 1% PhiX. One technical control was included per sample 
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batch and runs were sequenced using an Illumina MiSeq sequencing platform generating 
150 bp paired-end reads. 
Next-generation sequencing targeted enrichment design 
Sequencing was performed using the Illumina TruSeq custom amplicon v1.5 kit 
(San Diego, CA). Custom probes targeting the exonic regions of CYP3A4, CYP3A5, 
UGT1A1, and UGT1A4 were generated in silico using Illumina DesignStudio software. 
The chromosomal coordinates used were as follows: CYP3A4 7:99354583 – 7:99381811; 
CYP3A5 7:99245813 – 7:99277621; UGT1A1 2:234668919 – 2:234681945; UGT1A4 
2:234627438 – 2:234681945. The final design included 120 amplicons.  
Next-generation sequencing data analysis  
Secondary analysis of the base calls and Phred-like quality score (Qscore) 
generated by Real Time Analysis software was performed using on-instrument MiSeq 
Reporter software. Reads were mapped to the GRCh37 (hg19) reference assembly using 
a banded Smith-Waterman algorithm and variant calling was carried out using the 
Genome Analysis Toolkit. Variant call format files were annotated using Illumina 
VariantStudio software. Raw variant calls were filtered applying a read depth threshold > 
1500 bases per variant, a minimum base call Qscore of 30 (error rate of 1 in 1000), and 
an alternate variant frequency > 45%, followed by visual inspection using the Integrative 
Genome Viewer. Variants were ultimately cross-referenced with the National Center for 
Biotechnology Information database of Single Nucleotide Polymorphisms and variant 
alleles were assigned using the Karolinska Institutet’s Human Cytochrome P450 Allele 
Nomenclature Database and PharmGKB (10, 11). The phenotypic consequence of 
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missense variants was assigned using SIFT (sorts intolerant from tolerant substitutions; J. 
Craig Venter Institute online tool) and PolyPhen (polymorphism phenotyping; Harvard 
University online tool) in silico prediction tools where amino acid substitutions were 
scored. A SIFT score < 0.05 was suggestive of a damaging amino acid substitution and > 
0.05 a tolerated substitution, whereas a PolyPhen score > 0.908 was suggestive of a 
probably damaging, 0.447-0.908 a possibly damaging, or < 0.447 a benign amino acid 
substitution (12, 13). 
Measurement of plasma concentrations of RPV and oxidative metabolite M2 
Plasma RPV and metabolite M2 concentrations were determined using an ultra-
high performance liquid chromatography-tandem mass spectrometry assay as previously 
published (9). In preparation for mass spectral analysis, RPV and M2 standard stock 
solutions were prepared at 50 µg/mL in 50:50 acetonitrile (ACN):H2O and the internal 
standard (IS) RPV-d6 at 100 ng/mL in ACN. RPV and M2 were diluted to a working 
solution at 16,000 ng/mL in ACN:H2O and a standard curve was generated for each 
analyte using two-fold serial dilutions ranging from 16,000 ng/mL to 7.81 ng/mL. 
Calibration stocks for RPV and M2 were then prepared by diluting each standard curve 
1:10 in blank human plasma for a total volume of 100 µL. Calibrants were vortexed and 
incubated at room temperature (RT) for 30 min. Analytes and HPTN 076 participant 
plasma samples (100 µL) were extracted by adding 200 µL ice-cold IS to precipitate 
plasma proteins. Calibrants and samples were vortexed, incubated at RT for 10 min and 
centrifuged for 10 min at 10,000 x g at 4°C. Supernatant (200 µL) was collected per 
sample and dried under vacuum. Calibrants and unknown samples were reconstituted in 
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200 µL methanol, vortexed, incubated at RT for 10 min prior to centrifugation for 5 min 
at 10,000 x g at 4°C. Resulting supernatants (150 µL) were collected for mass spectral 
analyses, injecting 10 µL per calibrant and unknown sample. In selected reaction 
monitoring mode, fragment ions were detected by positive ionization using the following 
transitions (Q1→Q3): RPV (m/z 367.1→195.2), M2 (m/z 383.0→222.0) and RPV-d6 (m/z 
373.1→230.0). Calibration curves were prepared and analyzed in duplicate for each 
analyte and 12-point standard curves (1600 ng/mL to 0.781 ng/mL) were calculated by 
taking the ratio of analyte peak area over internal standard and fit using a weighted (1/y2) 
linear regression.   
Statistical Analysis 
Statistical analyses were performed using GraphPad Prism (San Diego, CA). 
Two-tailed unpaired t tests were performed and significance was denoted as follows: *, p 
≤ 0·05; **, p ≤ 0·01; ***, p ≤ 0·001. 
Results 
Next-generation sequencing of HPTN 076 clinical samples 
The HIV Prevention Trials Network study HPTN 076 recruited 136 HIV-
uninfected female participants from the Bronx Prevention Center CRS, Bronx, NY 
(n=19), New Jersey Medical School Clinical Research Center CRS, Newark, NJ (n=17), 
Emavundleni CRS, Cape Town, South Africa (n=48) and Spilhaus Clinical Research 
Site, Harare, Zimbabwe (n=52). For this study, we obtained whole blood samples from 
all 136 of these participants to investigate the presence of genetic polymorphisms that 
may impact RPV metabolism. In order to test for the existence of genetic variants, we 
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designed a targeted assay to sequence the exonic regions of CYP3A4, CYP3A5, UGT1A1, 
and UGT1A4. Using this assay, we successfully sequenced 135 of the 136 participants 
(Bronx n=19, New Jersey n=17, Emavundleni n=48, Spilhaus n=51). One individual 
exhibited poor sequencing coverage (≤ 1000 base calls per read) and, therefore, was not 
included in these analyses. 
Targeted sequencing of CYP3A4 
A total of 12 single nucleotide variants (SNVs) for the CYP3A4 mRNA transcript 
were detected in 56 participants (Bronx n=10, New Jersey n=6, Emavundleni n=17, 
Spilhaus n=23) of which carried one or more genetic variant for this gene (Table 1). Of 
the detected CYP3A4 variants, four missense variants rs72552799 (R130Q), rs4986907 
(R162Q, CYP3A4*15A), rs57409622 (R162W) and rs113667357 (Q200H), were detected 
in one (Bronx n=1), five (Bronx n=1, New Jersey n=1, Emavundleni n=1, Spilhaus n=3), 
one (Spilhaus n=1) and two (Emavundleni n=2) participants, respectively. Further, using 
in silico tools, two of the four observed missense variants, rs72552799 and rs57409622, 
were predicted to have a deleterious and damaging impact on protein function and were 





Table 1. CYP3A4 genetic variants detected in HPTN 076 participants. A total of 12 
previously reported CYP3A4 variants were detected in 56 HPTN 076 participants (Bronx 
n=10, New Jersey n=6, Emavundleni n=17, Spilhaus n=23) which carried one or more 
genetic variant for the coding DNA reference sequence NM_017460.5. The functional 
consequence of resulting amino acid mutations denoted as deleterious or tolerated were 
predicted using SIFT and PolyPhen in silico tools.  
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Targeted sequencing of CYP3A5 
A total of 20 SNVs that may impact the protein-coding potential of the CYP3A5 
mRNA transcript were detected in 129 participants (Bronx n=15, New Jersey n=15, 
Emavundleni n=48, Spilhaus n=51) of which carried one or more genetic variant for this 
gene (Table 2). Of the detected CYP3A5 variants, one splice variant rs776746 
(CYP3A5*3), two missense variants rs142823108 (I149T) and rs145774441 (I276T) and 
one frameshift variant rs41303343 (CYP3A5*7, T346Y) were detected in 126 (Bronx 
n=14, New Jersey n=13, Emavundleni n=48, Spilhaus n=51), 2 (Spilhaus n=2), 2 
(Spilhaus n=2) and 33 (Bronx n=0, New Jersey n=2, Emavundleni n=16, Spilhaus n=15) 
participants, respectively. Taken together, all four of these described variants were either 
predicted or have been determined by in vitro assay to be deleterious and have a 
damaging impact on protein function (14). Further, we observed these deleterious 




Table 2. CYP3A5 genetic variants detected in HPTN 076 participants. A total of 20 
previously reported CYP3A5 genetic variants were detected in 129 HPTN 076 
participants (Bronx n=15, New Jersey n=15, Emavundleni n=48, Spilhaus n=51) which 
carried one or more genetic variant for the coding DNA reference sequence 
NM_000777.3. The functional consequence of resulting amino acid mutations denoted as 
deleterious or tolerated were predicted using SIFT and PolyPhen in silico tools.  
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Targeted sequencing of UGT1A1 
A total of 8 SNVs that may impact the protein-coding potential of the UGT1A1 
mRNA transcript were detected in 134 participants (Bronx n=19, New Jersey n=17, 
Emavundleni n=48, Spilhaus n=50) which carried one or more genetic variant for this 
gene (Table 3). Of the detected UGT1A1 variants, one missense variant rs144217005 
(V109A) and one upstream promoter insert variant rs34983651 (UGT1A1*28) were 
detected in one (Spilhaus n=1) and 22 (Bronx n=0, New Jersey n=3, Emavundleni n=10, 
Spilhaus n=9) participants, respectively. Of these variants, rs34983651 (UGT1A1*28) is 
well-studied to impair the transcription of UGT1A1 thereby having a damaging impact on 
protein function and was observed with an overall frequency of 16.0% (22/135 




Table 3. UGT1A1 genetic variants detected in HPTN 076 participants. A total of 8 
previously reported UGT1A1 variants were detected in 134 HPTN 076 participants 
(Bronx n=19, New Jersey n=17, Emavundleni n=48, Spilhaus n=50) which carried one or 
more genetic variant for the coding DNA reference sequence NM_000463.2. The 
functional consequence of resulting amino acid mutations denoted as deleterious or 
tolerated were predicted using SIFT and PolyPhen in silico tools.  
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Targeted sequencing of UGT1A4 
A total of 20 SNVs that may impact the protein-coding potential of the UGT1A4 
mRNA transcript were detected in 135 participants (Bronx n=19, New Jersey n=17, 
Emavundleni n=48, Spilhaus n=51) which carried one or more genetic variant for this 
gene (Table 2). Of the detected UGT1A4 variants, eight missense variants rs3892221 
(UGT1A4*4, R11W), rs6755571 (UGT1A4*2, P24T), rs2011425 (UGT1A4*3b, L48V), 
rs141408391 (A58V), rs201935850 (K73N) rs146073833 (G158R), rs45540231 (I176F) 
and rs138822211 (I223L) were detected in seven (Bronx n=0, New Jersey n=2, 
Emavundleni n=4, Spilhaus n=1), four (Bronx n=1, New Jersey n=1, Emavundleni n=1, 
Spilhaus n=1), 21 (Bronx n=5, New Jersey n=3, Emavundleni n=5, Spilhaus n=8), one 
(Spilhaus n=1), one (Spilhaus n=1), seven (Bronx n=1, New Jersey n=1, Emavundleni 
n=3, Spilhaus n=2), 13 (Bronx n=2, New Jersey n=0, Emavundleni n=13, Spilhaus n=12), 
and three (New Jersey n=1, Spilhaus n=2) participants, respectively. Of these detected 
missense variants, only one variant, rs146073833, was predicted be deleterious and have 
a damaging impact on protein function. This variant was observed in our analyses with a 




Table 4. UGT1A4 genetic variants detected in HPTN 076 participants. A total of 20 
previously reported UGT1A4 variants were detected in 135 HPTN 076 participants 
(Bronx n=19, New Jersey n=17, Emavundleni n=48, Spilhaus n=51) which carried one or 
more genetic variant for the coding DNA reference sequence NM_007120.2. The 
functional consequence of resulting amino acid mutations denoted as deleterious or 
tolerated were predicted using SIFT and PolyPhen in silico tools.
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Quantitation of RPV and metabolite M2 in HPTN 076 participants 
 Although the primary aim of the HPTN 076 study was to investigate the safety 
and acceptability of a RPV-LA injectable, participants were dosed 25 mg RPV once-daily 
for four weeks to evaluate potential toxicities prior to initiating intramuscular dosing of 
the nanosuspension (8). We utilized ultra-high performance liquid chromatography-
tandem mass spectrometry to quantitate RPV and its primary oxidative metabolite in 83 
plasma samples of HPTN 076 participants (Bronx n=12, New Jersey n=11, Emavundleni 
n=25, Spilhaus n=35). Of the 83 samples analyzed, five participants had RPV plasma 
levels below the lower limit of quantitation (LLOQ) and, in addition, two separate 
participants had drug levels below the limit of detection (LLOD). That being said, for the 
remaining 76 participants, the mean RPV plasma level was 77.77 ng/mL ± 57.93 ng/mL 
and the distribution of RPV plasma levels across study sites is shown in Figure 1. The 
oxidative RPV metabolite M2 was detected in 58 of the 83 samples analyzed, with 17 
participants having M2 levels below the LLOQ, and eight participants with M2 levels 
below the LLOD. The mean M2 plasma level was 3.04 ng/mL ± 1.60 ng/mL and the 
distribution of metabolite plasma levels across study sites is shown in Figure 2. 
 RPV is primarily metabolized by the cytochrome P450 isozymes CYP3A4 and 
CYP3A5. Our sequencing analyses of HPTN 076 participants demonstrated CYP3A5 
exhibited the greatest frequency of potentially deleterious genetic variants. Therefore, we 
wanted to test if CYP3A5 loss of function genetic variants correlated with decreased M2 
formation. A statistically significant difference in RPV to metabolite M2 plasma ratios 
was not observed across CYP3A5 alleles (0, homozygous dysfunctional allele; 1, 
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heterozygous dysfunctional; 2, homozygous wild type) (Figure 3). However, there was a 
distinct stepwise trend, with carriers of homozygous dysfunctional CYP3A5 alleles 
having the highest ratio of RPV to M2 plasma levels (mean ratio = 35.47), followed by 
heterozygous dysfunctional CYP3A5 alleles (mean ratio =30.31) and then homozygous 
wild type CYPA5 alleles (mean ratio = 24.60).  
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Figure 1. HPTN 076 participant RPV plasma concentrations dosed 25 mg once-daily 
for four weeks. RPV plasma concentrations were determined using an ultra-high 
performance liquid chromatography-tandem mass spectrometry assay as previously 
published (9). HPTN 076 participant plasma samples (100 µL) were extracted for drug by 
adding 200 µL ice-cold 100 ng/mL RPV-d6. Supernatant (200 µL) was collected per 
sample and dried under vacuum. Dried samples were reconstituted in 200 µL methanol 
and 10 µL per sample was injected for analysis. Fragment ions were detected in selected 
reaction monitoring mode using the following transitions (Q1→Q3): RPV (m/z 
367.1→195.2) and RPV-d6 (m/z 373.1→230.0).  
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Figure 2. HPTN 076 participant metabolite M2 plasma concentrations dosed 25 mg 
RPV once-daily for four weeks. M2 plasma concentrations were determined using an 
ultra-high performance liquid chromatography-tandem mass spectrometry assay as 
previously published (9). HPTN 076 participant plasma samples (100 µL) were extracted 
for RPV metabolites by adding 200 µL ice-cold 100 ng/mL RPV-d6. Supernatant (200 
µL) was collected per sample and dried under vacuum. Dried samples were reconstituted 
in 200 µL methanol and 10 µL per sample was injected for analysis. Fragment ions were 
detected in selected reaction monitoring mode using the following transitions (Q1→Q3): 
M2 (m/z 383.0→222.0) and RPV-d6 (m/z 373.1→230.0). No significance difference was 





Figure 3. Correlation of RPV/metabolite M2 plasma levels to CYP3A5 genotype of 
HPTN 076 participants. HPTN 076 participants were grouped by CYP3A5 genotype: 0, 
homozygous dysfunctional, 1 heterozygous dysfunctional, 2 homozygous wild type, 
where CYP3A5*1 is the wild type allele. A ratio of RPV to metabolite M2 plasma levels 




Through previous work characterizing the human biotransformation of RPV, we 
identified CYP3A4, CYP3A5, UGT1A1, and UGT1A4 as candidates for examination in 
this retrospective clinical study (9). In genomic DNA isolated from participants of the 
HPTN 076 phase II clinical trial, we detected 60 previously reported variants in the genes 
encoding these drug metabolizing enzymes. While we did not validate these variants in 
parallel using Sanger sequencing, the coverage threshold implemented in our analyses 
was in line with the American College of Medical Genetics and Genomics clinical 
laboratory standards for next-generation sequencing, increasing the confidence in the 
variants called (16).  
We detected variants in all four drug metabolizing enzymes that could negatively 
impact function at the protein level, however, CYP3A5 exhibited the greatest frequency 
of potentially damaging and/or deleterious genetic variants. Of the detected CYP3A5 
variants, the non-functional splice variant CYP3A5*3 was observed at a frequency of 93.0 
%. This variant results from a 6986A>G mutation, which alters the reading frame causing 
a premature termination codon and is the most commonly occurring non-functional allele 
of CYP3A5 (14). In European American populations the CYP3A5*3 allele frequency is 
estimated to be 82 to 95% in contrast to African American populations with an allele 
frequency of 33% (17-21). The ethnicities of all HPTN 076 participants were blinded for 
this study, so it is problematic to make conclusions about ethnic-specific allele 
frequencies. That being said, of all individuals sequenced, Zimbabwean participants from 
this study may exhibit the most homogenous population and we observed 72.5% were 
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homozygous for CYP3A5*3. This is in strong agreement with a recent publication 
estimating Zimbabweans exhibit a CYP3A5*3 frequency of 77.6%, thereby bolstering our 
confidence in the sequencing analyses performed in this study (22). 
In order to put these findings within the context of RPV metabolism, we 
quantitated drug and metabolite levels in plasma samples obtained from HPTN 076 
participants taking a once-daily dose of RPV for a phase I clinical study. Adherence, 
however, is a confounding issue for HIV PrEP studies and this was apparent in our 
analyses as a large variability was observed in parent drug levels. Adherence aside, loss 
of function CYP3A5 alleles did appear to decrease RPV metabolism albeit not 
significantly compared to wild type allele. We previously observed that the primary 
oxidative metabolite of RPV, M2, can range from 1 to 2% of total metabolites formed 
(9). Further, the potential reactivity of this metabolite has not yet been characterized. 
Therefore, it is imperative that these analyses be extended to plasma samples obtained 
from HPTN 076 patients administered the 1200 mg RPV-LA injectable. This will enable 
a more powerful genotype-phenotype analysis as compliance will no longer be a limiting 
covariate.  
In conclusion, we detected deleterious and potentially damaging genetic variants 
in the genes encoding the drug metabolizing enzymes that contribute to RPV metabolism. 
Further investigation, however, is required in order to determine if these variants indeed 
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Chapter 4: Structure-Activity Relationship of Efavirenz-Mediated Activation of the 
Pregnane X Receptor 
Abstract 
Efavirenz (EFV) is a non-nucleoside reverse transcriptase inhibitor FDA-
approved for HIV maintenance therapy in 1998 and to date remains to be the most widely 
prescribed antiretroviral. EFV is extensively metabolized by the cytochromes P450s and 
has been observed to autoinduce its own metabolism with chronic administration. 
Previous reports have demonstrated EFV autoinduction is mediated chiefly through the 
ligand-activated nuclear receptor pregnane X receptor (NR1I2; PXR). In this study, we 
investigated the structure-activity relationship of the anti-HIV drug EFV and PXR in an 
effort to identify potential structural moieties that confer PXR activation. We utilized a 
panel of sixteen EFV analogs ranging 223 Da to 423 Da in size in addition to its primary 
oxidative metabolite of EFV, 8-hydroxy efavirenz (8-OHEFV), to test for PXR activation 
through target gene mRNA modulation in primary mouse hepatocytes, luciferase reporter 
assays in transiently transfected HepG2 cells and a cell-free competitive binding assay. 
We observed that analog 10 the smallest compound 223 Da in size tested and 8-OHEFV 
were unable to activate PXR. However, unlike analog 10, 8-OHEFV was able to 
competitively bind to the PXR-ligand-binding domain (PXR-LBD). Further, through 
molecular docking simulations we observed the polar hydroxyl functional group of 8-
OHEFV causes a potentially destabilizing interaction in a hydrophobic pocket of the 
PXR-LBD formed by residues Phe288, Trp299 and Tyr306. From these studies, we 




Efavirenz (EFV; Figure 1) is a first-generation non-nucleoside reverse 
transcriptase inhibitor FDA-approved for HIV maintenance therapy in 1998 and to date 
remains to be the most widely prescribed antiretroviral. This is in part due to the World 
Health Organization guidelines that recommend EFV be dosed as a third agent to 
treatment-naïve HIV-infected adults in combination with two nucleoside/nucleotide 
reverse transcriptase inhibitors tenofovir disoproxil fumarate and emtricitabine (1). EFV 
undergoes first-pass metabolism and is well-established to be extensively metabolized by 
heme-containing monooxygenases the cytochromes P450, mainly CYP2B6 and CYP3A4 
(2). Further, EFV has been observed to autoinduce its own metabolism with chronic 
administration and thereby exhibits a high incidence rate of drug-drug interactions upon 
co-administration with other cytochrome P450 substrates (3). In line with this, substantial 
evidence has mounted demonstrating EFV autoinduction is mediated chiefly through the 
ligand-activated nuclear receptor pregnane X receptor (NR1I2; PXR) (4-6). 
PXR is part of an extensive superfamily of transcription factors that contribute to 
the regulation of cellular growth, development and homeostasis through either gene 
activation or repression (7). Nuclear receptors in general exhibit a modular structure 
organized into five to six domains and, of these domains, the most conserved regions are 
the DNA-binding domain containing two zinc fingers and the ligand-binding domain 
which serves as the docking site for a ligand (8). Moreover, the coordinated actions of 
these domains culminate into the modulation of target gene expression. Under basal 
conditions, PXR is sequestered in the cytosol by the chaperones cytoplasmic CAR 
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retention protein and heat shock protein 90 (9, 10). Upon ligand binding, PXR dissociates 
from the chaperone protein complex and translocates to the nucleus where it then 
heterodimerizes with 9-cis retinoic acid receptor (RXR) and binds to response elements 
in the promoter regions of target genes to facilitate transcription (11). Although not an 
exhaustive list, PXR/RXR binding sites have been detected in the promoter regions of 
drug metabolizing enzymes mainly the cytochrome P450 subfamilies CYP1A, CYP2A, 
CYP2B, CYP2C, CYP3A, CYP4F12, carboxyesterases CES1 and CES2, and the uridine 
diphosphate glucuronosyltransferase isozymes UGT1A1, UGT1A3, UGT1A6,  as well as 
the drug transporter multidrug resistance gene MDR1 (12-17).  
Transcriptional activation, however, is spurred by ligand binding and to that end 
PXR requires broad substrate specificity in order to function as a “xenobiotic sensor.” 
PXR’s ligand-binding pocket is large, approximately 1150 Å3 in size, relatively 
hydrophobic in nature and highly flexible and thus can accommodate an array of 
xenobiotics (18). In this study, we aimed to investigate the structure-activity relationship 
of the anti-HIV drug EFV and PXR in an effort to identify potential pharmacophores that 
regulate PXR activation. We utilized a panel of sixteen EFV analogs ranging 223 Da to 
423 Da in size in addition to the primary oxidative metabolite of EFV, 8-hydroxy 
efavirenz (8-OHEFV), to test for PXR activation through target gene mRNA modulation 
in primary mouse hepatocytes, luciferase reporter assays in transiently transfected HepG2 
cells and a cell-free competitive binding assay. Supplementary to these in vitro studies, 
we also performed molecular docking simulations to investigate the interactions of all of 
the compounds in our study with the PXR ligand-binding domain to aid in visualizing 
123 
 
potential ligand-receptor interactions. From these studies, we observed that ligand size 
and polarity are key determinants in conferring PXR agonism. 
 
Figure 1. Structural comparison of EFV, 8-OHEFV and sixteen EFV analogs. EFV 
is a first generation non-nucleoside reverse transcriptase inhibitor that has been 
previously demonstrated to activate mouse and human PXR. In this work, we aimed to 
test the activity of mouse and human PXR towards EFV’s primary oxidative metabolite 
8-OHEFV and sixteen EFV analogs spanning from 223 to 423 Da in size. Atoms that 





Materials and Methods 
Reagents 
Pregnenolone 16α-carbonitrile (PCN), rifampicin (RIF) and SR12813 were 
purchased from Sigma-Aldrich (St. Louis, MO). EFV, 8-OHEFV and all EFV analogs 
were synthesized by and purchased from Toronto Research Chemicals (Toronto, ON).  
Isolation of primary mouse hepatocytes and drug treatments 
Hepatocytes were isolated from 9-13 week-old male C57BL/6J (wild type, WT) 
mice from Jackson Laboratories (Bar Harbor, ME) as well as from 9-13 week-old male 
humanized pregnane X receptor (hPXR) and pregnane X receptor knockout (PXR-/-) mice 
bred on a C57BL/6J background were purchased from Taconic Biosciences (Hudson, 
NY). Primary mouse hepatocytes were isolated using retrograde liver perfusion with 25 
mL 0.5 mM EGTA (Amresco LLC, Solon, OH) prepared in 1X PBS (Thermo Fisher 
Scientific, Waltham, MA) at 5 mL/min, followed by 25 mL 1X PBS at 5 mL/min, and 
lastly 20 mL of liver digest medium (Thermo Fisher Scientific) supplemented with 0.15 
mg/mL collagenase (Sigma-Aldrich) at 2 mL/min. Following perfusion, livers were 
removed and cells were gently dissociated in 15 mL of ice-cold hepatocyte wash medium 
(Thermo Fisher Scientific) using a cell scraper and filtered through a 70 µm nylon mesh 
cell strainer. Hepatocytes were then pelleted at 50 x g for 5 min at 4°C and washed twice 
with 10 mL hepatocyte wash medium. Cells were resuspended in 25 mL Williams E 
medium (Thermo Fisher Scientific) with 20 mL percoll (Sigma-Aldrich; 1 part 10X 
HBSS and 9 parts percoll) and inverted six times prior to pelleting at 300 x g for 10 min 
at 4°C. Hepatocytes were washed with 10 mL Williams E medium, pelleted at 50 x g for 
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5 min at 4°C, and resuspended in 10 mL Williams E medium supplemented with 10% 
fetal bovine serum (Thermo Fisher Scientific), 1% L-glutamine (Thermo Fisher 
Scientific), and 1% penicillin-streptomycin (Sigma-Aldrich). Hepatocytes were plated in 
six-well collagen-coated plates (Corning, Tewksbury, MA) at a density of 2.4 x 105 cells 
per well. Cells were incubated overnight at 37°C and 5% CO2 prior to replacing the cell 
culture medium with fresh Williams E medium containing 10% fetal bovine serum, 1% 
L-glutamine, and 1% penicillin-streptomycin for drug treatments. Hepatocytes were 
treated with either DMSO (0.1%) vehicle or 10 µM drug for RNA isolation over a range 
of time points. For 48 h and 72 h drug treatments, cell culture medium was replaced 
every 24 h and hepatocytes were retreated with DMSO or drug. A total of four 
independent experiments were performed for hepatocytes isolated from WT, hPXR and 
PXR-/- mice. 
RNA isolation and quantitative real-time PCR (qPCR) 
RNA was prepared from primary mouse hepatocytes using TRIzol (Thermo 
Fisher Scientific) following the manufacturer’s instructions for cells grown in a 
monolayer. Total RNA (1 µg) was reverse transcribed using Maxima First Strand cDNA 
Synthesis Kit (Thermo Fisher Scientific). The following primers were used for qPCR: 
Cyp3a11 forward 5’-ATAGAGCTTTGCTGTCCCCC-3’ and reverse 5’-
CGGCTTTCCTTCATTCTGTC-3’; Gapdh forward 5’- 
GAAGGCCGGGGCCCACTTGA-3’ and reverse 5’-TCTCCAGGCGGCACGTCAGA-
3’. A Gapdh PCR product was generated from mouse hepatocyte RNA using 
conventional PCR and ligated into CloneJET PCR cloning kit for subcloning (Thermo 
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Fisher Scientific). Serial dilutions of the resulting Gapdh plasmid were used to generate a 
standard curve for the quantitation of mRNA levels using Maxima SYBR Green qPCR 
Master Mix (Thermo Fisher Scientific). Gapdh served as the housekeeping gene for 
mRNA level normalization. The following qPCR cycling reactions were performed: 
denaturation of dsDNA for 10 min at 95°C proceeded by 40 cycles of denaturation for 15 
sec at 95°C, annealing for 30 sec at 60°C, and extension for 30 sec at 72°C. Resulting 
Cyp3a11 copy numbers were normalized by Gapdh for each treatment and data was 
reported as fold change from DMSO control for each time point. 
Transient transfection and dual-luciferase reporter gene assay 
HepG2 human hepatocellular carcinoma cells (American Type Culture 
Collection, Manassas, VA) were cultured in T-75 flasks in high glucose Dulbecco’s 
Modified Eagle Medium (DMEM; American Type Culture Collection) supplemented 
with 10% fetal bovine serum and 1% penicillin and streptomycin. Cells were maintained 
at 37°C and 5% CO2 prior to sub-culturing for transfection. At approximately 80-90% 
confluency, HepG2 T-75 flasks were trypsinized and plated at 2 x 106 cells/mL into a 
new flask. After 24 h, culture medium was replaced with Opti-MEM I reduced serum 
medium (Thermo Fisher Scientific) and T-75 flasks were transfected with a master mix 
containing FuGENE 6 transfection reagent (3 µL/µg plasmid DNA per flask; Promega, 
Madison, WI), Opti-MEM I reduced serum medium (500µL per flask), pGL4.74 
[hRluc/TK] internal control vector (500 ng per flask; Promega), pGL3-basic-CYP3A4-
362(7836/7208ins)-luc reporter construct (2 µg per flask; Blue Heron Biotech, Bothell, 
WA), a receptor construct (6 µg pCMV6-entry-mPXR or 2 µg pCMV6-XL4-hPXR per 
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flask; OriGene Technologies, Rockville, MD) or an empty vector (6 µg pCMV6-entry or 
2 µg pCMV6-XL4 per flask; OriGene Technologies). Cells were transfected for 24 h and 
then trypsinized, counted and plated into fresh DMEM at 1 x 105 cells/well into a 96-well 
white plate (Costar). Following 24 h plating (48 h post-transfection), cells were treated in 
triplicate with either 0.1% DMSO control or 10 µM drug prepared in DMEM for a total 
of 24 h. After treatment, cells were lysed and the firefly luciferase and R. reniformis 
luciferase activities were quantified using a Dual-Glo Luciferase Reporter Assay 
(Promega). Luminescence was measured directly in the 96-well plate using a Synergy HT 
plate reader (BioTek, Winooski, VT). Firefly luciferase activity was normalized by taking 
the ratio of firefly luminescence to that of R. reniformis and results were expressed as 
fold change from DMSO control. A total of four independent experiments were 
performed. 
Competitive ligand binding assay 
  A LanthaScreen hPXR competitive binding assay was employed to compare 
compound interactions with the receptor’s ligand-binding domain. For these studies, 
purified human PXR ligand-binding domain (amino acids 111 to 434) containing an N-
terminal glutathione S-transferase (GST) tag (10 nM hPXR-LBD-GST; Thermo Fisher 
Scientific) was incubated with a range of concentrations of the positive control SR 12813 
(Sigma-Aldrich), EFV, 8-OHEFV and EFV analogs in the presence of a Fluormone PXR 
ligand (40 nM; Thermo Fisher Scientific) and a terbium labeled anti-GST antibody (10 
nM; Thermo Fisher Scientific) using a 384-well low-volume black plate (Costar). 
Reactions were incubated at room temperature for 1 h covered prior to reading 
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fluorescence. Using a monochromator-based plate reader, specifically a Tecan Safire 2 
(Tecan Group Ltd., Männedorf, Switzerland), the terbium fluorophore was excited at 332 
nm, yielding an emission peak at 485 nm. Under the same excitation conditions, the 
Fluormone acceptor emission was observed at 515 nm due to energy transfer from the 
terbium donor known as fluorescence resonance energy transfer or FRET. Data was 
expressed as a ratio of Fluormone (515 nm) over terbium (485 nm) emission and fit to a 
log(inhibitor) versus response curve with variable slope to determine IC50 values for each 
compound. 
Molecular docking simulations 
 To date, there are 21 high-resolution crystal structures of hPXR-LBD published in 
the RCSB Protein Data Bank and 14 of these structures are of the hPXR-LBD in complex 
with ligand. To select a hPXR-LBD-ligand complex suitable for molecular docking, 
structures were ranked by resolution ≤ 2.5 Å, Rvalue ≤ resolution/10 and the difference of 
Rvalue and Rfree ≤ 0.05, which are criteria previously employed in computational studies 
investigating this nuclear receptor (19). Rvalue is a measure of the quality of the atomic 
model obtained from the observed X-ray diffraction data compared to simulated data in 
order to make refinements to the final structure. Alternatively, the Rfree value is calculated 
by how well the simulated model predicts a portion of observed diffraction data that was 
not subjected to the refinement process. Further, the difference between Rvalue and Rfree 
reflects the extent to which a structure may have been overfit to the model (20). There 
were two hPXR-LBD crystal structures that met these criteria 1M13 (co-crystalized with 
hyperforin, resolution of 2.15 Å, Rvalue = 0.212, Rfree = 0.246) and 4X1G (co-crystallized 
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with estrogen, resolution of 2.00 Å, Rvalue = 0.182, Rfree = 0.210) and are overlayed in 
Figure 2A. The macromolecule 4X1G, however, is missing residues Thr311, Ala312, 
Gly313, Gly314 and Phe315 of the characteristic PXR flexible loop which extends from 
Glu309 to Glu321. Because of this, 1M13 was selected to move forward with for 
molecular docking and this structure was previously vetted and confirmed for use in 
computational studies (19, 21).  
 Molecular docking was simulated using the open-source software PyRx which 
utilizes the automated tool AutoDock (1, 22). Structure data files were generated for each 
ligand using ChemBioDraw, imported into PyRx for energy minimization and converted 
into PDBQT files for docking. The 1M13 receptor file was imported into PyRx from the 
RCS Protein Data Bank and prepared by removing the bound ligand in addition to non-
polar hydrogens and water molecules. The active site was defined using the 28 residues 
known to line the hPXR ligand-binding pocket: Leu240, Met243, Ala244, Met246, 
Ser247, Phe251, Phe281, Cys284, Gln285, Phe288, Trp299, Tyr306, Thr311, Gly314, 
Phe315, Leu319, Met323, His407, Leu411, Ile414, Gln415, Ile417, His418, Phe420, 
Ala421, Met425, Gln426 and Phe429 (23). All ligands were docked into the 1M13 
structure using the AutoDock v. 4.2 tool and a 25 x 25 x 25 point grid with 1 Å spacing in 
order to encompass the ligand-binding pocket as depicted in Figure 2B. The Lamarckian 
algorithm was used to search for low energy binding modes and in doing so the 
parameters were set to a total of ten runs with a maximum of 2.5 x 106 energy evaluations 
per docked ligand. The resulting poses were ranked in order of binding energy and nearly 
all of the docking simulations were within 1.0 kcal/mol of the lowest energy pose; 
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therefore, the most populated pose was used for subsequent analyses. The Pymol 
molecular graphics system v. 1.8 was used for the analysis of PyRx docking simulation 
results and employed for the generation of structural models. Further, the amino acid 
residues within a radius of 4 Å of compound were used to define the ligand binding site.  
 
Figure 2. Selection and preparation of 1M13 hPXR-ligand-binding domain crystal 
structure for molecular docking. (A) The high resolution crystal structures 1M13 (2.15 
Å, blue) and 4X1F (2.00 Å, purple) co-crystallized with hyperforin and estrogen, 
respectively, were overlayed to demonstrate 4X1F is not suitable for molecular docking 
as it is missing the flexible loop region of PXR from residues Glu309 to Glu321 as 
highlighted in 1M13 (orange). (B) 1M13 was prepared for ligand docking in PyRx using 
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a 25 x 25 x 25 point grid with 1 Å spacing encompassing the 28 residues of the ligand-
binding pocket as seen labeled in white. 
Determination of ligand-binding pocket interactions 
The open-source software LigPlot+ was utilized to compare the PyRx docking 
results for each compound (24). Receptor-ligand PDB format files were generated in 
Pymol prior to importing into LigPlot+ for analysis of ligand-protein interactions. 
LigPlot+ was then used to produce a two-dimensional diagram of ligand-protein 
interactions, identifying both polar and hydrophobic contacts. 
Statistical Analysis of Data 
Results are expressed as means ± standard deviation. Comparisons between 
experimental conditions were performed using an unpaired one-tailed Student’s t-test 
(GraphPad Prism 6 software). Statistical significances are denoted as: *, p ≤ 0.05; **, p ≤ 
0.01; ***, p ≤ 0.001. 
Results 
Effect of EFV, 8-OHEFV and EFV analogs on Cyp3a11 mRNA expression in 
primary hepatocytes isolated from WT and transgenic mice 
 EFV was previously demonstrated to activate both human and mouse PXR using 
a luciferase reporter assay and was observed to modulate CYP3A4 mRNA expression in 
primary human hepatocytes (6). We first sought to recapitulate the modulation of PXR 
target gene expression by EFV using hepatocytes isolated from WT male mice. EFV (10 
µM) increased the murine PXR target gene Cyp3a11 in a time-dependent manner similar 
to the positive control PCN (Figure 3A).  Further at 72 h, EFV increased Cyp3a11 
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mRNA to almost 80-fold compared to 46-fold for PCN. In addition, all EFV analogs 
significantly increased Cyp3a11 mRNA ranging from 2- to 41-fold following 72 h of 
treatment with the exclusion of the smallest analog 10 (223 Da) and analog 16 which 
lacks an amine compared to EFV. Unexpectedly, the primary oxidative metabolite of 
EFV, 8-OHEFV, which differs in mass from the parent drug by a single hydroxyl group, 
exhibited no modulation of Cyp3a11 mRNA across all time points tested. 
In order to investigate potential species-specific differences, these same drug 
treatments were performed using hepatocytes isolated from humanized mice expressing 
hPXR. These mice express hPXR, but not mPXR, in the liver and intestines at both the 
mRNA and protein level (25). Moreover, the humanized hPXR mouse line was deemed 
functional as modulation of Cyp3a11 mRNA expression was observed with dosing of the 
prototypic hPXR agonist RIF (25). EFV and RIF treatment of hepatocytes isolated from 
humanized hPXR mice increased Cyp3a11 mRNA to 28- and 24-fold, respectively, at 72 
h (Figure 3B). Interestingly, the second largest EFV analog 6 (409 Da), which lacks an 
intact oxazinone ring compared to EFV, increased Cyp3a11 mRNA levels to the greatest 
extent by 84-fold following 72 h treatment. In contrast, the smallest increase of Cyp3a11 
mRNA abundance observed was 2.5-fold mediated by analog 13, which is roughly the 
same size as EFV, but contains a trans alkene and is quinazolinone derivative. Of note, 
analogs 10, 16 and 8-OHEFV did not significantly impact Cyp3a11 mRNA similar to 
WT drug treatments. In addition, analogs 1, 11, 14 and 15 failed to increase target gene 
expression relative to DMSO control. 
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Taking this work a step further, hepatocytes isolated from male mice genetically 
deficient of PXR (PXR-/-) were treated in order to test for PXR-dependent modulation of 
Cyp3a11 mRNA as a downstream readout for receptor activation. In addition to PXR, the 
constitutive androstane receptor (CAR) has also been demonstrated to exhibit 
transactivation of CYP3a genes and EFV is a known agonist of CAR (5, 26). EFV-
mediated modulation of Cyp3a11 mRNA was almost fully abrogated in hepatocytes 
isolated from PXR-/- mice compared to WT and hPXR treatment groups following 72 h of 
treatment (Figure 3C). Yet, analogs 7, 10, 15, 16 and 8-OHEFV drug treatments were not 
significantly decreased for PXR-/- treatments compared to WT at 72 h. Further, when 
comparing PXR-/- to hPXR hepatocyte treatments, analogs 1, 4, 9, 10, 11, 13, 14, 15, 16 
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Figure 3. Comparative effects of EFV, 8-OHEFV and EFV analogs on the 
modulation of the PXR target gene Cyp3a11 mRNA expression in primary mouse 
hepatocytes. Hepatocytes were isolated from (A) WT and (B) humanized male mice 
expressing hPXR and treated for 24, 48 and 72 h with either 0.1% DMSO as vehicle 
control or 10 µM drug. PCN and RIF, 10 µM each, served as positive controls for WT 
and hPXR treatment groups, respectively. Following drug treatment, RNA was isolated 
from hepatocytes using TRIzol. RNA (1 µg) was then reverse transcribed to cDNA for 
use in qPCR to measure Cyp3a11 and Gapdh mRNA levels. To demonstrate target gene 
expression was modulated in a PXR-dependent manner, (C) WT and hPXR 72h drug 
treatments were compared to corresponding Cyp3a11 mRNA levels in hepatocytes 
isolated from male mice genetically deficient of PXR (PXR-/-). Data are shown as mean 
fold change from DMSO control ± S.D. for four independent experiments. Statistical 
significance from control (A, B) or PXR-/- drug treatment (C) is shown as *, p ≤ 0.05, **, 
p ≤ 0.01 and ***, p ≤ 0.001. 
Comparison of EFV, 8-OHEFV and EFV analogs on mPXR and hPXR activation 
using transiently transfected HepG2 cells 
We demonstrated EFV and select EFV analogs modulated Cyp3a11 mRNA 
expression in a PXR-dependent manner. Moving forward, we utilized a luciferase 
reporter assay in order to test for direct activation of PXR by these compounds. Two 
regulatory regions of CYP3A4 have been previously identified to contain PXR response 
elements critical for facilitating transcriptional activation by xenobiotics, specifically a 
proximal promoter region from bases -362 to +53 and a more distal region spanning 
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bases -7836 to 7208 upstream of the transcription start site (27). Knowing this, human 
hepatocellular carcinoma HepG2 cells were transfected with the plasmid pGL3-basic-
CYP3A4-362(7836/7208ins)-luc, containing a firefly luciferase gene under the control of 
the PXR-activated regulatory elements, as a critical component for assaying 
transcriptional activity in addition to overexpressing full-length PXR (28). In agreement 
with previously published data, EFV (10 µM) activated both mouse and human PXR 
(Figures 4A and 4B) (6). PCN, the positive control for mPXR activation, yielded the 
most robust increase in firefly luciferase activity of 3-fold relative to empty vector drug 
treatment indicating mPXR activation followed by EFV and analogs 14 and 3 with 
increases of 2.5-, 2.2- and 2.0- fold, respectively (Figure 4A). As anticipated, RIF had no 
effect on mPXR activation. There were several drug treatments, however, that did not 
exhibit firefly luciferase activity significantly greater than the empty vector control, and 
hence failed to activate mPXR, those being 8-OHEFV and analogs 1, 2, 5, 10, 12, 13, 15 
and 16. RIF, the positive control for hPXR activation, yielded the greatest increase in 
firefly luciferase activity of 9.5-fold relative to empty vector drug treatment indicative of 
strong hPXR activation (Figure 4B). In contrast, PCN had no effect on hPXR activation 
as expected. Second to RIF treatment, two of the largest EFV analogs 6 (409 Da) and 7 
(423 Da) increased firefly activity by 6.7- and 6.9-fold, respectively. Interestingly, analog 
5, with the chiral center in the R configuration relative to the S configuration of 
stereoisomer analog 6, increased firefly luciferase activity to a much lesser extent by a 
difference of 3-fold. In addition to EFV, all drug treatments increased firefly luciferase 
activity, thereby demonstrated hPXR activation, significantly greater than their 
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corresponding empty vector control with the exclusion of 8-OHEFV and the smallest 
analog 10. 
Figure 4. Comparative effects of EFV, 8-OHEFV and EFV analogs on the activation 
of mouse and human PXR in transiently transfected HepG2 cells. HepG2 cells were 
transfected with a pGL4.74 [hRluc/TK] internal control vector, a pGL3-basic-CYP3A4-
362(7836/7208ins)-luc reporter construct, a receptor construct (A) pCMV6-entry-mPXR, 
(B) pCMV6-XL4-hPXR or a corresponding empty vector. Following 48 h post-
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transfection, cells were treated in triplicate with either 0.1% DMSO control or 10 µM 
drug for 24 h. PCN and RIF, 10 µM each, served as positive controls for mPXR and 
hPXR activation, respectively. After treatment, firefly luciferase and R. reniformis 
luciferase activities were quantified using a dual-glo luciferase reporter assay. Firefly 
luciferase activity was normalized by taking the ratio of firefly luminescence to that of R. 
reniformis. Data are shown as mean fold change from DMSO control ± S.D. for four 
independent experiments. Statistical significance from empty vector drug treatment is 
shown as *, p ≤ 0.05, **, p ≤ 0.01 and ***, p ≤ 0.001. 
Competitive ligand binding of EFV, 8-OHEFV and select EFV analogs to the hPXR 
ligand-binding domain 
 Building upon the observations that EFV and select EFV analogs could stimulate 
a biological effect mediated through PXR activation, specifically modulation of Cyp3a11 
mRNA expression in primary mouse hepatocytes and transactivation of CYP3A4 by 
reporter assay in HepG2 cells, we next wanted to compare strengths of ligand-receptor 
interactions using a competitive binding assay. In this assay, PXR ligands were 
characterized through their ability to compete with and displace a fluorescent PXR ligand 
Fluormone green, thereby resulting in a corresponding decrease in fluorescence. RIF has 
been well-demonstrated to interfere with the emission of both the terbium and Fluormone 
fluorophores implemented in this assay, therefore, the hPXR ligand SR12813 was used as 
the positive control (29). SR12813 (0.062 nM to 100 µM) demonstrated a dose-
dependent decrease in 515 nm/485 nm TR-FRET ratio with a half-maximal inhibitory 
concentration (IC50) value of 0.14 µM, which is in agreement with previously published 
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studies (Figure 5) (30). It is important to note that compound solubility limited the 
maximal concentration, either 300 µM or 900 µM, tested for compounds in subsequent 
studies. EFV (0.062 nM to 300 µM) resulted in an IC50 of 18.74 µM. PXR is a high-
capacity, low-affinity nuclear receptor and the observed IC50 for EFV falls in line with 
previously characterized “moderate binders” ranging from half-maximal excitatory 
values of 1 µM to 100 µM (31). Analog 10 (0.062 nM to 900 µM), which in our former 
studies exhibited no biological effect mediated through PXR activation, was unable to 
displace the Fluormone ligand even at the highest compound concentration tested at 900 
µM. That being said, 8-OHEFV (0.062 nM to 900 µM), which also had no impact on 
Cyp3a11 mRNA expression or CYP3A4 transactivation, was able to displace the 
competitive ligand with an IC50 of 12.14 µM comparable to that of EFV. Analog 6, the 
second to largest analog tested of 409 Da and the most potent agonist of hPXR by our 
studies, inhibited ligand binding with an IC50 of 4.46 µM, four times lower than that of 
EFV. Interestingly, analog 5, the stereoisomer of analog 6, exhibited a slightly more 
potent IC50 of 1.93 µM. Three additional analogs 14, 15 and 16 were investigated for 
ligand-receptor binding interactions by this assay as these compounds differed 
structurally from EFV by a single atom. Moreover, for analog 14, the heterocyclic 
oxygen of EFV is substituted with a carbon atom, whereas analogs 15 and 16 lack the 
heterocyclic amine of EFV, which is substituted with an oxygen or carbon atom, 
respectively. These substitutions within the heterocyclic ring of EFV may disrupt and/or 
enhance polar interactions within PXR’s ligand-binding pocket. All three analogs 
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exhibited IC50 values two to seven times lower than EFV of 8.38 µM, 5.55 µM and 2.52 
µM for analogs 14, 15 and 16, respectively. 
 
Figure 5. Competitive ligand binding of EFV, 8-OHEFV and select EFV analogs to 
the hPXR ligand-binding domain. hPXR-LBD (10 nM) with an N-terminal GST tag 
was incubated individually with a range of concentrations of the positive control 
SR12813, EFV, 8-OHEFV and EFV analogs 5, 6, 10, 14, 15 and 16 in the presence of a 
Fluormone PXR ligand (40 nM) and a terbium labeled anti-GST antibody (10 nM). 
DMSO (1%) was a vehicle control for all reactions. Excitation of the terbium fluorophore 
at 332 nm, yielded an emission peak at 485 nm. Under the same excitation conditions, the 
Fluormone acceptor emission was observed at 515 nm due to FRET. Data are expressed 
as a ratio of Fluormone (515 nm) over terbium (485 nm) emission and normalized to 
DMSO treatment as the maximally observed time-resolved FRET ratio. Normalized data 
from four independent experiments were then fit to a log(inhibitor) versus response curve 




Molecular docking of EFV, 8-OHEFV and EFV analogs in the ligand-binding 
domain of hPXR 
With the aim of understanding ligand-receptor interactions that may confer PXR 
activation, we performed a molecular modeling study in which EFV, 8-OHEFV and 
sixteen EFV analogs were docked into the ligand-binding pocket of hPXR (1M13; Figure 
6). Our docking results showed all investigational compounds occupied an area in the 
ligand-binding pocket primarily sandwiched between helices 3 and 6. The ligand-binding 
pocket is largely hydrophobic and, consistent with previous molecular docking studies, 
majority of the ligand contacts observed were with non-polar residues as analyzed using 
two-dimensional renderings of energetically favorable ligand poses (Figure 7) (32). 
Overall, docked ligands were predicted to form contacts with ten hydrophobic residues 
M243, M246, M250, F251, F281, F288, W299, M323, L411 and F429 and six polar 
residues S247, C284, Q285, Y306, H327 and H407 as summarized in Table 1. Molecular 
docking was also performed with the prototypic hPXR agonists hyperforin (HYP), 
SR12813 and RIF in addition to the negative control PCN and all hydrophobic and/or 
polar contacts observed in these simulations were in line with previous published reports 
(18, 33, 34). Further, docked ligands made polar contacts with the side-chain Ser247 to 
the greatest extent (12 ligands out of 18), followed by Q285 (6 ligands out of 18), Cys284 
(2 ligands out of 18) and Met243 (1 ligand out of 18). More specifically, EFV made 
simultaneous polar contacts with Ser247 and Q285 with the amine of the oxazinone ring 
and a fluorine of the trifluoromethyl group, respectively (Figure 7).  In addition, the Cl-
phenyl group of EFV was observed to fit stably into the hydrophobic pocket formed by 
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the side-chains Phe288 (helix 6), Trp299 (beta strand 1) and Tyr306 (beta strand 2) 
(Figure 8). The Cl-phenyl group of EFV appears to make a favorable “edge-on” Cl-π 
interaction with Phe288 and this electrostatic interaction was conserved for the docking 
conformations of analogs 11 and 12 (35). In contrast, 8-OHEFV, which is the only 
compound investigated in our study to contain any modification to the Cl-phenyl ring of 
EFV, formed unfavorable and potentially destablizing interactions with the highly 
hydrophobic area defined by Phe288, Trp299 and Tyr306 mediated by the ligand’s 
hydroxyl group meta to the Cl atom in addition to the oxazinone amine and carbonyl 
oxygen (Figure 8). Interestingly, analog 10, which failed to activate hPXR and 
competitively bind to the receptor’s ligand-binding domain, was able to make side-chain 
polar contacts to S247 and C284 and a main-chain contact to Met243 within the active 
site (Figure 7). That being said, analog 10 is the smallest ligand investigated of 223 Da 
with a molecular surface area of 192 Å2 and as such made the fewest number of 




Figure 6. Molecular docking of EFV, 8-OHEFV and sixteen EFV analogs into the 
ligand-binding pocket of hPXR (1M13). Molecular docking was simulated using PyRx. 
All ligands were docked into the 1M13 structure using AutoDock and a 25 x 25 x 25 
point grid with 1 Å spacing in order to encompass the ligand-binding pocket. The most 
populated pose for each ligand is shown docked into the PXR-LBD simultaneously with 
the co-crystallized ligand hyperforin (black). The amino acid residues within a radius of 4 
Å of EFV, 8-OHEFV and EFV analogs were M243, M246, S247,M250, F251, F281, 





Figure 7. Two-dimensional representation of binding modes for EFV, 8-OHEFV 
and select EFV analogs in the ligand-binding pocket of hPXR (1M13). The open-
source software LigPlot+ was used to generate two-dimensional diagrams of ligand-
protein interactions in order to compare PyRx docking results across compounds. This 
analysis was performed for all eighteen investigational ligands, however, representative 





Table 1. Tabular representation of predicted active site ligand-hPXR interactions. 
Summary of molecular docking simulations generated in PyRx and analyzed using 
LigPlot+.  The polar and hydrophobic contacts formed for eighteen investigational ligands 
are shown in comparison to the potent and prototypic hPXR agonists hyperforin (HYP), 
SR12813 and RIF in addition to the negative control PCN. Hydrophobic residues are 
italicized and polar residues are shown in bold. M250 is not highlighted as this residue 




Figure 8. Docking comparison of EFV, 8-OHEFV and EFV analogs 11 and 12 into 
the ligand-binding pocket of hPXR (1M13). (A) The energetically favorable docking 
modes of EFV (green) and EFV analogs 11 (purple) and 12 (gray) in the hPXR active 
site. The Cl-phenyl group across all three compounds fits stably into the hydrophobic 
pocket formed by the side-chains Phe288, Trp 299 and Tyr306. In contrast, (B) the more 
polar compound 8-OHEFV (in cyan overlayed with EFV in green) forms unfavorable and 
potentially destablizing interactions with the highly hydrophobic area mediated by the 
ligand’s hydroxyl group meta to the Cl atom in addition to the oxazinone amine and 
carbonyl oxygen. 
Discussion 
 PXR is a ligand-activated transcription factor that is involved in the regulation of 
biologically important genes that contribute to cellular homeostasis within the liver and 
intestines (36). In addition to its endogenous function(s), PXR exhibits broad substrate 
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specificity and can accommodate binding of structurally diverse activators enabling the 
receptor to act as a xenobiotic sensor. Further, a consequence of agonist binding to PXR 
stimulates the induction of target genes encoding drug metabolizing enzymes that can 
thereby enhance global drug metabolism and yield potential drug-drug interactions. 
Enzyme induction mediated by PXR activation, primarily of the cytochromes P450 which 
metabolize approximately 75% of pharmaceuticals, is a constant obstacle for drug 
discovery and development (37). Therefore, characterization of compounds that activate 
PXR will inform the structure-activity relationship of a series of ligands and the receptor 
and may enable the prediction of xenobiotics that bind PXR and modulate drug 
biotransformation and clearance.  
 In this study, we investigated the structure-activity relationship of the anti-HIV 
drug EFV and PXR. In doing so, we utilized a panel of sixteen EFV analogs ranging from 
223 to 423 Da in size that contained either subtle or dramatic modifications to the 
oxazinone ring of EFV (analogs 1, 2, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 and 16) in 
addition to modification of the alkyne bond of EFV to a trans alkene (analogs 3 and 13) 
and ring opening of the cyclopropyl group (analog 4). We also included the primary 
oxidative metabolite of EFV, 8-OHEFV, in these studies as the only investigational 
compound to contain a modification to the Cl-phenyl group of EFV. Further, using these 
compounds of a similar scaffold, we observed that ligand size and polarity were key 
determinants in conferring agonism of PXR. 
 A previous report by Xio et al. suggested that molecular weight may serve as a 
useful marker for the identification of PXR binders (31). Moreover, this group proposed 
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ligands ≤ 300 Da in size are unable to form meaningful interactions within PXR’s ligand-
binding pocket. Prior to our work, EFV, which is 316 Da in size thereby approaching the 
proposed 300 Da molecular weight cut-off, was demonstrated to be a strong agonist of 
PXR by in vitro assay (28). In addition to recapitulating this observation, several EFV 
analogs were tested in our study that are less than 300 Da, analogs 1 (289Da), 2 (289 Da) 
and 10 (223 Da). Analogs 1 and 2 are R and S stereoisomers, respectively, that lack an 
intact oxazinone ring, but despite their molecular weights were able to activate both 
mouse and human PXR as demonstrated by time-dependent modulation of Cyp3a11 
mRNA in hepatocytes isolated from both WT mice and humanized mice expressing 
hPXR in addition to facilitating transactivation of CYP3A4 by reporter assay in HepG2 
cells. That being said, we did observe that the smallest compound tested, analog 10 (223 
Da), was unable to neither competitively bind to PXR’s ligand-binding domain nor 
confer PXR activation. Using molecular docking simulations, we further observed that 
analog 10 was surprisingly able to make polar contacts within the ligand-binding pocket 
of PXR, however, failed to form extensive potentially stabilizing hydrophobic contacts. 
On average, the ligands investigated in our docking simulations formed contacts with 
eight hydrophobic residues, whereas analog 10 interacted with just four non-polar 
residues, Met246, Gln285, Phe288 and Trp299, which may be attributed to the ligand’s 
small molecular surface area of 192 Å2. Moreover, building upon these former studies, 
our work suggests a more narrow range of < 223 Da to > 289 Da for a molecular weight 
cutoff that may confer PXR activation in a species-independent manner. 
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 In addition to confirming ligand size is indeed a limitation for promoting PXR 
activation, we observed that a compound’s polarity may also have a substantial impact on 
stimulating a biological effect. EFV is extensively metabolized by the cytochromes P450 
to form the major oxygenated metabolite 8-OHEFV (2). Further, EFV autoinduces its 
own metabolism through PXR activation thereby causing the circulating levels of 8-
OHEFV to surpass that of parent drug with chronic administration (3). In line with this, 
our laboratory has previously demonstrated that 8-OHEFV is a reactive metabolite that 
may contribute to EFV-mediated hepatotoxicity (38). Therefore, we were interested in 
testing if this metabolite could also activate PXR and further contribute to the disruption 
of cellular homeostasis within the liver. We observed that chronic treatment of 
hepatocytes isolated from WT mice of humanized mice expressing hPXR with 8-OHEFV 
caused no significant modulation of Cyp3a11 mRNA expression. Of note, 8-OHEFV has 
been observed in human liver microsomes to be subsequently metabolized to the 
dioxygenated metabolite 8,14-OHEFV and can also undergo O-linked glucuronidation in 
human and rodent liver microsomes, so it is plausible the metabolite exhibited poor 
hepatocyte stability despite retreatment with drug every 24 h (2, 39). However, bolstering 
our previous observation, 8-OHEFV failed to activate PXR by a CYP3A4 luciferase 
reporter assay using transfected HepG2 cells, which characteristically express drug 
metabolizing enzymes at significantly lower basal levels compared to primary 
hepatocytes (40). It is also worth noting that hepatocyte and HepG2 cellular permeability 
of 8-OHEFV was not directly tested in these studies, yet the logP value of this metabolite 
is estimated to be 3.2 compared to 3.7 of EFV and, therefore, should be sufficiently 
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lipophilic to passively diffuse across the plasma membrane. Based upon the performed 
cellular assays, it was unanticipated to observe that 8-OHEFV could competitively bind 
to PXR-LBD and at a similar inhibitory potency to EFV. Subsequent molecular docking 
simulations, however, aided in the interpretation of these results. Unlike EFV which is 
predicted to form a favorable electrostatic Cl-π interaction of its Cl-phenyl group within a 
hydrophobic pocket formed by side-chain residues Phe288, Trp299 and Tyr306, the 
hydroxyl group of 8-OHEFV in addition to the oxazinone amine and carbonyl oxygen 
form a potentially destablizing interaction within this pocket. Structural studies of PXR 
have identified these three hydrophobic residues as the most important hot spot for ligand 
binding within the active site (41). Adding to this, a former study by Gao et al. have 
reported PXR activation may be attenuated with the addition of a single polar functional 
group, such as –OH or –NH2, to a known agonist (42). Further, in support of our 
experimental observations, these authors demonstrated that phenyl groups, and 
specifically Cl-phenyl groups, are particularly optimal for fitting into this hydrophobic 
pocket of PXR (42).  
 In summary, we investigated the structure-activity relationship of the anti-HIV 
drug EFV and PXR and found through using compounds of a similar scaffold, ligand size 
and polarity were key determinants in conferring agonism of PXR. These findings can 
directly inform next-generation antiretroviral drug development in an effort to identify 
pharmacological agents that maintain antiviral potency with minimal drug-drug 
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Chapter 5: Mechanisms of Dyslipidemia in Response to the Anti-HIV Drug 
Efavirenz  
Abstract 
Efavirenz (EFV) and rilpivirine (RPV) are nonnucleoside reverse transcriptase 
inhibitors used for the treatment of HIV infection. EFV-based regimens have been 
observed to increase high-density lipoprotein, low-density lipoprotein and total 
cholesterol levels, whereas RPV-based regimens exhibit less of an impact on lipid 
profiles. Dyslipidemia is a risk factor for atherosclerosis and cardiovascular disease and 
studies investigating the molecular mechanism(s) by which EFV, but not RPV, causes 
dyslipidemia are lacking. In this work, we have started to probe the mechanism(s) by 
which EFV, but not RPV, impacts hepatic cholesterol homeostasis using primary mouse 
hepatocytes.  
Introduction 
Efavirenz (EFV) is a first generation nonnucleoside reverse transcriptase inhibitor 
(NNRTI) and is the most widely prescribed antiretroviral for the treatment of HIV 
infection (Figure 1). Rilpivirine (RPV) is a more recently FDA approved second 
generation NNRTI that has a flexible diarylpyrimidine structure enabling a greater 
genetic barrier to viral resistance relative to EFV (Figure 1) (1). Interestingly, EFV-based 
regimens have been observed to increase high-density lipoprotein, low-density 
lipoprotein and total cholesterol levels, whereas RPV-based regimens exhibit less of an 
impact on lipid profiles (2). Dyslipidemia is characterized by the elevation of lipoprotein 




cardiovascular disease. Studies probing the molecular mechanism(s) by which EFV 
stimulates the onset of dyslipidemia have yet to be reported.  
In preliminary studies, we observed that EFV, but not RPV, increased small 
heterodimer partner (SHP; NR0B2) mRNA expression in primary mouse hepatocytes. 
SHP is an orphan nuclear receptor that is basally expressed at low levels in the liver and 
can be transiently up-regulated through the direct binding of endogenous bile acids to its 
primary transcriptional regulator FXR (3). Further, SHP has been functionally implicated 
in a complex FXR-dependent autoregulating signaling cascade for maintaining bile acid 
and cholesterol homeostasis (3, 4). Activation of this FXR signaling pathway results in 
the transcriptional repression of CYP7A1, mediated through SHP inhibition of liver 
receptor homolog-1, a positive regulator of CYP7A1 gene expression (4). CYP7A1 is a 
member of the cytochromes P450 (P450) family of monooxygenases and is the rate-
limiting enzyme in the conversion of cholesterol to bile acids. Interestingly, the 
overexpression of CYP7A1 in transgenic mice prevented the development of diet-
induced hypercholesterolemia and atherosclerosis (5, 6). Additionally, a separate murine 
model demonstrated that hepatocyte-specific deletion of SHP expression was protective 
against the development of diet-induced dyslipidemia (7). Taken together, these data 
suggest that repression of CYP7A1 decreases the rate of cholesterol metabolism and 
exhibits deleterious effects by promoting the onset of atherosclerosis and dyslipidemia.  
In addition to these observations, our laboratory and others have determined EFV 
to also be extensively metabolized by xenobiotic P450 monooxygenases (8-10). 




and, correspondingly, oxidative metabolism of RPV can result in methyl hydroxylation at 
the 2 and 6 positions (Figure 1). Our laboratory has also demonstrated that the synthetic 
primary metabolite, 8-hydroxy EFV (8-OHEFV), stimulates hepatotoxicity to a greater 
extent than EFV through activation of the c-Jun N-terminal kinase signaling pathway 
(11). This is a key finding in understanding EFV-induced hepatotoxicities as clinical 
studies have demonstrated 8-OHEFV plasma concentrations exceed that of the parent 
drug with chronic administration due to autoinduction (12). With these data in mind, a 
potential role for P450-dependent metabolite activation of the FXR signaling pathway 
should be taken into consideration as an alternative mechanism through which EFV may 
disrupt cholesterol and bile acid homeostasis. 
 
Figure 1. Structural comparison of NNRTIs efavirenz and rilpivirine. EFV is a first-
generation NNRTI and is the most widely-prescribed antiretroviral to date. RPV is a 
second-generation NNRTI that has an increased genetic barrier to resistance relative to 
EFV as well as an improved safety profile. Numbered carbon atoms indicate sites of 




Materials and Methods 
EFV and RPV were obtained through the National Institutes of Health AIDS 
Reagents Program. The c-Jun N-terminal kinase chemical inhibitor SP600125 was 
purchased from Tocris Bioscience (Avonmouth, Bristol, United Kingdom). 
Isolation of primary mouse hepatocytes and drug treatments 
Hepatocytes were isolated from 9-13 week-old male C57BL/6J (wild type, WT) 
mice as well as from 9-13 week-old male farnesoid X receptor knockout (FXR-/-) mice 
bred on a C57BL/6J background and purchased from Jackson Laboratories (Bar Harbor, 
ME). Hepatocytes were also isolated from mice 9-13 week-old male pregnane X receptor 
knockout (PXR-/-) mice bred on a C57BL/6J background and purchased from Taconic 
Biosciences (Hudson, NY). Primary mouse hepatocytes were isolated using retrograde 
liver perfusion with 25 mL 0.5 mM EGTA (Amresco LLC, Solon, OH) prepared in 1X 
PBS (Thermo Fisher Scientific, Waltham, MA) at 5 mL/min, followed by 25 mL 1X PBS 
at 5 mL/min, and lastly 20 mL of liver digest medium (Thermo Fisher Scientific) 
supplemented with 0.15 mg/mL collagenase (Sigma-Aldrich) at 2 mL/min. Following 
perfusion, livers were removed and cells were gently dissociated in 15 mL of ice-cold 
hepatocyte wash medium (Thermo Fisher Scientific) using a cell scraper and filtered 
through a 70 µm nylon mesh cell strainer. Hepatocytes were then pelleted at 50 x g for 5 
min at 4°C and washed twice with 10 mL hepatocyte wash medium. Cells were 
resuspended in 25 mL Williams E medium (Thermo Fisher Scientific) with 20 mL 
percoll (Sigma-Aldrich; 1 part 10X HBSS and 9 parts percoll) and inverted six times 




Williams E medium, pelleted at 50 x g for 5 min at 4°C, and resuspended in 10 mL 
Williams E medium supplemented with 10% fetal bovine serum (Thermo Fisher 
Scientific), 1% L-glutamine (Thermo Fisher Scientific), and 1% penicillin-streptomycin 
(Sigma-Aldrich). Hepatocytes were plated in six-well collagen-coated plates (Corning, 
Tewksbury, MA) at a density of 2.4 x 105 cells per well for RNA isolation. For assaying 
lipid droplet formation, hepatocytes were plated in 12-well collagen-coated plated 
(Corning) at a density of 1.0 x 105 cells per well. Cells were incubated overnight at 37°C 
and 5% CO2 prior to replacing the cell culture medium with fresh Williams E medium 
containing 10% fetal bovine serum, 1% L-glutamine, and 1% penicillin-streptomycin for 
drug treatments. Hepatocytes were treated with either DMSO (0.1%) vehicle or drug over 
a range of time points. For 48 h and 72 h drug treatments, cell culture medium was 
replaced every 24 h and hepatocytes were retreated with DMSO or drug. A total of four 
independent experiments were performed for hepatocytes isolated from WT and FXR-/- 
mice. 
RNA isolation and quantitative real-time PCR (qPCR) 
RNA was prepared from primary mouse hepatocytes using TRIzol (Thermo 
Fisher Scientific) following the manufacturer’s instructions for cells grown in a 
monolayer. Total RNA (1 µg) was reverse transcribed using Maxima First Strand cDNA 
Synthesis Kit (Thermo Fisher Scientific). The following primers were used for qPCR: 
Shp forward 5’- TGGGTCCCAAGGAGTATGC-3’ and reverse 5’- 
GCTCCAAGACTTCACACAGTG-3’; Gapdh forward 5’- 




3’. A Gapdh PCR product was generated from mouse hepatocyte RNA using 
conventional PCR and ligated into CloneJET PCR cloning kit for subcloning (Thermo 
Fisher Scientific). Serial dilutions of the resulting Gapdh plasmid were used to generate a 
standard curve for the quantitation of mRNA levels using Maxima SYBR Green qPCR 
Master Mix (Thermo Fisher Scientific). Gapdh served as the housekeeping gene for 
mRNA level normalization. The following qPCR cycling reactions were performed: 
denaturation of dsDNA for 10 min at 95°C proceeded by 40 cycles of denaturation for 15 
sec at 95°C, annealing for 30 sec at 60°C, and extension for 30 sec at 72°C. Resulting 
Shp copy numbers were normalized by Gapdh for each treatment and data was reported 
as fold change from DMSO control for each time point. 
Oil Red O staining of primary mouse hepatocytes  
 Intracellular lipid droplet formation was assayed using a steatosis colorimetric 
assay kit (Cayman Chemical, Ann Arbor, MI). The vendor’s protocol was followed for a 
12-well format. Following drug treatment, cell medium was aspirated and cells were 
fixed prior to staining with a 60% Oil Red O solution. After staining, wells were rinsed 
thoroughly with distilled water. Lipid accumulation was then quantified by incubating 
cells with the provided lipid droplet assay dye extraction solution. The extracted dye was 
then transferred to a 96-well plate and the absorbance was read at 490 nm. For qualitative 
assessment of intracellular distribution of lipid droplets, nuclei were stained with 






Statistical Analysis of Data 
Results are expressed as means ± standard deviation. Comparisons between 
experimental conditions were performed using an unpaired one-tailed Student’s t-test 
(GraphPad Prism 6 software). Statistical significances are denoted as: *, p ≤ 0.05; **, p ≤ 
0.01; ***, p ≤ 0.001. 
Results 
EFV, but not RPV, increased Shp mRNA expression in primary mouse hepatocytes 
Treatment of primary hepatocytes isolated from WT male mice demonstrated 
EFV, but not RPV, increased SHP mRNA expression in a time-dependent manner 
(Figure 2). A 2-fold increase of Shp mRNA expression was observed with 3 h of 10 µM 
EFV treatment. Increased Shp mRNA levels were sustained with chronic drug treatment 
resulting in a maximal 3-fold increase relative to DMSO control at 72 h. To test if this 
mRNA increase was FXR-dependent, hepatocytes were isolated from male mice 
genetically deficient of the nuclear receptor and treated with 10 µM EFV over a range of 
time (Figure 3). The 3 h transient increase of Shp mRNA expression previously observed 
in hepatocytes isolated from WT mice was significantly decreased in EFV treated 
hepatocytes isolated from FXR-/- mice. With chronic treatment of hepatocytes isolated 
from FXR-/- mice, however, EFV increased Shp mRNA levels to 2-fold at 72 h.  
The c-Jun N-terminal kinase (JNK) stress-activated signaling pathway can 
transcriptionally modulate Shp in an FXR-independent manner. To test if JNK activation 
could contribute to the EFV-mediated Shp mRNA expression observed in primary mouse 




prior to exposing to EFV and assaying for mRNA modulation (Figure 4). Interestingly, 
SP600125 fully abrogated the increase of Shp mRNA following 3 h of co-treatment with 
EFV. Although cells were retreated with inhibitor and EFV every 24 h, SP600125 failed 
to block an increase of Shp mRNA expression following 24, 48 and 72 h of co-treatment.  
 
Figure 2. Comparative effects of EFV and RPV on the modulation of Shp mRNA 
expression in primary mouse hepatocytes. Hepatocytes were isolated from WT male 
mice and treated for 3, 6, 12, 24, 48 and 72 h with either 0.1% DMSO as vehicle control 
or 10 µM drug. Following drug treatment, RNA was isolated from hepatocytes using 
TRIzol. RNA (1 µg) was then reverse transcribed to cDNA for use in qPCR to measure 
Shp and Gapdh mRNA levels. Data are shown as mean fold change from DMSO control 
± S.D. for four independent experiments. Statistical significance from control is shown as 





Figure 3. Treatment of hepatocytes isolated from FXR null mice does not fully 
abrogate EFV-mediated Shp mRNA increase. Hepatocytes were isolated from WT and 
FXR null male mice and treated for 3, 6, 12, 24, 48 and 72 h with either 0.1% DMSO as 
vehicle control or 10 µM EFV. Following drug treatment, RNA was isolated from 
hepatocytes using TRIzol. RNA (1 µg) was then reverse transcribed to cDNA for use in 
qPCR to measure Shp and Gapdh mRNA levels. Data are shown as mean fold change 
from DMSO control ± S.D. for four independent experiments. Statistical significance 






Figure 4. Chemical inhibition of c-Jun N-terminal kinase transiently abolished EFV-
mediated Shp mRNA increase. Hepatocytes were isolated from WT male mice and 
pretreated with the c-Jun N-terminal kinase chemical inhibitor SP600125 (25 µM) for 30 
min. Following pre-treatment with inhibitor, cells were then treated with either 0.1% 
DMSO as vehicle control or 10 µM EFV for 3, 24, 48 and 72 h. Following drug 
treatment, RNA was isolated from hepatocytes using TRIzol. RNA (1 µg) was then 
reverse transcribed to cDNA for use in qPCR to measure Shp and Gapdh mRNA levels. 
Data are shown as mean fold change from DMSO control ± S.D. for four independent 
experiments. Statistical significance from EFV drug treatment is shown as *, p ≤ 0.05, 
**, p ≤ 0.01 and ***, p ≤ 0.001. 
EFV, but not RPV, promotes lipid droplet formation in primary mouse hepatocytes 
 In an effort to establish EFV indeed disrupts lipid homeostasis, primary mouse 




increase of lipid droplet formation from control of 2- and almost 3-fold following 48 h 
and 72 h treatment, respectively (Figure 5A and 5B). A more physiologically relevant 
concentration of EFV (10 µM) qualitatively increased lipid droplet formation (data not 
shown), however, this difference was not captured quantitatively due to assay sensitivity 
limitations. RPV at neither 10 µM nor 50 µM concentrations stimulated lipid droplet 
formation. Further, chronic treatment of hepatocytes with RPV at 50 µM appeared cause 
cell death and, at this same concentration, RPV caused an approximate 40% decrease in 





Figure 5. EFV, but not RPV, promotes lipid droplet formation in primary mouse 




colorimetric assay kit and lipid droplets were stained using a 60% Oil Red O solution. 
(A) Lipid accumulation was quantified by extracting Oil Red O and reading the 
absorbance at 490 nm. (B) For qualitative assessment of intracellular distribution of lipid 
droplets, nuclei were stained with hematoxylin and imaged using a phase contrast 
microscope. Data are shown as mean fold change from DMSO control ± S.D. for three 
independent experiments. Statistical significance from control is shown as *, p ≤ 0.05. 
Future Directions 
There are several questions that remain unanswered with this work. Thus far, our 
data suggests EFV is not a direct activator of FXR. Further, in an effort to take an 
unbiased approach toward investigating the mechanism by which EFV modulates hepatic 
cholesterol homeostasis, we tested for lipid droplet formation in hepatocytes isolated 
from WT male mice. In these experiments, we were excited to see that EFV treatment, 
but not RPV, resulted in a distinct phenotype of hepatic lipid droplet formation in a time-
dependent manner. Although lipid droplets were observed qualitatively in 10 µM EFV 
treatments, which is approximately equal to steady-state plasma levels with once-daily 
dosing in humans, the most dramatic phenotype was observed with 72 h treatment of 50 
µM EFV. In an attempt to recapitulate this observation in primary human hepatocytes, we 
performed these treatments in isolates from three individual human donors, yet lipid 
droplet formation was not observed with EFV treatment suggesting a potential species-
specific difference.  
That being said, we have begun to probe for potential signaling pathways that 




formation. For example, chronic pregnane X receptor (PXR) activation has been 
demonstrated in mice to lead to the disruption of lipid and cholesterol homeostasis. EFV 
is a strong activator of PXR as we and others have previously demonstrated, however, 
lipid droplet formation was not abrogated upon chronic treatment of hepatocytes isolated 
from mice deficient of PXR (Figure 6). Moving forward, it is imperative to test the 
impact of Shp siRNA knockdown on EFV-mediated lipid droplet formation in primary 
mouse hepatocytes. If Shp is indeed found to play a causal role in the establishment of 
this phenotype, then there are several hepatic signaling pathways regulated by Shp that 
can be further investigated, such as the mevalonate metabolic pathway that produces 





Figure 6. Genetic deficiency of the PXR does not abrogate lipid droplet formation in 




assayed using a steatosis colorimetric assay kit and lipid droplets were stained using a 
60% Oil Red O solution. (A) Lipid accumulation was quantified by extracting Oil Red O 
and reading the absorbance at 490 nm. (B) For qualitative assessment of intracellular 
distribution of lipid droplets, nuclei were stained with hematoxylin and imaged using a 
phase contrast microscope. Data are shown as mean fold change from DMSO control ± 
S.D. for three independent experiments. Statistical significance from control is shown as 
*, p ≤ 0.05. 
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Chapter 6: Discovery of Genetic Variants of the Kinases that Activate Tenofovir in 
a Compartment-Specific Manner 
Abstract  
Tenofovir (TFV) is used in combination with other antiretroviral drugs for human 
immunodeficiency virus (HIV) treatment and prevention. TFV requires two 
phosphorylation steps to become pharmacologically active; however, the kinases that 
activate TFV in cells and tissues susceptible to HIV infection have yet to be identified. 
Peripheral blood mononuclear cells (PBMC), vaginal, and colorectal tissues were 
transfected with siRNA targeting nucleotide kinases, incubated with TFV, and TFV-
monophosphate (TFV-MP) and TFV-diphosphate (TFV-DP) were measured using mass 
spectrometry-liquid chromatography. Adenylate kinase 2 (AK2) performed the first TFV 
phosphorylation step in PBMC, vaginal, and colorectal tissues. Interestingly, both 
pyruvate kinase isozymes, muscle (PKM) or liver and red blood cell (PKLR), were able 
to phosphorylate TFV-MP to TFV-DP in PBMC and vaginal tissue, while creatine 
kinase, muscle (CKM) exclusively catalyzed this conversion in colorectal tissue. In 
addition, next-generation sequencing of the Microbicide Trials Network MTN-001 
clinical samples detected 71 previously unreported genetic variants in the genes encoding 
these kinases. In conclusion, our results demonstrate that TFV is activated in a 
compartment-specific manner. Further, genetic variants have been identified that could 







Within the last decade, tenofovir (TFV), prescribed as tenofovir disoproxil 
fumarate in its prodrug formulation, has emerged as a critical component of antiretroviral 
combination therapy for the treatment of human immunodeficiency virus (HIV) (1, 2). 
More recently, oral as well as vaginal and rectal microbicide gel preparations of TFV 
have been investigated for use in pre-exposure prophylaxis (PrEP) as an HIV prevention 
strategy for individuals at high-risk of viral exposure (3-5). TFV is a drug desirable 
candidate for PrEP due to the long half-life of active drug TFV-diphosphate (TFV-DP) 
reported to be 53 h in vaginal tissue homogenate and up to 139 h in vaginal CD4+ cells 
following an oral dosing of HIV-uninfected women (6, 7). That being said, there has been 
discrepancy in the prophylactic effect observed for TFV-based regimens. For example, 
the Partners in Prevention study demonstrated a 67-75% reduction in HIV acquisition in 
serodiscordant heterosexual couples, iPrEx demonstrated a 44% reduction in men or 
transgender women who have sex with men, and FEM-PrEP and VOICE trials showed no 
significant reduction in the rate of infection in heterosexual women (8-10). This disparity 
has been primarily due to poor adherence. Adjusting for adherence, the differences 
among these clinical trials has been attributed to the increased accumulation of active 
drug in colon versus vaginal tissue. As such, these findings suggest that the enzymes 
responsible for TFV activation may differ between colon and vaginal tissue, however, 
this has not been tested thus far. Further, while yet to be explored, it can be envisioned 




inter-individual differences in tissue TFV-DP concentrations that has been noted even 
when adherence is high (7, 11, 12).  
As TFV requires phosphorylation by nucleotide kinases in order to become 
pharmacologically active, both local mucosal tissue cell phosphorylation and distant 
peripheral blood CD4+ cell phosphorylation with secondary migration to mucosal tissue 
may be critical in achieving effective TFV-DP concentrations. If mucosal tissue 
phosphorylation is an essential contribution to mucosal tissue cell TFV-DP 
concentrations, then the kinases responsible for TFV transformation are expressed in cells 
and tissues associated with HIV infection (2, 13). To date, the expression profiles of 
nucleotide kinases in peripheral blood mononuclear cells (PBMC), vaginal tissue, and 
colorectal tissue have not been characterized and data demonstrating kinase activity 
towards TFV and TFV-MP are lacking. In vitro studies using human T-lymphoid cells 
demonstrated the mitochondrial and cytosolic enzyme adenylate kinase isoform 2 (AK2) 
could catalyze the phosphorylation of TFV to form TFV-monophosphate (TFV-MP) (14-
16). Experimental evidence is deficient, however, with regards to the nucleotide kinase(s) 
capable of transforming TFV-MP to TFV-DP. TFV-MP has been reported as a substrate 
of NME/NM23 nucleoside diphosphate kinase 1 (NME1) as this enzyme demonstrates 
broad activity towards purine nucleoside diphosphates (2, 17). Yet, in separate studies, 
NME1 exhibited low to non-detectable rates of catalysis, while creatine kinase, muscle 
(CKM) efficiently phosphorylated TFV-MP and minor catalytic efficiency towards TFV-
MP was demonstrated by rabbit pyruvate kinase, muscle (PKM) (18, 19). Nevertheless, 




systems, whether or not they are expressed in cells and tissues susceptible to HIV 
infection is unknown. 
In the present study, we characterized nucleotide kinase expression in PBMC, 
vaginal tissue, and colorectal tissue in order to identify those that catalyze the 
phosphorylation of TFV to TFV-MP and TFV-MP to TFV-DP. Towards this end, we 
knocked down the protein expression of AK2, CKM, PKM, pyruvate kinase, liver and 
red blood cell (PKLR), and guanylate kinase 1 (GUK1) using siRNA. Neither PKLR nor 
GUK1 have been previously reported to activate TFV; however, PKLR exhibits an 
approximate 70% amino acid sequence identity to the isozyme PKM and GUK1 has been 
demonstrated to phosphorylate the antiviral drug adefovir which is structurally similar to 
TFV.(20) Taking these studies a step further, we wanted to leverage our identification of 
the nucleotide kinases that activate TFV and test for the existence of genetic variants in 
AK2, CKM, PKM, and PKLR. To do so, we performed next-generation targeted 
sequencing of genomic DNA isolated from the plasma of 142 HIV-uninfected female 
participants of the Microbicide Trials Network study MTN-001 (11). In this work, we 
have demonstrated at an enzymatic level that TFV is activated in a tissue-specific 
manner. We also put forth an innovative concept that variation in the genes that encode 
the nucleotide kinases that activate TFV may contribute to inter-individual differences 
observed clinically. Taken together, these findings represent a shift in thinking about the 






Materials and Methods 
siRNA knockdown of nucleotide kinases  
PBMC were obtained from Bioreclamation (Westbury, NY), and fresh vaginal 
and colorectal biopsies were obtained from the Johns Hopkins University School of 
Medicine Tissue Bank (Baltimore, MD). Donor information is as follows: PBMC (n=3; 
38 y.o. male, 24 y.o. female, and 27 y.o. female); vaginal tissue (n=3; 31 y.o. female, 48 
y.o. female, and 37 y.o. female); colorectal tissue (n=3; 35 y.o. male, 39 y.o. female, 42 
y.o. male). All donors were healthy, HIV-uninfected individuals. Nucleotide kinases were 
knocked down using siGENOME siRNA (Dharmacon, GE Healthcare Life Sciences, 
Lafayette, CO). PBMC and tissues transfected with non-targeting siRNA were used as 
controls. For transfection of PBMC, a Neon™ Transfection System (Life Technologies, 
Fredrick, MD) was used. Electroporation conditions were as follows: pulse voltage 2100 
V, pulse width 15 ms, 1 pulse, 1 x 10
6 
cells, and 500 nM siRNA. For tissue 
electroporation, a total of 5 mg of tissue was used for a single electroporation. The tissues 
were electroporated in 0.4 cm cuvettes (Bio-Rad, Hercules, CA) using a Gene Pulser 
Xcell™ electroporater (Bio-Rad). A square waveform (500 V and 10 ms) and 500 nM of 
siRNA was used. 
Immunoblotting of nucleotide kinases  
Following electroporation, tissues were cultured for 24 h and PBMC for 48 h in 
DMEM supplemented with 10% FBS prior to homogenization. For immunoblots, 10 μg 
of homogenized cells and tissues were resolved by SDS-PAGE gel electrophoresis. 




PKM, PKLR, and GUK1 antibodies (Thermo Fisher Scientific, Waltham, MA). Anti-β-
actin was used for normalization (Cell Signaling, Danvers, MA).  
Detection of TFV, TFV-MP, and TFV-DP using ultra-high performance liquid 
chromatography-tandem mass spectrometry  
TFV (10 μM; NIH AIDS Reagent Program) was added to the culture medium 24 
h (for vaginal and colorectal tissues) or 48 h (for PBMC) after electroporation with 
siRNA. Following 12 h of incubation with TFV, the tissues and cells were harvested and 
homogenized in 70% methanol. Samples were centrifuged for 10 min at 1,500 x g at 4ºC 
and the supernatant was dried under vacuum. An ultra-high performance liquid 
chromatography-tandem mass spectrometry (uHPLC-MS/MS) assay was developed for 
the quantification of TFV, TFV-MP, and TFV-DP using a Dionex Ultimate 3000 uHPLC 
system coupled to a TSQ Vantage Triple Stage Quadrupole mass spectrometer (Thermo 
Fisher Scientific). Analytes were separated using a Hypersil GOLD-C18 column (3 μm, 
100 mm x 1 mm, Thermo Fisher Scientific) at a flow rate of 0.05 mL/min. Solvent A was 
2 mM ammonium phosphate (Thermo Fisher Scientific) with 3 mM hexylamine (Thermo 
Fisher Scientific) in water, pH 9.2, and solvent B was acetonitrile (Thermo Fisher 
Scientific). The gradient used is as follows: 9% B from 0 to 0.5 min, 9% B to 60% B 
from 0.5 to 15.5 min, 60% B to 9% B from 15.5 to 15.6 min, and held at 9% B until 29.6 
min. In selected reaction monitoring mode, fragment ions were detected by positive 
ionization using the following transitions (Q1→Q3): TFV (m/z 288→176), TFV-MP (m/z 
368→270), and TFV-DP (m/z 448→270). Dried cell and tissue extracts were 





Plasma was obtained from HIV-uninfected females (n=142) enrolled in the 
Microbicide Trials Network study MTN-001 across seven study sites: Umkomaas and 
Botha’s Hill, Durban, South Africa; Makerere University-Johns Hopkins University 
Research Collaboration, Kampala, Uganda; Case Western Reserve University in 
Cleveland, OH, United States of America (USA); University of Pittsburgh, Pittsburgh, 
PA, USA; University of Alabama at Birmingham, Birmingham, AL, USA; Bronx-
Lebanon Hospital Center, New York City, NY, USA (11). The current analysis was 
approved by the Johns Hopkins Medicine IRB (NA_00016287).  
Genomic DNA isolation  
Genomic DNA was isolated from 200 µL of plasma using the GeneJET Whole 
Blood Genomic DNA Purification Mini Kit (Thermo Fisher Scientific, Waltham, MA). 
Purified DNA was eluted using 50 µL of elution buffer. 
Sample preparation for Next-generation sequencing  
Samples were prepared following the TSCA library preparation guide using 50 ng 
of template DNA per reaction. Agencourt AMPure XP beads (Beckman Coulter, Inc., 
Brea, CA) were used for PCR clean-up and library normalization was performed 
according to the TSCA protocol. The final pooled DNA library (6 μL) was diluted in 594 
μL HT1 buffer and spiked with 1% PhiX. One technical control was included per sample 
batch and runs were sequenced using an Illumina MiSeq sequencing platform generating 





Next-generation sequencing targeted enrichment design 
Sequencing was performed using the Illumina TruSeq custom amplicon v1.5 kit 
(San Diego, CA). Custom probes targeting the exonic regions of AK2, CKM, PKM, and 
PKLR were generated in silico using Illumina DesignStudio software. The chromosomal 
coordinates used were as follows: AK2 1:33473531 – 1:33502522; CKM 19:45809661 – 
19:45826243; PKM 15:72492805 – 15:72523694; PKLR 1:155259074 – 1:155271235. 
The final design included 102 amplicons. All genetic variants reported in this study have 
been submitted to the SNP database under the submitter handle “BUMPUSLAB.”  
Next-generation sequencing data analysis  
Secondary analysis of the base calls and Phred-like quality score (Qscore) 
generated by Real Time Analysis software was performed using on-instrument MiSeq 
Reporter software. Reads were mapped to the GRCh37 (hg19) reference assembly using 
a banded Smith-Waterman algorithm and variant calling was carried out using the 
Genome Analysis Toolkit. Variant call format files were annotated using Illumina 
VariantStudio software. Raw variant calls were filtered applying a coverage threshold > 
30X, a minimum base call Qscore of 30, and an alternate variant frequency > 20%. 
Variants were cross-referenced with the National Center for Biotechnology Information 
database of Single Nucleotide Polymorphisms. The phenotypic consequence of missense 
variants was assigned using (sorts intolerant from tolerant substitutions; J. Craig Venter 
Institute online tool) and PolyPhen (polymorphism phenotyping; Harvard University 
online tool) in silico prediction tools where amino acid substitutions were scored. A SIFT 




substitution, whereas a PolyPhen score > 0.908 was suggestive of a probably damaging, 
0.447-0.908 a possibly damaging, or < 0.447 a benign amino acid substitution (21, 22). 
Statistical Analysis 
Statistical analyses were performed using GraphPad Prism (San Diego, CA). 
Two-tailed unpaired t tests were performed and significance was denoted as follows: *, p 
≤ 0·05; **, p ≤ 0·01; ***, p ≤ 0·001. 
Results 
Nucleotide kinase activation of TFV in cells and tissues susceptible to HIV infection 
In order to identify the nucleotide kinases that activate TFV in PBMC, vaginal, 
and colorectal tissue, we delivered siRNA targeted to AK2, GUK1, PKM, PKLR, and 
CKM to cells and tissues followed by incubation with TFV to test the impact on drug 
activation. The experiments described herein were performed in cells and tissues from 
healthy, HIV-uninfected donors that were not administered TFV. Candidate kinases were 
screened using immunoblotting in order to test for their expression in PBMC, vaginal, 
and colorectal tissues shown in Figure 1. The non-targeting, or no target, siRNA lane in 
the representative immunoblot is commensurate with basal expression of each kinase in 
PBMC, colon, and vaginal tissues, respectively. We found that AK2, which has been 
previously reported to catalyze the phosphorylation of TFV to TFV-MP, was expressed 
ubiquitously in the cells and tissues investigated in this study. A similar protein 
expression profile was observed for the nucleotide kinase GUK1. Interestingly, of the 
candidates examined for the transformation of TFV-MP to TFV-DP, PKM and PKLR 




isoenzyme was not detectable in colorectal tissue using immunoblot analyses. In contrast, 
CKM was observed to be exclusively expressed in colorectal tissue and not detectable at 
the protein level in PBMC or vaginal tissue. It is important to note that NME1, which has 
been reported to transform TFV-MP to TFV-DP with weak catalytic efficiency, was not 
detectable at the protein level in PBMC, vaginal tissue, or colorectal tissue (data not 
shown). 
  Guided by our preliminary findings, siRNA was used to knockdown the following 
nucleotide kinases AK2, GUK1, PKM, and PKLR in PBMC (n=3), AK2, GUK1, and 
CKM in colorectal tissue (n=3), and AK2, GUK1, PKM, and PKLR in vaginal tissue 
(n=3). Decreased expression of each targeted kinase was evaluated by immunoblot 
analysis relative to the non-targeting siRNA control (Figure 1). The intracellular 
formation of TFV metabolites was detected using uHPLC-MS/MS and the impact of 
enzyme loss-of-function on TFV-MP and TFV-DP formation following incubation with 
TFV are shown as bar graphs in Figure 1. When AK2 was knocked down, TFV-MP 
decreased to 17 ± 1.4% (17/100 ± 1.4/100), 9.5 ± 1.1% (9.5/100 ± 1.1/100), and 12 ± 
1.5% (12/100 ± 1.5/100; p-value = 3.4E-6, 3.6E-5, and 7.2E-5) of the non-targeting 
siRNA control in PBMC, colorectal tissue, and vaginal tissue, respectively. Knockdown 
of AK2 protein expression also resulted in a decrease of TFV-DP to 13 ± 1.7% (13/100 ± 
1.7/100), 15 ± 2.3% (15/100 ± 2.3/100), and 9 ± 2.2% (9/100 ± 2.2/100; p-value = 3.9E-
6, 4.5E-6, and 2.7E-5) of non-targeting control in PBMC, colorectal tissue, and vaginal 
tissue, respectively. Knockdown of PKM decreased TFV-DP to 33 ± 5.8% (33/100 ± 




PBMC and vaginal tissue, respectively. Additionally, knockdown of PKLR decreased 
TFV-DP to 78 ± 6.6% (78/100 ± 6.6/100) and 81 ± 7.4% (81/100 ± 7.4/100; p-value = 
0.008 and 0.017) of control in PBMC and vaginal tissue, respectively. When CKM was 
knocked down in colorectal tissue, TFV-DP was decreased to 8 ± 2.9% (8/100 ± 2.9/100; 
p-value = 2.2E-5) of control. The observed tissue-specific activation of TFV has been 






Figure 1. Targeted siRNA knockdown of nucleotide kinases in PBMC, colorectal 
tissue, and vaginal tissue and the resulting impact on TFV-MP and TFV-DP 
intracellular formation. PBMC, colorectal tissue, and vaginal tissue were electroporated 
with 500nM non-targeting siRNA or siRNA targeting AK2, GUK1, PKM, PKLR, and 
CKM and incubated for 24 h or 48 h for tissue or PBMC, respectively. Representative 




siRNA treatment relative to the non-targeting siRNA control. siRNA treated (A) PBMC, 
(B) colorectal tissue, and (C) vaginal tissue were incubated with 10 µM TFV for 12 h 
(n=3 per treatment). Intracellular anabolites were extracted from which TFV-MP and 
TFV-DP were detected using uHPLC-MS/MS as depicted in the corresponding bar 
graphs showing mean ± standard deviation for each treatment. Statistical analyses were 
performed using a two-tailed unpaired t test to compare relative levels of anabolite 
production between non-targeted and targeted siRNA conditions; * = p ≤ 0.05; ** = p ≤ 
0.01; *** = p ≤ 0.001. 
 
Figure 2. Schematic summarizing the intracellular activation of the antiretroviral 
drug TFV in cells and tissues susceptible to HIV infection. AK2 can transform TFV to 
TFV-MP in PBMC, colorectal, and vaginal tissues. PKM and PKLR can transform TFV-
MP to the active anabolite TFV-DP in PBMC and vaginal tissue, while CKM can 
transform TFV-MP to TFV-DP in colorectal tissue. 
MTN-001 participant demographics and ethnicities 
For this retrospective study, we obtained plasma from 142 of the total 144 




and self-identified ethnicities are summarized in Table 1. An approximate half of these 
participants were enrolled at the United States study sites (USA; n=72) and the remaining 
participants were enrolled at either the South Africa (SA; n=46) or Uganda (UGA; n=24) 
study sites.  
 
Table 1. MTN-001 participant demographics and self-identified ethnicities.  
Plasma samples were obtained from 142 HIV-uninfected female participants of the 
MTN-001 clinical trial for genomic DNA isolation. Participants were enrolled in study 
sites across the United States (USA; n=72), South Africa (SA; n=46), and Uganda (UGA; 
n=24). 
Next-generation sequencing of MTN-001 clinical samples 
In order to test for the existence of genetic variants within the nucleotide kinases 
that activate TFV, we designed a targeted assay to sequence the exonic regions of AK2, 




observed 57 subjects (40%, 57/142) to carry single-base variations or deletions in their 
DNA that may result in a mutation at the amino acid level. Though this assay was 
targeted to exonic regions, we detected genetic variation within flanking intronic regions 
as well. The distribution of the variants and deletions detected for each kinase are 
depicted using a Venn diagram in Figure 3. In 40 participants, we observed genetic 
variants within only one nucleotide kinase, while 17 individuals carried variants within 
two (n=16) or three (n=1) nucleotide kinases.  
 
Figure 3. Distribution of nucleotide kinase genetic variants detected in 57 MTN-001 
participants. Each colored oval is representative of a nucleotide kinase AK2 (blue), CKM 
(red), PKM (green), and PKLR (yellow). Non-overlapping regions demonstrate the 
number of participants observed to carry single nucleotide variants (SNVs) and deletions 
within only one gene (n=40; AK2 n=6, CKM n=8, PKM n=14, PKLR n=12). Overlapping 
regions demonstrate the number of participants that were observed to carry SNVs and 




the diagram, six participants carried AK2 genetic variants alone, two participants carried 
variants for AK2 and PKM, one participant carried variants for AK2, PKM, and PKLR, 
and one participant carried variants for AK2 and PKLR. 
Targeted sequencing of AK2 
A total of 12 previously unreported single nucleotide variants (SNVs) and 
deletions that may impact the protein-coding potential of the AK2 mRNA transcript were 
detected in 11 participants, six enrolled in USA study sites, two in SA, and three in UGA. 
Of the detected AK2 variants, seven missense variants, which cause a mutation at the 
amino acid level for the encoded protein, were detected in seven heterozygous 
individuals at a frequency of one individual per variant (Table 2). Using in silico tools, 
three of the observed missense variants were predicted to have a deleterious and 





Table 2. AK2 missense variants detected in MTN-001 participants. A total of seven 
previously unreported AK2 missense variants were detected in seven heterozygous MTN-
001 participants for the coding DNA reference sequence NM_001625.3. The functional 
consequence of resulting amino acid mutations were predicted using SIFT and PolyPhen 
in silico tools. A SIFT score < 0.05 was suggestive of a damaging amino acid substitution 
and > 0.05 a tolerated substitution. A PolyPhen score > 0.908 was suggestive of a 
probably damaging, 0.447-0.908 a possibly damaging, or < 0.447 a benign amino acid 
substitution. Deleterious and probably damaging AK2 missense variants was observed at 




Targeted sequencing of CKM 
A total of 18 previously unreported SNVs and deletions that may impact the 
protein-coding potential of the CKM mRNA transcript were detected in 17 participants, 
eight enrolled in USA study sites, four in SA, and five in UGA. Of the detected SNVs, 15 
heterozygous participants were found to carry 15 CKM missense variants with a 
frequency of one individual per variant (Table 3). Using in silico tools, four of the 
observed missense variants were predicted to have a deleterious and damaging impact on 
protein function with a frequency of 3% (4/142 individuals). Further, the following 
reference single nucleotide polymorphism (SNP) missense variants rs11559024 
(NM_001824.4:c.248T>C) and rs17357122 (NM_001824.4:c.497G>A) were detected in 
two heterozygous USA participants (one individual per variant), and rs17875625 
(NM_001824.4:c.728C>A) was detected in one heterozygous SA participant. Of the 
detected reference SNPs, only rs17875625 was predicted to have a deleterious and 





Table 3. CKM missense variants detected in MTN-001 participants. A total of 15 
previously unreported CKM missense variants were detected in 15 heterozygous MTN-
001 participants for the coding DNA reference sequence NM_001824.4. The functional 
consequence of resulting amino acid mutations were predicted using SIFT and PolyPhen 
in silico tools. A SIFT score < 0.05 was suggestive of a damaging amino acid substitution 
and > 0.05 a tolerated substitution. A PolyPhen score > 0.908 was suggestive of a 
probably damaging, 0.447-0.908 a possibly damaging, or < 0.447 a benign amino acid 
substitution. Deleterious and probably damaging CKM missense variants was observed at 




Targeted sequencing of PKM 
A total of 19 previously unreported SNVs and deletions that may impact the 
protein-coding potential of the PKM mRNA transcript were detected in 19 participants, 
nine enrolled in USA study sites, five in SA, and five in UGA. Of the detected SNVs, 14 
PKM missense variants were detected in 14 heterozygous participants at a frequency of 
one individual per variant (Table 4). In silico tools were unable to predict the functional 
impact of the observed missense variants due to the lack of sequence diversity required 
for the performed multiple sequence alignments. In addition to the observed PKM SNVs, 
three heterozygous USA participants (one individual per variant) were found to carry the 
following reference SNPs: stop gained variants rs180716407 
(NM_001206796.1:c.14G>C) and rs151078084 (NM_001206796.1:c.1354G>A) and the 





Table 4. PKM missense variants detected in MTN-001 participants. A total of 14 
previously unreported PKM missense variants were detected in 14 heterozygous MTN-
001 participants for the coding DNA reference sequence NM_001206796.1. SIFT and 
PolyPhen in silico tools could not predict the functional impact of the observed missense 
variants with a high degree of confidence due to the lack of sequence diversity that is 




Targeted sequencing of PKLR 
A total of 22 previously unreported SNVs and deletions that may impact the 
protein-coding potential of the PKLR mRNA transcript were detected in 21 participants, 
14 enrolled in USA study sites, four in SA, and three in UGA. Of the observed SNVs, 15 
PKLR missense variants were detected in 15 heterozygous participants at a frequency of 
one individual per variant (Table 5). Using in silico tools, four of the detected missense 
variants were predicted to have both a deleterious and damaging impact on protein 
function with a frequency of 3% (4/142 individuals). The reference SNP missense variant 
missense variant rs147689373 (NM_000298.5:c.829C>T) was detected in one 





Table 5. PKLR missense variants detected in MTN-001 participants. A total of 15 
previously unreported PKLR missense variants were observed in 15 heterozygous MTN-
001 participants for the coding DNA reference sequence NM_000298.5. The functional 
consequence of resulting amino acid substitutions were predicted using SIFT and 
PolyPhen in silico tools. A SIFT score < 0.05 was suggestive of a damaging amino acid 
substitution and > 0.05 a tolerated substitution. A PolyPhen score > 0.908 was suggestive 
of a probably damaging, 0.447-0.908 a possibly damaging, or < 0.447 a benign amino 
acid substitution. Deleterious and probably damaging PKLR missense variants was 





This study identified the nucleotide kinases that activate TFV in cells and tissues 
susceptible to HIV infection. Our data suggests that AK2 may be a key contributor to 
systemic and localized TFV activation as siRNA knockdown in PBMC, vaginal tissue, 
and colorectal tissue resulted in significantly decreased formation of TFV metabolites. 
Additionally, we demonstrated PKLR can contribute to TFV-DP formation in PBMC and 
vaginal tissue. PKLR is highly expressed in the liver and therefore may be critical for the 
activation of oral TFV preparations that undergo first-pass metabolism. Interestingly, we 
observed CKM protein expression to be limited to colorectal tissue. TFV-DP 
concentrations in colon exceed those in vaginal tissue with an oral dose of TFV and 
tissue-specific expression of CKM could contribute to this phenomenon. Further, 
although these data do not comprehensively explain the increased incidence of HIV PrEP 
failure in heterosexual individuals relative to men who have sex with men, our findings 
are in support of a genetic basis for the reported “colon advantage” described for 
tenofovir tissue distribution. Additionally in this study, we examined a potential role for 
the nucleotide diphosphate kinase NME1. We did not detect NME1 expression at the 
protein level in PBMC, vaginal, or colorectal tissue, suggesting NME1 is unlikely to 
contribute to the activation of TFV in the cells and tissues investigated. 
Through our work, we identified AK2, CKM, PKM, and PKLR as candidates for 
examination in a retrospective clinical study. In doing so, we detected 71 previously 
unreported variants in the genes encoding these kinases. The coverage threshold 




and Genomics clinical laboratory standards for next-generation sequencing, increasing 
the confidence in the variants called.(23) These discovered variants, however, were not 
validated in parallel using Sanger sequencing. We detected seven genetic variants in 
CKM, PKM, and PKLR that have been reported in the SNP database. The CKM SNPs 
rs11559024 and rs17357122 detected in MTN-001 European American participants have 
frequencies of 1 – 3% in Western European populations as reported by the 1000 
Genomes Project.(24) These populations also exhibit a comparable frequency for the 
PKM SNP rs180716407 detected in one European American participant, and African sub-
populations of Nigeria, Kenya, and Sierra Leone have a frequency of 1 – 2% for the 
PKLR SNP rs147689373 detected in one South African participant. Population genetics 
aside, the impact of these discovered and reported genetic variants on enzymatic activity 
is unknown. For the detected missense variants, however, we were able to predict the 
phenotypic consequence of resulting amino acid mutations using in the silico 
bioinformatic tools SIFT and PolyPhen. For example, one MTN-001 participant carried 
the CKM missense variant NM_001824.4:c.389G>A, causing a deleterious and damaging 
amino acid mutation of R130H. In line with this, a study characterizing TFV-MP binding 
within the active site of CKM observed this particular amino acid residue R130 to form 
strong ionic interactions with its substrates.(19) Moreover, one can envision that such a 
mutation may interfere with substrate binding and, therefore, decrease rates of 
phosphorylation. That being said, the variants predicted in our study to negatively impact 
kinase function ultimately need to be recapitulated in vitro using site-directed 




Due to the frequency of the genetic variants detected within the MTN-001 
participants, we were unable to make strong correlations with our published TFV 
pharmacokinetic data.(11) Additionally, adherence is a confounding issue for HIV PrEP 
studies making it particularly difficult to execute these analyses in a retrospective study. 
As a proof of concept, however, it is worth noting an African American participant 
carrying a predicted dysfunctional missense variant for PKLR exhibited a three-fold 
greater ratio of TFV to TFV-DP in vaginal tissue compared to homozygous wild-type 
participants with daily use of a 1% TFV microbicide gel and is commensurate with lower 
TFV-DP tissue concentrations. In order to perform a powerful analysis, a 
pharmacokinetic study design is required in which healthy volunteers would be enrolled 
based on genotype in the same manner used for our recent study of the anti-HIV drug 
maraviroc.(25) Further, as this preliminary pharmacogenomics study was limited to 
females it would also be of interest to perform a similar analysis in men in order to 
investigate potential sexual dimorphisms in allele frequencies.  
In conclusion, our results present a fundamental shift when considering the factors 
that govern TFV disposition as differing routes of activation could contribute to tissue-
specific pharmacokinetic-pharmacodynamic relationships. Further, in identifying the 
nucleotide kinases responsible for TFV activation in PBMC, vaginal tissue, and 
colorectal tissue, we were able to perform targeted sequencing of the genes encoding 
these kinases using clinical samples of the MTN-001 Microbicide Trials Network study. 
We detected genetic variants in these kinases predicted to have deleterious and damaging 




variation in TFV drug levels. Taken together, the results from this study are pushing an 
important concept forward in that HIV PrEP is not a one-size-fits-all preventative 
approach, and these data can guide future clinical studies to investigate the impact of 
nucleotide kinase genetic variants on TFV pharmacokinetics. 
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Chapter 7: Final Conclusions 
 
 With the advent of antiretroviral drug therapy in the late 1980s, human 
immunodeficiency virus (HIV) is no longer a death sentence, but remains to be a chronic 
disease. Of concern, however, an estimated 2.1 million individuals were newly infected 
with HIV globally as of 2015. Further, HIV remains to be a pandemic that requires 
attention from scientific researchers to push forward the development of novel drug 
therapies that mitigate viral resistance and improve overall safety profiles.  
Rilpivirine (RPV), a second generation non-nucleoside reverse transcriptase 
inhibitor (NNRTI), was FDA approved in 2011 for administration to treatment-naïve 
HIV-infected individuals. We were the first to characterize and publish the human 
biotransformation of RPV. A reverse phase ultra-high performance liquid 
chromatography-tandem mass spectrometry assay was developed in order to detect RPV 
and characterize its polar metabolites using fragmentation spectra. By in vitro assay, we 
observed the cytochrome P450s CYP3A4 and CYP3A5 primarily contributed to the 
oxidative metabolism of RPV and the uridine diphosphate glucuronosyl transferases 
UGT1A1 and UGT1A4 could contribute to the conjugation of RPV and its metabolites. 
In addition to this work, we also developed and published a targeted metabolomics screen 
allowing for the investigation of intracellular small molecule homeostasis that may be 
impacted by chronic antiretroviral therapy. Further, these studies most importantly laid 
the foundation for the bioanalysis of RPV and its metabolites in the plasma of HPTN 076 
study participants in addition to guiding the selection of drug metabolizing enzymes 




In the former studies, it was observed RPV could modulate CYP3A4 mRNA 
expression through activation of the nuclear receptor and xenobiotic sensor pregnane X 
receptor (PXR). In line with this, efavirenz (EFV) a first generation NNRTI and the most-
widely prescribed antiretroviral despite exhibiting a poor safety profile, was observed to 
be a more potent activator of PXR. Using an extensive panel of sixteen analogs, we 
explored the structure-activity relationship of EFV and PXR. These analyses primarily 
required the use of primary mouse hepatocytes in order to study PXR target gene 
modulation and required the development of a luciferase reporter assay to test for direct 
activation of the receptor. In doing so, we identified a lower size limit ranging from < 223 
Da to > 289 Da for ligand-dependent activation of PXR. In addition, we observed that the 
incorporation of a hydroxyl group onto a PXR agonist did not impede ligand binding but 
attenuated PXR activation potentially through destabilizing a key hydrophobic area 
within the ligand-binding pocket. These findings may inform next-generation NNRTI 
development in order to dial out PXR activation to mitigate unwanted drug-drug 
interactions. 
Building upon this work, we investigated other hepatic pathways that may be 
stimulated by EFV and/or impacted by PXR activation. To this end, we observed EFV, 
but not RPV, could disrupt hepatic cholesterol homeostasis by stimulating lipid droplet 
formation as evidenced in treatment of primary mouse hepatocytes. We were unable to be 
recapitulate this observation in primary human hepatocytes suggesting potential species-
specific differences leading to the formation of this phenotype. EFV was also observed to 
increase the expression of the nuclear receptor small heterodimer partner (SHP), which 




studies need to be performed in order to determine whether an EFV-mediated increase of 
SHP has a causal role in lipid droplet formation.  
In addition to studying antiretrovirals within the context of chronic HIV 
maintenance therapy, we also investigated RPV and the nucleoside reverse transcriptase 
inhibitor tenofovir (TFV) as pharmacological agents for HIV pre-exposure prophylaxis 
(PrEP). Moreover, in retrospective analyses using clinical samples from the HIV 
Prevention Trials Network Study HPTN 076 and the Microbicide Trials Network study 
MTN-001, we identified genetic variants in the genes encoding enzymes responsible for 
RPV metabolism (60 previously reported genetic variants in CYP3A4, CYP3A5, UGT1A1 
and UGT1A4) and TFV activation (71 previously unreported genetic variants in AK2, 
CKM, PKM and PKLR), respectively. These findings push an important concept forward 
of personalizing HIV therapy and PrEP by highlighting the potential contribution of 
genetic polymorphisms to pharmacokinetic inter-individual variability and drug-
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